data_2n1c_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2n1c _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 CA--C 1.505 -0.755 0 N-CA-C 110.641 -0.133 . . . . 0.0 110.641 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -81.96 -13.12 57.91 Favored 'General case' 0 C--N 1.356 0.862 0 C-N-CA 123.847 0.859 . . . . 0.0 110.125 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -69.95 -28.87 71.27 Favored Glycine 0 C--N 1.356 1.642 0 C-N-CA 123.823 0.725 . . . . 0.0 111.745 178.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.4 t-80 -74.35 -39.54 62.72 Favored 'General case' 0 N--CA 1.434 -1.252 0 C-N-CA 124.778 1.231 . . . . 0.0 111.249 175.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.3 mt -73.41 -36.65 49.12 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.731 0 C-N-CA 125.979 1.712 . . . . 0.0 111.435 -169.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 19.8 pt20 -77.07 -7.84 56.41 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 123.693 0.797 . . . . 0.0 112.197 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.35 -35.17 3.46 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.54 -21.23 52.93 Favored 'General case' 0 CA--C 1.47 -2.115 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -169.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -62.07 -32.51 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.272 0 C-N-CA 125.929 1.692 . . . . 0.0 111.529 178.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -75.64 -41.52 53.9 Favored 'General case' 0 CA--C 1.503 -0.844 0 CA-C-N 112.658 -2.064 . . . . 0.0 109.959 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.4 t30 -71.37 -32.5 68.56 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.987 1.315 . . . . 0.0 110.386 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.0 t60 . . . . . 0 N--CA 1.421 -1.882 0 C-N-CA 127.701 2.4 . . . . 0.0 110.98 179.896 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 . . . . . 0 CA--C 1.506 -0.712 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -79.66 -23.33 42.57 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.73 1.212 . . . . 0.0 108.866 174.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -77.76 -14.4 82.43 Favored Glycine 0 C--N 1.355 1.633 0 C-N-CA 124.39 0.995 . . . . 0.0 111.504 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 32.3 m170 -89.49 -35.52 15.92 Favored 'General case' 0 CA--C 1.502 -0.896 0 C-N-CA 124.244 1.018 . . . . 0.0 108.56 174.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -72.57 -30.93 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 C-N-CA 125.898 1.679 . . . . 0.0 111.74 -171.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 5.4 pp0? -78.31 -5.96 53.67 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 124.13 0.972 . . . . 0.0 111.927 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.9 t -83.95 -41.18 16.31 Favored 'Isoleucine or valine' 0 C--N 1.357 0.919 0 C-N-CA 124.023 0.929 . . . . 0.0 108.558 174.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -72.06 -16.23 62.03 Favored 'General case' 0 CA--C 1.491 -1.306 0 C-N-CA 127.426 2.29 . . . . 0.0 113.009 -165.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.1 t -49.55 -37.32 11.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 C-N-CA 129.07 2.948 . . . . 0.0 111.368 170.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -55.97 -36.38 67.78 Favored 'General case' 0 C--N 1.349 0.571 0 C-N-CA 126.886 2.074 . . . . 0.0 113.158 -175.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -86.32 -48.59 8.35 Favored 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 126.089 1.756 . . . . 0.0 107.697 -178.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 . . . . . 0 N--CA 1.431 -1.376 0 C-N-CA 126.722 2.009 . . . . 0.0 112.706 -175.655 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -80.24 -11.06 59.77 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.474 1.109 . . . . 0.0 110.151 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -73.02 -18.52 79.18 Favored Glycine 0 C--N 1.357 1.712 0 C-N-CA 124.205 0.907 . . . . 0.0 111.857 178.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.2 m170 -85.03 -40.63 16.63 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.365 1.066 . . . . 0.0 109.204 175.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.2 mt -68.18 -34.69 67.88 Favored 'Isoleucine or valine' 0 C--N 1.352 0.708 0 C-N-CA 127.185 2.194 . . . . 0.0 111.73 -171.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -80.25 12.6 2.8 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 124.595 1.158 . . . . 0.0 112.719 -176.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -107.32 -32.7 2.57 Favored 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.1 mmmt -86.65 -9.73 55.37 Favored 'General case' 0 CA--C 1.485 -1.551 0 C-N-CA 124.508 1.123 . . . . 0.0 110.647 -170.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.5 p -61.14 -36.74 74.68 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 C-N-CA 126.094 1.758 . . . . 0.0 110.595 170.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -77.37 -29.35 53.25 Favored 'General case' 0 CA--C 1.506 -0.714 0 C-N-CA 126.613 1.965 . . . . 0.0 110.209 -178.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -73.83 -41.07 62.83 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.368 1.067 . . . . 0.0 109.091 177.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 35.5 m-70 . . . . . 0 N--CA 1.428 -1.552 0 C-N-CA 125.357 1.463 . . . . 0.0 110.222 178.245 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.5 m120 . . . . . 0 CA--C 1.503 -0.827 0 CA-C-O 120.354 0.121 . . . . 0.0 111.247 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -84.8 -10.23 57.4 Favored 'General case' 0 CA--C 1.505 -0.76 0 C-N-CA 124.452 1.101 . . . . 0.0 110.045 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.7 5.36 83.92 Favored Glycine 0 C--N 1.355 1.585 0 C-N-CA 124.09 0.852 . . . . 0.0 111.966 179.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.2 m-70 -91.37 -40.33 11.51 Favored 'General case' 0 CA--C 1.501 -0.908 0 C-N-CA 123.893 0.877 . . . . 0.0 108.645 175.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.3 mp -72.51 -32.7 42.71 Favored 'Isoleucine or valine' 0 C--N 1.352 0.694 0 C-N-CA 126.476 1.91 . . . . 0.0 110.488 -171.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 4.4 pp0? -80.75 9.07 6.76 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.884 0.873 . . . . 0.0 112.493 -177.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -97.65 -33.27 4.26 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 171.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 mmmt -89.63 -8.75 51.84 Favored 'General case' 0 CA--C 1.483 -1.608 0 C-N-CA 124.843 1.257 . . . . 0.0 111.208 -166.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.9 p -64.23 -37.35 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 C-N-CA 125.295 1.438 . . . . 0.0 110.315 168.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -79.1 -26.87 42.9 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.898 -178.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -75.71 -40.36 55.82 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.263 1.025 . . . . 0.0 109.219 178.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.432 -1.355 0 C-N-CA 124.909 1.284 . . . . 0.0 113.072 -172.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 . . . . . 0 CA--C 1.498 -1.03 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 35.4 t80 -80.97 -10.17 59.75 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.489 1.115 . . . . 0.0 110.313 -177.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.06 3.32 77.21 Favored Glycine 0 C--N 1.356 1.686 0 C-N-CA 123.908 0.765 . . . . 0.0 112.005 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 58.5 m170 -109.04 -31.9 7.44 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.174 1.389 . . . . 0.0 107.782 174.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -76.71 -33.53 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.742 0 C-N-CA 125.827 1.651 . . . . 0.0 110.563 -172.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.53 -16.98 58.36 Favored 'General case' 0 N--CA 1.445 -0.695 0 C-N-CA 123.495 0.718 . . . . 0.0 111.515 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -91.1 -43.04 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 C-N-CA 124.15 0.98 . . . . 0.0 109.072 -176.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -19.68 65.11 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -163.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.4 m -57.28 -29.42 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.268 0 C-N-CA 127.916 2.487 . . . . 0.0 113.191 177.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.12 -36.77 71.05 Favored 'General case' 0 CA--C 1.511 -0.533 0 C-N-CA 127.745 2.418 . . . . 0.0 112.661 -176.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -70.07 -53.84 15.69 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 126.49 1.916 . . . . 0.0 108.98 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 . . . . . 0 N--CA 1.428 -1.539 0 C-N-CA 125.172 1.389 . . . . 0.0 112.897 -173.706 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 4.0 p30 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -82.46 -5.78 58.9 Favored 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 173.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.72 24.94 9.14 Favored Glycine 0 C--N 1.356 1.666 0 C-N-CA 124.506 1.051 . . . . 0.0 110.803 175.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.7 m-70 -114.29 -40.48 3.65 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 168.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.6 mp -76.71 -42.82 34.17 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.98 0 C-N-CA 125.91 1.684 . . . . 0.0 110.173 -172.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -76.78 -26.25 54.28 Favored 'General case' 0 CA--C 1.508 -0.649 0 O-C-N 121.956 -0.465 . . . . 0.0 110.71 -177.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.9 t -78.23 -24.26 13.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 C-N-CA 125.345 1.458 . . . . 0.0 109.976 -175.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.67 -25.56 53.83 Favored 'General case' 0 CA--C 1.475 -1.923 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -176.422 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.7 -33.06 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 C-N-CA 125.207 1.403 . . . . 0.0 108.286 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 15.8 m-30 -81.45 -28.5 34.15 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 113.317 -1.765 . . . . 0.0 108.787 -172.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -75.89 -46.0 32.45 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.06 1.344 . . . . 0.0 108.521 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 . . . . . 0 N--CA 1.425 -1.677 0 C-N-CA 126.466 1.906 . . . . 0.0 111.649 -175.698 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.3 m-80 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -83.6 2.2 38.48 Favored 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.604 1.161 . . . . 0.0 110.83 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 12.68 66.48 Favored Glycine 0 C--N 1.355 1.62 0 C-N-CA 124.37 0.986 . . . . 0.0 110.745 173.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -118.44 -27.23 6.02 Favored 'General case' 0 C--N 1.355 0.845 0 C-N-CA 124.93 1.292 . . . . 0.0 108.834 174.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -76.85 -40.26 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.997 0 C-N-CA 125.198 1.399 . . . . 0.0 108.062 -177.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -66.23 -25.17 66.78 Favored 'General case' 0 C--N 1.348 0.514 0 C-N-CA 123.834 0.854 . . . . 0.0 112.375 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 66.5 t -73.81 -29.19 25.62 Favored 'Isoleucine or valine' 0 C--N 1.357 0.914 0 C-N-CA 125.464 1.506 . . . . 0.0 110.132 -176.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.08 -25.7 52.63 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -174.416 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 88.5 t -68.63 -33.32 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 125.163 1.385 . . . . 0.0 108.149 179.228 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.4 m-30 -80.29 -28.29 38.34 Favored 'General case' 0 CA--C 1.504 -0.801 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.351 -172.007 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -76.07 -43.13 45.07 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.838 1.255 . . . . 0.0 108.211 176.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 81.4 t60 . . . . . 0 N--CA 1.421 -1.912 0 C-N-CA 127.268 2.227 . . . . 0.0 110.913 -178.319 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 . . . . . 0 N--CA 1.446 -0.65 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -77.02 -34.22 57.37 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 125.175 1.39 . . . . 0.0 111.029 -178.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.84 14.2 62.4 Favored Glycine 0 C--N 1.35 1.358 0 C-N-CA 124.07 0.843 . . . . 0.0 111.96 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 t60 -102.59 -38.24 7.6 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.855 -1.905 . . . . 0.0 105.855 170.001 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.7 mt -71.2 -31.39 44.09 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 C-N-CA 125.697 1.599 . . . . 0.0 110.249 -175.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -71.72 -26.82 62.64 Favored 'General case' 0 N--CA 1.422 -1.857 0 C-N-CA 127.557 2.343 . . . . 0.0 110.476 -178.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.7 t -94.01 -34.56 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 C-N-CA 124.382 1.073 . . . . 0.0 109.457 -177.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.2 pptp? -79.22 -19.83 49.75 Favored 'General case' 0 CA--C 1.469 -2.159 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -166.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.1 p -64.6 -32.84 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-O 123.293 1.521 . . . . 0.0 111.006 177.434 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -78.86 -30.52 45.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.669 -2.06 . . . . 0.0 109.921 -178.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -80.42 -36.88 33.09 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 124.073 0.949 . . . . 0.0 110.056 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.43 -1.453 0 C-N-CA 125.616 1.566 . . . . 0.0 113.935 -168.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 . . . . . 0 CA--C 1.498 -1.021 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -82.62 -13.48 56.43 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 124.298 1.039 . . . . 0.0 110.139 -175.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.09 7.88 65.52 Favored Glycine 0 C--N 1.355 1.618 0 C-N-CA 123.702 0.668 . . . . 0.0 111.784 178.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 66.9 m170 -102.99 -30.68 10.63 Favored 'General case' 0 CA--C 1.503 -0.858 0 C-N-CA 124.975 1.31 . . . . 0.0 107.775 171.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 31.9 mm -75.14 -38.74 42.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 C-N-CA 125.832 1.653 . . . . 0.0 110.27 -170.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -77.97 -8.49 58.21 Favored 'General case' 0 N--CA 1.441 -0.915 0 C-N-CA 123.507 0.723 . . . . 0.0 111.435 -176.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -101.48 -31.05 3.12 Favored 'Isoleucine or valine' 0 C--N 1.357 0.899 0 C-N-CA 125.139 1.376 . . . . 0.0 108.679 -177.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.9 pptp? -79.49 -19.13 50.49 Favored 'General case' 0 CA--C 1.472 -2.023 0 N-CA-C 115.107 1.521 . . . . 0.0 115.107 -166.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 28.7 m -67.87 -32.09 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 C-N-CA 125.077 1.351 . . . . 0.0 110.72 175.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -84.58 -24.26 29.28 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-N 112.6 -2.091 . . . . 0.0 109.912 -177.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -73.19 -45.45 56.35 Favored 'General case' 0 C--N 1.356 0.865 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 43.2 m170 . . . . . 0 N--CA 1.425 -1.707 0 C-N-CA 125.869 1.668 . . . . 0.0 111.527 179.865 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 36.1 m120 . . . . . 0 CA--C 1.504 -0.801 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -82.57 -12.65 57.57 Favored 'General case' 0 C--N 1.354 0.792 0 C-N-CA 125.149 1.38 . . . . 0.0 109.913 177.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.03 8.42 76.51 Favored Glycine 0 C--N 1.356 1.655 0 C-N-CA 124.253 0.93 . . . . 0.0 111.873 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -92.94 -32.45 14.55 Favored 'General case' 0 CA--C 1.503 -0.858 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.1 mp -76.82 -32.75 20.53 Favored 'Isoleucine or valine' 0 C--N 1.354 0.785 0 C-N-CA 125.734 1.613 . . . . 0.0 109.811 -174.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -71.94 -16.47 62.1 Favored 'General case' 0 C--N 1.35 0.628 0 C-N-CA 123.342 0.657 . . . . 0.0 112.384 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.9 t -98.92 -36.85 5.79 Favored 'Isoleucine or valine' 0 C--N 1.358 0.96 0 C-N-CA 124.103 0.961 . . . . 0.0 108.718 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.57 -19.35 57.99 Favored 'General case' 0 CA--C 1.471 -2.069 0 N-CA-C 114.505 1.298 . . . . 0.0 114.505 -168.057 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.87 -33.61 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.187 0 C-N-CA 125.771 1.628 . . . . 0.0 111.226 177.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -77.2 -28.86 54.06 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.617 -2.083 . . . . 0.0 110.863 -176.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 -80.07 -43.3 22.06 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 123.92 0.888 . . . . 0.0 108.63 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 16.7 t-160 . . . . . 0 N--CA 1.428 -1.536 0 C-N-CA 127.149 2.179 . . . . 0.0 112.753 -175.434 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.1 m-80 . . . . . 0 CA--C 1.505 -0.767 0 CA-C-O 120.405 0.145 . . . . 0.0 111.261 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -84.95 -10.96 56.53 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.546 1.138 . . . . 0.0 109.845 178.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.62 -22.98 78.59 Favored Glycine 0 C--N 1.355 1.628 0 C-N-CA 125.162 1.363 . . . . 0.0 111.877 178.262 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -71.12 -40.79 71.21 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 117.934 0.867 . . . . 0.0 111.08 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.8 mp -76.05 -36.51 31.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 C-N-CA 124.925 1.29 . . . . 0.0 110.558 -170.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -81.24 -3.8 53.51 Favored 'General case' 0 N--CA 1.446 -0.664 0 O-C-N 121.828 -0.545 . . . . 0.0 112.374 -176.465 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.5 t -112.2 -26.13 3.21 Favored 'Isoleucine or valine' 0 C--N 1.358 0.969 0 C-N-CA 124.424 1.09 . . . . 0.0 108.486 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.73 -20.59 49.64 Favored 'General case' 0 CA--C 1.471 -2.09 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -173.62 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.3 p -64.47 -35.71 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.327 0 C-N-CA 125.009 1.324 . . . . 0.0 110.619 174.004 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -83.01 -24.78 32.72 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-N 112.898 -1.955 . . . . 0.0 109.939 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.2 t-20 -72.25 -43.31 64.55 Favored 'General case' 0 C--N 1.356 0.888 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.5 m170 . . . . . 0 N--CA 1.421 -1.896 0 C-N-CA 126.634 1.974 . . . . 0.0 110.215 176.807 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 . . . . . 0 CA--C 1.507 -0.707 0 CA-C-O 120.576 0.227 . . . . 0.0 110.741 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -83.92 -14.99 49.61 Favored 'General case' 0 C--N 1.352 0.713 0 C-N-CA 124.796 1.239 . . . . 0.0 110.159 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.57 -2.83 72.35 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -93.84 -11.35 31.38 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 118.007 0.903 . . . . 0.0 108.983 174.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 47.8 mm -77.09 -36.21 24.31 Favored 'Isoleucine or valine' 0 C--N 1.356 0.861 0 C-N-CA 125.008 1.323 . . . . 0.0 108.842 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.39 0.65 40.99 Favored 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 122.896 0.478 . . . . 0.0 111.436 -179.089 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.78 -40.59 9.26 Favored 'Isoleucine or valine' 0 C--N 1.358 0.94 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 171.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.25 -17.58 58.3 Favored 'General case' 0 CA--C 1.47 -2.106 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -167.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -63.67 -34.41 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 C-N-CA 125.402 1.481 . . . . 0.0 110.826 176.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -80.44 -29.81 37.58 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 112.724 -2.035 . . . . 0.0 110.357 -177.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.5 t30 -73.05 -40.99 64.64 Favored 'General case' 0 C--N 1.354 0.774 0 C-N-CA 124.216 1.007 . . . . 0.0 108.609 176.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.2 t60 . . . . . 0 N--CA 1.418 -2.026 0 C-N-CA 127.462 2.305 . . . . 0.0 110.266 179.905 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 . . . . . 0 CA--C 1.498 -1.023 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -88.94 1.31 55.63 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.681 1.192 . . . . 0.0 110.784 -174.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.95 -10.44 80.85 Favored Glycine 0 C--N 1.356 1.666 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 176.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.4 m-70 -95.04 -31.22 13.7 Favored 'General case' 0 CA--C 1.502 -0.876 0 C-N-CA 124.122 0.969 . . . . 0.0 108.701 173.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.2 mt -75.82 -33.39 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 C-N-CA 125.508 1.523 . . . . 0.0 110.6 -171.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -74.1 -13.14 60.79 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 123.506 0.722 . . . . 0.0 112.163 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.14 -33.18 3.93 Favored 'Isoleucine or valine' 0 C--N 1.357 0.915 0 C-N-CA 124.766 1.226 . . . . 0.0 108.957 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.74 -19.78 47.94 Favored 'General case' 0 CA--C 1.476 -1.883 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -164.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 m -68.98 -30.24 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 C-N-CA 125.207 1.403 . . . . 0.0 110.822 175.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -87.08 -20.7 26.75 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.472 -2.149 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -75.7 -31.25 59.61 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.174 0.99 . . . . 0.0 109.056 177.167 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 56.5 m170 . . . . . 0 N--CA 1.434 -1.272 0 C-N-CA 125.704 1.602 . . . . 0.0 112.379 177.092 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 . . . . . 0 N--CA 1.435 -1.215 0 N-CA-C 104.538 -2.393 . . . . 0.0 104.538 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -86.68 -1.09 57.42 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.862 1.265 . . . . 0.0 110.898 -174.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.04 -30.02 39.65 Favored Glycine 0 C--N 1.355 1.633 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.1 m80 -76.81 -30.42 56.41 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 124.605 1.162 . . . . 0.0 110.363 177.016 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -73.58 -31.1 31.34 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 C-N-CA 126.029 1.731 . . . . 0.0 109.61 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.38 -27.84 64.63 Favored 'General case' 0 N--CA 1.437 -1.114 0 C-N-CA 125.441 1.497 . . . . 0.0 111.261 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 83.9 t -85.77 -44.87 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.864 0 C-N-CA 123.287 0.635 . . . . 0.0 109.502 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 pptp? -66.69 -21.28 66.09 Favored 'General case' 0 CA--C 1.483 -1.628 0 N-CA-C 116.191 1.922 . . . . 0.0 116.191 -160.279 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -55.39 -30.66 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 C-N-CA 127.953 2.501 . . . . 0.0 113.127 176.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.19 -37.24 71.86 Favored 'General case' 0 CA--C 1.509 -0.629 0 C-N-CA 127.903 2.481 . . . . 0.0 112.974 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -75.61 -47.3 27.17 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 126.007 1.723 . . . . 0.0 108.474 -177.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 44.0 m170 . . . . . 0 N--CA 1.432 -1.346 0 C-N-CA 126.22 1.808 . . . . 0.0 113.216 -175.1 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 . . . . . 0 N--CA 1.435 -1.219 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -82.69 -5.19 58.73 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.928 1.291 . . . . 0.0 111.371 -173.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -84.93 2.35 88.31 Favored Glycine 0 C--N 1.356 1.644 0 C-N-CA 124.064 0.84 . . . . 0.0 111.288 176.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -112.3 -26.62 8.67 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.207 1.403 . . . . 0.0 108.302 175.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.7 mt -75.73 -34.44 28.49 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 125.503 1.521 . . . . 0.0 109.888 -176.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.33 -11.06 59.79 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 123.799 0.84 . . . . 0.0 111.994 -179.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.7 t -98.17 -31.35 3.71 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 124.696 1.198 . . . . 0.0 108.93 -175.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.58 -19.25 58.07 Favored 'General case' 0 CA--C 1.475 -1.92 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -167.475 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.3 m -63.86 -31.37 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 C-N-CA 126.31 1.844 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -77.07 -34.72 56.99 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.252 -2.249 . . . . 0.0 109.972 -176.168 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 37.4 t30 -74.67 -43.39 55.5 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 124.369 1.068 . . . . 0.0 108.85 177.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.1 t-80 . . . . . 0 N--CA 1.429 -1.499 0 C-N-CA 127.124 2.17 . . . . 0.0 112.637 -175.874 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 41.0 t30 . . . . . 0 N--CA 1.444 -0.739 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -79.05 -17.06 55.92 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 124.511 1.125 . . . . 0.0 110.247 -178.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.56 29.67 7.6 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.107 0.861 . . . . 0.0 111.078 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 55.3 m-70 -112.64 -35.11 5.61 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 168.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mp -73.06 -44.75 56.05 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 109.243 -173.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 3.2 pp0? -78.69 -6.48 55.87 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.529 0.732 . . . . 0.0 112.22 -176.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.91 -28.2 3.82 Favored 'Isoleucine or valine' 0 C--N 1.358 0.949 0 C-N-CA 124.325 1.05 . . . . 0.0 109.171 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.69 -21.7 54.99 Favored 'General case' 0 CA--C 1.473 -2.006 0 N-CA-C 114.181 1.178 . . . . 0.0 114.181 -169.427 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.4 m -64.98 -28.78 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 126.629 1.971 . . . . 0.0 111.428 -176.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -71.6 -41.5 68.87 Favored 'General case' 0 CA--C 1.506 -0.746 0 CA-C-N 111.84 -2.436 . . . . 0.0 109.947 -175.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -80.94 -41.82 22.3 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.463 1.105 . . . . 0.0 109.594 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 71.0 t60 . . . . . 0 N--CA 1.426 -1.634 0 C-N-CA 127.933 2.493 . . . . 0.0 112.452 -170.065 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.7 m120 . . . . . 0 CA--C 1.496 -1.13 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -81.13 -12.46 59.24 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.445 1.098 . . . . 0.0 110.004 -178.028 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.27 9.32 61.42 Favored Glycine 0 C--N 1.356 1.694 0 C-N-CA 123.652 0.644 . . . . 0.0 112.145 178.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -109.43 -32.02 7.31 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 168.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.3 -34.55 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.827 0 C-N-CA 125.933 1.693 . . . . 0.0 110.956 -170.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -80.12 -24.66 40.33 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.149 0.58 . . . . 0.0 110.608 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t -81.92 -28.34 9.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.813 0 C-N-CA 125.224 1.41 . . . . 0.0 109.803 -175.283 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.85 -19.17 57.81 Favored 'General case' 0 CA--C 1.477 -1.846 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 -171.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 82.1 t -67.55 -36.02 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.227 0 C-N-CA 125.454 1.502 . . . . 0.0 108.67 176.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -85.76 -23.86 27.11 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.659 -1.609 . . . . 0.0 108.808 -175.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -73.95 -35.23 64.53 Favored 'General case' 0 N--CA 1.44 -0.948 0 C-N-CA 123.922 0.889 . . . . 0.0 108.776 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.427 -1.602 0 C-N-CA 124.5 1.12 . . . . 0.0 109.437 174.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 . . . . . 0 CA--C 1.501 -0.922 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -79.66 -18.04 52.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 C-N-CA 124.585 1.154 . . . . 0.0 109.877 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.41 28.82 6.54 Favored Glycine 0 C--N 1.357 1.718 0 C-N-CA 124.376 0.989 . . . . 0.0 111.241 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -115.22 -32.43 5.67 Favored 'General case' 0 CA--C 1.501 -0.916 0 C-N-CA 124.654 1.182 . . . . 0.0 108.08 171.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.0 mp -80.59 -37.95 17.16 Favored 'Isoleucine or valine' 0 C--N 1.354 0.774 0 C-N-CA 125.19 1.396 . . . . 0.0 109.005 -172.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -83.32 11.53 6.6 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.435 0.694 . . . . 0.0 111.378 179.16 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 82.0 t -118.16 -33.34 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 C-N-CA 125.253 1.421 . . . . 0.0 107.713 178.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.87 -21.65 40.5 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -170.731 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 p -65.93 -33.72 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 C-N-CA 125.317 1.447 . . . . 0.0 110.751 175.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -81.68 -24.97 35.92 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 112.797 -2.001 . . . . 0.0 110.052 -178.595 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -71.78 -46.7 57.49 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 54.3 m-70 . . . . . 0 N--CA 1.424 -1.767 0 C-N-CA 124.701 1.201 . . . . 0.0 112.126 -179.99 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 . . . . . 0 CA--C 1.494 -1.184 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -85.05 -1.29 56.66 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.733 1.213 . . . . 0.0 110.773 -177.005 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -88.79 8.42 79.53 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.236 0.922 . . . . 0.0 110.929 175.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.1 t60 -106.84 -31.21 8.48 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 173.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -74.83 -38.46 44.1 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.889 0 C-N-CA 125.127 1.371 . . . . 0.0 108.798 -174.069 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.0 4.59 11.82 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 179.123 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -105.79 -38.36 4.45 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 C-N-CA 124.909 1.284 . . . . 0.0 108.411 173.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.63 -21.75 51.78 Favored 'General case' 0 CA--C 1.476 -1.868 0 N-CA-C 115.122 1.527 . . . . 0.0 115.122 -163.756 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.9 m -69.35 -29.66 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 C-N-CA 125.468 1.507 . . . . 0.0 110.99 176.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -86.87 -24.74 24.79 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 112.513 -2.131 . . . . 0.0 109.866 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -72.21 -41.09 67.32 Favored 'General case' 0 C--N 1.356 0.868 0 C-N-CA 124.378 1.071 . . . . 0.0 108.202 176.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 57.2 m170 . . . . . 0 N--CA 1.428 -1.542 0 C-N-CA 126.301 1.841 . . . . 0.0 110.618 174.617 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 . . . . . 0 N--CA 1.443 -0.811 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -77.88 -13.87 59.74 Favored 'General case' 0 C--N 1.356 0.863 0 C-N-CA 124.557 1.143 . . . . 0.0 109.872 178.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -79.57 0.33 81.65 Favored Glycine 0 C--N 1.357 1.734 0 C-N-CA 124.124 0.868 . . . . 0.0 112.29 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -96.81 -36.23 10.69 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 172.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.2 mt -73.94 -48.47 38.59 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.929 0 C-N-CA 126.073 1.749 . . . . 0.0 110.94 -169.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -75.94 -23.09 55.4 Favored 'General case' 0 CA--C 1.508 -0.671 0 C-N-CA 124.317 1.047 . . . . 0.0 112.397 -171.053 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 84.3 t -81.19 -25.5 10.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 C-N-CA 125.099 1.36 . . . . 0.0 109.658 -175.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 24.9 tptp -84.57 -20.3 31.72 Favored 'General case' 0 N--CA 1.429 -1.501 0 C-N-CA 125.858 1.663 . . . . 0.0 111.454 -171.478 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 58.8 t -60.33 -37.54 74.43 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.927 0 C-N-CA 126.599 1.96 . . . . 0.0 109.563 168.377 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -86.52 -12.35 49.07 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.196 -175.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -80.46 -28.66 37.57 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.38 1.072 . . . . 0.0 108.57 173.263 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 46.3 m170 . . . . . 0 C--N 1.365 1.276 0 C-N-CA 125.36 1.464 . . . . 0.0 112.754 177.703 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 50.2 p90 . . . . . 0 N--CA 1.489 1.493 0 CA-C-O 121.379 0.609 . . . . 0.0 111.788 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -88.85 -83.1 0.23 Allowed 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -154.66 101.53 2.32 Favored 'General case' 0 N--CA 1.433 -1.299 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 177.094 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 94.8 mt -101.01 159.27 29.96 Favored Pre-proline 0 CA--C 1.501 -0.93 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -75.85 -173.81 1.8 Allowed 'Trans proline' 0 CA--C 1.501 -1.144 0 C-N-CA 123.159 2.573 . . . . 0.0 110.945 177.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 -65.17 -51.3 61.97 Favored 'General case' 0 CA--C 1.505 -0.755 0 C-N-CA 125.806 1.643 . . . . 0.0 110.641 -176.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -81.96 -13.12 57.91 Favored 'General case' 0 C--N 1.356 0.862 0 C-N-CA 123.847 0.859 . . . . 0.0 110.125 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -69.95 -28.87 71.27 Favored Glycine 0 C--N 1.356 1.642 0 C-N-CA 123.823 0.725 . . . . 0.0 111.745 178.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.4 t-80 -74.35 -39.54 62.72 Favored 'General case' 0 N--CA 1.434 -1.252 0 C-N-CA 124.778 1.231 . . . . 0.0 111.249 175.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.3 mt -73.41 -36.65 49.12 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.731 0 C-N-CA 125.979 1.712 . . . . 0.0 111.435 -169.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 19.8 pt20 -77.07 -7.84 56.41 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 123.693 0.797 . . . . 0.0 112.197 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.35 -35.17 3.46 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.54 -21.23 52.93 Favored 'General case' 0 CA--C 1.47 -2.115 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -169.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -62.07 -32.51 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.272 0 C-N-CA 125.929 1.692 . . . . 0.0 111.529 178.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -75.64 -41.52 53.9 Favored 'General case' 0 CA--C 1.503 -0.844 0 CA-C-N 112.658 -2.064 . . . . 0.0 109.959 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.4 t30 -71.37 -32.5 68.56 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.987 1.315 . . . . 0.0 110.386 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -67.4 -31.9 72.43 Favored 'General case' 0 N--CA 1.421 -1.882 0 C-N-CA 127.701 2.4 . . . . 0.0 110.98 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -80.85 -97.38 0.38 Allowed Glycine 0 C--N 1.353 1.484 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 177.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 48.5 mm-40 63.29 42.41 6.99 Favored 'General case' 0 C--N 1.357 0.902 0 C-N-CA 126.199 1.8 . . . . 0.0 111.428 -176.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 72.6 m80 -152.81 -95.13 0.05 OUTLIER 'General case' 0 CA--C 1.493 -1.249 1 N-CA-C 100.17 -4.011 . . . . 0.0 100.17 177.247 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.3 pp -92.88 155.18 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 105.518 -2.03 . . . . 0.0 105.518 157.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 18.8 t-80 61.49 47.39 6.68 Favored 'General case' 0 C--N 1.356 0.858 0 C-N-CA 125.565 1.546 . . . . 0.0 109.123 -167.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 85.3 t60 . . . . . 0 C--O 1.26 1.62 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.155 -175.55 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 52.9 p90 . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 121.491 0.662 . . . . 0.0 111.993 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -93.19 -71.23 0.66 Allowed 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 177.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -160.26 106.51 1.55 Allowed 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 104.475 -2.417 . . . . 0.0 104.475 175.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -89.13 162.74 36.7 Favored Pre-proline 0 N--CA 1.445 -0.7 0 C-N-CA 124.601 1.16 . . . . 0.0 108.447 177.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -76.7 -168.49 0.58 Allowed 'Trans proline' 0 CA--C 1.498 -1.28 0 C-N-CA 122.583 2.189 . . . . 0.0 112.901 -169.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 -72.19 -30.81 65.32 Favored 'General case' 0 CA--C 1.506 -0.712 0 C-N-CA 126.334 1.854 . . . . 0.0 110.039 175.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -79.66 -23.33 42.57 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.73 1.212 . . . . 0.0 108.866 174.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -77.76 -14.4 82.43 Favored Glycine 0 C--N 1.355 1.633 0 C-N-CA 124.39 0.995 . . . . 0.0 111.504 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 32.3 m170 -89.49 -35.52 15.92 Favored 'General case' 0 CA--C 1.502 -0.896 0 C-N-CA 124.244 1.018 . . . . 0.0 108.56 174.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -72.57 -30.93 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 C-N-CA 125.898 1.679 . . . . 0.0 111.74 -171.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 5.4 pp0? -78.31 -5.96 53.67 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 124.13 0.972 . . . . 0.0 111.927 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.9 t -83.95 -41.18 16.31 Favored 'Isoleucine or valine' 0 C--N 1.357 0.919 0 C-N-CA 124.023 0.929 . . . . 0.0 108.558 174.795 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -72.06 -16.23 62.03 Favored 'General case' 0 CA--C 1.491 -1.306 0 C-N-CA 127.426 2.29 . . . . 0.0 113.009 -165.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.1 t -49.55 -37.32 11.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 C-N-CA 129.07 2.948 . . . . 0.0 111.368 170.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -55.97 -36.38 67.78 Favored 'General case' 0 C--N 1.349 0.571 0 C-N-CA 126.886 2.074 . . . . 0.0 113.158 -175.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -86.32 -48.59 8.35 Favored 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 126.089 1.756 . . . . 0.0 107.697 -178.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . 0.484 ' HD1' ' CE1' ' A' ' 20' ' ' HIS . 52.2 t-80 -59.57 148.08 34.75 Favored 'General case' 0 N--CA 1.431 -1.376 0 C-N-CA 126.722 2.009 . . . . 0.0 112.706 -175.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -171.29 31.11 0.13 Allowed Glycine 0 N--CA 1.436 -1.36 0 N-CA-C 108.056 -2.018 . . . . 0.0 108.056 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -116.15 64.94 0.7 Allowed 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 178.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.484 ' CE1' ' HD1' ' A' ' 17' ' ' HIS . 75.7 m80 -91.27 -97.71 0.12 Allowed 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 -177.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 12.2 pt -86.89 157.01 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.212 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 173.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -141.7 -50.92 0.41 Allowed 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 -177.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 81.0 m-70 . . . . . 0 C--O 1.261 1.659 0 C-N-CA 126.251 1.82 . . . . 0.0 110.785 -177.678 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 16.1 t80 . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 121.543 0.687 . . . . 0.0 109.753 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 53.8 mm-40 -79.69 -49.89 11.42 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 125.155 1.382 . . . . 0.0 109.985 -173.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -147.34 98.73 3.05 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 -177.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 6.6 mp -78.98 152.59 77.14 Favored Pre-proline 0 N--CA 1.44 -0.933 0 C-N-CA 125.431 1.493 . . . . 0.0 108.358 -176.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -78.57 176.93 9.33 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 123.112 2.542 . . . . 0.0 109.821 -174.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -81.04 -49.78 10.48 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 124.878 1.271 . . . . 0.0 108.531 -176.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -80.24 -11.06 59.77 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.474 1.109 . . . . 0.0 110.151 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -73.02 -18.52 79.18 Favored Glycine 0 C--N 1.357 1.712 0 C-N-CA 124.205 0.907 . . . . 0.0 111.857 178.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.2 m170 -85.03 -40.63 16.63 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.365 1.066 . . . . 0.0 109.204 175.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.2 mt -68.18 -34.69 67.88 Favored 'Isoleucine or valine' 0 C--N 1.352 0.708 0 C-N-CA 127.185 2.194 . . . . 0.0 111.73 -171.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -80.25 12.6 2.8 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 124.595 1.158 . . . . 0.0 112.719 -176.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -107.32 -32.7 2.57 Favored 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.1 mmmt -86.65 -9.73 55.37 Favored 'General case' 0 CA--C 1.485 -1.551 0 C-N-CA 124.508 1.123 . . . . 0.0 110.647 -170.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.5 p -61.14 -36.74 74.68 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 C-N-CA 126.094 1.758 . . . . 0.0 110.595 170.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -77.37 -29.35 53.25 Favored 'General case' 0 CA--C 1.506 -0.714 0 C-N-CA 126.613 1.965 . . . . 0.0 110.209 -178.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -73.83 -41.07 62.83 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.368 1.067 . . . . 0.0 109.091 177.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 35.5 m-70 -67.83 127.63 33.52 Favored 'General case' 0 N--CA 1.428 -1.552 0 C-N-CA 125.357 1.463 . . . . 0.0 110.222 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.55 -43.58 1.73 Allowed Glycine 0 C--N 1.354 1.547 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -175.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 80.21 116.58 0.06 Allowed 'General case' 0 CA--C 1.495 -1.139 0 C-N-CA 127.957 2.503 . . . . 0.0 110.225 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 59.9 m170 -80.02 -75.86 0.24 Allowed 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 173.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 15.6 pt -89.9 150.91 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 N-CA-C 106.814 -1.551 . . . . 0.0 106.814 167.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 39.0 m80 -112.83 -37.06 4.96 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 -179.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 43.4 p-80 . . . . . 0 C--O 1.259 1.593 0 C-N-CA 125.1 1.36 . . . . 0.0 109.312 175.931 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 121.613 0.72 . . . . 0.0 111.037 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -99.4 -54.39 2.96 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 176.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -164.22 113.65 1.2 Allowed 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 102.673 -3.084 . . . . 0.0 102.673 -178.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 5.4 mp -76.13 156.26 84.02 Favored Pre-proline 0 N--CA 1.443 -0.822 0 C-N-CA 124.624 1.169 . . . . 0.0 109.088 -178.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -76.26 -178.31 4.33 Favored 'Trans proline' 0 CA--C 1.501 -1.158 0 C-N-CA 123.107 2.538 . . . . 0.0 110.795 -176.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.5 m120 -64.23 -53.39 49.85 Favored 'General case' 0 CA--C 1.503 -0.827 0 C-N-CA 126.238 1.815 . . . . 0.0 111.247 -171.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -84.8 -10.23 57.4 Favored 'General case' 0 CA--C 1.505 -0.76 0 C-N-CA 124.452 1.101 . . . . 0.0 110.045 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.7 5.36 83.92 Favored Glycine 0 C--N 1.355 1.585 0 C-N-CA 124.09 0.852 . . . . 0.0 111.966 179.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.2 m-70 -91.37 -40.33 11.51 Favored 'General case' 0 CA--C 1.501 -0.908 0 C-N-CA 123.893 0.877 . . . . 0.0 108.645 175.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.3 mp -72.51 -32.7 42.71 Favored 'Isoleucine or valine' 0 C--N 1.352 0.694 0 C-N-CA 126.476 1.91 . . . . 0.0 110.488 -171.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 4.4 pp0? -80.75 9.07 6.76 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.884 0.873 . . . . 0.0 112.493 -177.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -97.65 -33.27 4.26 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 171.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 mmmt -89.63 -8.75 51.84 Favored 'General case' 0 CA--C 1.483 -1.608 0 C-N-CA 124.843 1.257 . . . . 0.0 111.208 -166.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.9 p -64.23 -37.35 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 C-N-CA 125.295 1.438 . . . . 0.0 110.315 168.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -79.1 -26.87 42.9 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.898 -178.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -75.71 -40.36 55.82 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.263 1.025 . . . . 0.0 109.219 178.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -65.47 160.81 21.33 Favored 'General case' 0 N--CA 1.432 -1.355 0 C-N-CA 124.909 1.284 . . . . 0.0 113.072 -172.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.02 36.84 17.25 Favored Glycine 0 C--N 1.353 1.475 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -177.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -106.53 58.78 0.64 Allowed 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 -176.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 63.8 m80 67.13 -118.03 0.23 Allowed 'General case' 0 C--N 1.357 0.923 0 C-N-CA 126.38 1.872 . . . . 0.0 109.434 -177.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 23.6 pt -87.52 166.5 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 C-N-CA 124.723 1.209 . . . . 0.0 108.741 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 59.1 t-80 -89.87 -44.33 10.0 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 9.9 p80 . . . . . 0 C--O 1.258 1.539 0 C-N-CA 125.596 1.558 . . . . 0.0 109.55 -176.916 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 38.5 p90 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 121.324 0.583 . . . . 0.0 112.024 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -83.12 -81.47 0.16 Allowed 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -151.85 100.87 2.71 Favored 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 105.861 -1.903 . . . . 0.0 105.861 175.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 89.8 mt -124.29 161.02 50.01 Favored Pre-proline 0 N--CA 1.44 -0.964 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 176.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -79.4 176.82 9.23 Favored 'Trans proline' 0 CA--C 1.502 -1.08 0 C-N-CA 122.764 2.309 . . . . 0.0 110.085 -171.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -93.85 -56.34 2.92 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -175.389 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 35.4 t80 -80.97 -10.17 59.75 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.489 1.115 . . . . 0.0 110.313 -177.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.06 3.32 77.21 Favored Glycine 0 C--N 1.356 1.686 0 C-N-CA 123.908 0.765 . . . . 0.0 112.005 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 58.5 m170 -109.04 -31.9 7.44 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.174 1.389 . . . . 0.0 107.782 174.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -76.71 -33.53 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.742 0 C-N-CA 125.827 1.651 . . . . 0.0 110.563 -172.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.53 -16.98 58.36 Favored 'General case' 0 N--CA 1.445 -0.695 0 C-N-CA 123.495 0.718 . . . . 0.0 111.515 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -91.1 -43.04 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 C-N-CA 124.15 0.98 . . . . 0.0 109.072 -176.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -19.68 65.11 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -163.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.4 m -57.28 -29.42 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.268 0 C-N-CA 127.916 2.487 . . . . 0.0 113.191 177.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.12 -36.77 71.05 Favored 'General case' 0 CA--C 1.511 -0.533 0 C-N-CA 127.745 2.418 . . . . 0.0 112.661 -176.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -70.07 -53.84 15.69 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 126.49 1.916 . . . . 0.0 108.98 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 -66.17 150.27 49.03 Favored 'General case' 0 N--CA 1.428 -1.539 0 C-N-CA 125.172 1.389 . . . . 0.0 112.897 -173.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.63 -50.71 0.42 Allowed Glycine 0 CA--C 1.492 -1.398 0 N-CA-C 105.501 -3.04 . . . . 0.0 105.501 -175.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 9.7 mp0 66.0 70.91 0.42 Allowed 'General case' 0 C--N 1.358 0.956 0 C-N-CA 126.573 1.949 . . . . 0.0 110.202 178.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 74.3 t60 -103.47 169.74 8.36 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 178.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 19.3 pt -83.08 161.38 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 C-N-CA 124.416 1.086 . . . . 0.0 109.279 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -95.35 -60.74 1.6 Allowed 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 175.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 84.2 t60 . . . . . 0 C--O 1.261 1.673 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 179.942 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 . . . . . 0 N--CA 1.488 1.447 0 CA-C-O 121.751 0.786 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 62.1 mm-40 -102.81 -44.34 5.31 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 173.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -142.9 105.14 4.43 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 101.31 -3.589 . . . . 0.0 101.31 176.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -75.94 154.26 84.87 Favored Pre-proline 0 N--CA 1.443 -0.82 0 C-N-CA 125.323 1.449 . . . . 0.0 110.781 -174.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -77.38 -179.45 5.44 Favored 'Trans proline' 0 CA--C 1.501 -1.167 0 C-N-CA 122.605 2.204 . . . . 0.0 112.016 -168.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -82.04 -45.18 15.63 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 125.905 1.682 . . . . 0.0 110.248 -173.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -82.46 -5.78 58.9 Favored 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 173.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.72 24.94 9.14 Favored Glycine 0 C--N 1.356 1.666 0 C-N-CA 124.506 1.051 . . . . 0.0 110.803 175.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.7 m-70 -114.29 -40.48 3.65 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 168.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.6 mp -76.71 -42.82 34.17 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.98 0 C-N-CA 125.91 1.684 . . . . 0.0 110.173 -172.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -76.78 -26.25 54.28 Favored 'General case' 0 CA--C 1.508 -0.649 0 O-C-N 121.956 -0.465 . . . . 0.0 110.71 -177.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.9 t -78.23 -24.26 13.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 C-N-CA 125.345 1.458 . . . . 0.0 109.976 -175.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.67 -25.56 53.83 Favored 'General case' 0 CA--C 1.475 -1.923 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -176.422 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.7 -33.06 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 C-N-CA 125.207 1.403 . . . . 0.0 108.286 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 15.8 m-30 -81.45 -28.5 34.15 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 113.317 -1.765 . . . . 0.0 108.787 -172.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -75.89 -46.0 32.45 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.06 1.344 . . . . 0.0 108.521 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 -64.1 -65.37 0.69 Allowed 'General case' 0 N--CA 1.425 -1.677 0 C-N-CA 126.466 1.906 . . . . 0.0 111.649 -175.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 103.4 76.63 1.14 Allowed Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 106.157 -2.777 . . . . 0.0 106.157 -177.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -100.44 67.45 1.32 Allowed 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 -178.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 73.0 m80 -99.05 -93.93 0.25 Allowed 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 104.826 -2.287 . . . . 0.0 104.826 178.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 20.2 pt -86.34 159.04 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.284 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 170.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -135.74 59.21 1.72 Allowed 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 104.626 -2.361 . . . . 0.0 104.626 177.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 36.4 m170 . . . . . 0 C--O 1.259 1.575 0 C-N-CA 125.926 1.69 . . . . 0.0 110.631 -179.873 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 42.8 p90 . . . . . 0 N--CA 1.488 1.473 0 CA-C-O 121.279 0.562 . . . . 0.0 111.758 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -89.39 -84.51 0.22 Allowed 'General case' 0 CA--C 1.503 -0.827 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -152.93 102.58 2.68 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 104.773 -2.306 . . . . 0.0 104.773 176.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 95.0 mt -121.61 160.32 46.89 Favored Pre-proline 0 N--CA 1.44 -0.951 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -77.13 -179.1 5.1 Favored 'Trans proline' 0 CA--C 1.5 -1.179 0 C-N-CA 123.296 2.664 . . . . 0.0 109.971 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.3 m-80 -68.26 -50.04 56.51 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 125.435 1.494 . . . . 0.0 109.967 -176.015 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -83.6 2.2 38.48 Favored 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.604 1.161 . . . . 0.0 110.83 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 12.68 66.48 Favored Glycine 0 C--N 1.355 1.62 0 C-N-CA 124.37 0.986 . . . . 0.0 110.745 173.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -118.44 -27.23 6.02 Favored 'General case' 0 C--N 1.355 0.845 0 C-N-CA 124.93 1.292 . . . . 0.0 108.834 174.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -76.85 -40.26 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.997 0 C-N-CA 125.198 1.399 . . . . 0.0 108.062 -177.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -66.23 -25.17 66.78 Favored 'General case' 0 C--N 1.348 0.514 0 C-N-CA 123.834 0.854 . . . . 0.0 112.375 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 66.5 t -73.81 -29.19 25.62 Favored 'Isoleucine or valine' 0 C--N 1.357 0.914 0 C-N-CA 125.464 1.506 . . . . 0.0 110.132 -176.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.08 -25.7 52.63 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -174.416 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 88.5 t -68.63 -33.32 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 125.163 1.385 . . . . 0.0 108.149 179.228 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.4 m-30 -80.29 -28.29 38.34 Favored 'General case' 0 CA--C 1.504 -0.801 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.351 -172.007 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -76.07 -43.13 45.07 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.838 1.255 . . . . 0.0 108.211 176.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -70.32 159.18 34.59 Favored 'General case' 0 N--CA 1.421 -1.912 0 C-N-CA 127.268 2.227 . . . . 0.0 110.913 -178.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -157.13 -96.14 0.12 Allowed Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 105.03 -3.228 . . . . 0.0 105.03 178.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 61.46 78.74 0.28 Allowed 'General case' 0 C--N 1.356 0.863 0 C-N-CA 126.2 1.8 . . . . 0.0 112.095 176.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 19.2 p80 -94.48 179.0 5.42 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 36.1 pt -88.0 -167.36 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 C-N-CA 124.888 1.275 . . . . 0.0 109.544 -173.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -78.83 -42.6 27.23 Favored 'General case' 0 CA--C 1.503 -0.831 0 C-N-CA 124.596 1.159 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 56.5 m80 . . . . . 0 C--O 1.26 1.623 0 C-N-CA 127.433 2.293 . . . . 0.0 109.841 -177.85 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 . . . . . 0 N--CA 1.487 1.401 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 79.57 -6.89 1.77 Allowed 'General case' 0 C--N 1.36 1.045 0 C-N-CA 128.239 2.616 . . . . 0.0 110.943 -171.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -159.27 108.17 1.86 Allowed 'General case' 0 N--CA 1.428 -1.545 0 N-CA-C 102.045 -3.317 . . . . 0.0 102.045 176.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 88.7 mt -80.15 156.7 74.06 Favored Pre-proline 0 N--CA 1.443 -0.82 0 C-N-CA 124.218 1.007 . . . . 0.0 109.582 -174.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -75.53 -177.21 3.4 Favored 'Trans proline' 0 CA--C 1.501 -1.166 0 C-N-CA 123.926 3.084 . . . . 0.0 109.764 175.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -71.07 -49.9 39.63 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 124.647 1.179 . . . . 0.0 109.15 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -77.02 -34.22 57.37 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 125.175 1.39 . . . . 0.0 111.029 -178.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.84 14.2 62.4 Favored Glycine 0 C--N 1.35 1.358 0 C-N-CA 124.07 0.843 . . . . 0.0 111.96 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 t60 -102.59 -38.24 7.6 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.855 -1.905 . . . . 0.0 105.855 170.001 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.7 mt -71.2 -31.39 44.09 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 C-N-CA 125.697 1.599 . . . . 0.0 110.249 -175.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -71.72 -26.82 62.64 Favored 'General case' 0 N--CA 1.422 -1.857 0 C-N-CA 127.557 2.343 . . . . 0.0 110.476 -178.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.7 t -94.01 -34.56 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 C-N-CA 124.382 1.073 . . . . 0.0 109.457 -177.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.2 pptp? -79.22 -19.83 49.75 Favored 'General case' 0 CA--C 1.469 -2.159 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -166.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.1 p -64.6 -32.84 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-O 123.293 1.521 . . . . 0.0 111.006 177.434 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -78.86 -30.52 45.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.669 -2.06 . . . . 0.0 109.921 -178.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -80.42 -36.88 33.09 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 124.073 0.949 . . . . 0.0 110.056 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -71.44 -174.71 1.12 Allowed 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.616 1.566 . . . . 0.0 113.935 -168.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -147.93 -50.33 0.02 OUTLIER Glycine 0 CA--C 1.491 -1.434 0 N-CA-C 106.442 -2.663 . . . . 0.0 106.442 -178.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 49.4 mm-40 65.25 56.89 0.96 Allowed 'General case' 0 C--N 1.357 0.933 0 C-N-CA 126.126 1.77 . . . . 0.0 110.946 177.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 8.7 p80 -123.61 -164.65 1.24 Allowed 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 105.22 -2.141 . . . . 0.0 105.22 178.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 11.8 pt -95.83 143.82 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.262 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 175.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 48.0 m80 70.39 23.99 4.79 Favored 'General case' 0 C--N 1.356 0.888 0 C-N-CA 126.15 1.78 . . . . 0.0 109.91 -169.326 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 82.3 t60 . . . . . 0 C--O 1.259 1.581 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 178.959 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.347 0.594 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -84.16 -20.34 32.58 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 125.012 1.325 . . . . 0.0 107.951 170.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . 0.426 ' CG ' ' H ' ' A' ' 4' ' ' LEU . 31.8 t0 -93.08 -143.13 0.22 Allowed 'General case' 0 N--CA 1.422 -1.86 0 N-CA-C 103.56 -2.755 . . . . 0.0 103.56 170.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.426 ' H ' ' CG ' ' A' ' 3' ' ' ASP . 0.8 OUTLIER -64.71 155.71 81.25 Favored Pre-proline 0 N--CA 1.445 -0.712 0 C-N-CA 127.755 2.422 . . . . 0.0 111.471 -177.382 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -79.42 -175.34 2.68 Favored 'Trans proline' 0 CA--C 1.5 -1.199 0 C-N-CA 122.241 1.961 . . . . 0.0 112.026 -169.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 -112.4 -63.71 1.39 Allowed 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -82.62 -13.48 56.43 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 124.298 1.039 . . . . 0.0 110.139 -175.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.09 7.88 65.52 Favored Glycine 0 C--N 1.355 1.618 0 C-N-CA 123.702 0.668 . . . . 0.0 111.784 178.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 66.9 m170 -102.99 -30.68 10.63 Favored 'General case' 0 CA--C 1.503 -0.858 0 C-N-CA 124.975 1.31 . . . . 0.0 107.775 171.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 31.9 mm -75.14 -38.74 42.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 C-N-CA 125.832 1.653 . . . . 0.0 110.27 -170.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -77.97 -8.49 58.21 Favored 'General case' 0 N--CA 1.441 -0.915 0 C-N-CA 123.507 0.723 . . . . 0.0 111.435 -176.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -101.48 -31.05 3.12 Favored 'Isoleucine or valine' 0 C--N 1.357 0.899 0 C-N-CA 125.139 1.376 . . . . 0.0 108.679 -177.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.9 pptp? -79.49 -19.13 50.49 Favored 'General case' 0 CA--C 1.472 -2.023 0 N-CA-C 115.107 1.521 . . . . 0.0 115.107 -166.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 28.7 m -67.87 -32.09 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 C-N-CA 125.077 1.351 . . . . 0.0 110.72 175.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -84.58 -24.26 29.28 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-N 112.6 -2.091 . . . . 0.0 109.912 -177.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -73.19 -45.45 56.35 Favored 'General case' 0 C--N 1.356 0.865 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 43.2 m170 -69.73 158.65 34.99 Favored 'General case' 0 N--CA 1.425 -1.707 0 C-N-CA 125.869 1.668 . . . . 0.0 111.527 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -178.73 55.02 0.09 OUTLIER Glycine 0 CA--C 1.491 -1.442 0 N-CA-C 107.085 -2.406 . . . . 0.0 107.085 178.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 67.16 100.5 0.05 OUTLIER 'General case' 0 C--N 1.358 0.937 0 C-N-CA 126.716 2.007 . . . . 0.0 111.763 178.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -97.23 175.47 6.27 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.9 pp -88.85 173.03 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 C-N-CA 124.666 1.186 . . . . 0.0 108.99 179.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -96.46 -65.55 0.96 Allowed 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 105.674 -1.973 . . . . 0.0 105.674 174.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 63.7 t-80 . . . . . 0 C--O 1.26 1.651 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 179.853 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -88.89 -62.89 1.38 Allowed 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 172.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -155.12 104.12 2.43 Favored 'General case' 0 N--CA 1.432 -1.358 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 172.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -94.77 161.29 29.14 Favored Pre-proline 0 N--CA 1.444 -0.733 0 C-N-CA 124.607 1.163 . . . . 0.0 108.367 -178.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -77.58 -170.93 1.04 Allowed 'Trans proline' 0 CA--C 1.499 -1.231 0 C-N-CA 122.416 2.077 . . . . 0.0 112.43 -171.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -70.63 -37.86 73.83 Favored 'General case' 0 CA--C 1.504 -0.801 0 C-N-CA 126.253 1.821 . . . . 0.0 109.696 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -82.57 -12.65 57.57 Favored 'General case' 0 C--N 1.354 0.792 0 C-N-CA 125.149 1.38 . . . . 0.0 109.913 177.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.03 8.42 76.51 Favored Glycine 0 C--N 1.356 1.655 0 C-N-CA 124.253 0.93 . . . . 0.0 111.873 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -92.94 -32.45 14.55 Favored 'General case' 0 CA--C 1.503 -0.858 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.1 mp -76.82 -32.75 20.53 Favored 'Isoleucine or valine' 0 C--N 1.354 0.785 0 C-N-CA 125.734 1.613 . . . . 0.0 109.811 -174.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -71.94 -16.47 62.1 Favored 'General case' 0 C--N 1.35 0.628 0 C-N-CA 123.342 0.657 . . . . 0.0 112.384 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.9 t -98.92 -36.85 5.79 Favored 'Isoleucine or valine' 0 C--N 1.358 0.96 0 C-N-CA 124.103 0.961 . . . . 0.0 108.718 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.57 -19.35 57.99 Favored 'General case' 0 CA--C 1.471 -2.069 0 N-CA-C 114.505 1.298 . . . . 0.0 114.505 -168.057 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.87 -33.61 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.187 0 C-N-CA 125.771 1.628 . . . . 0.0 111.226 177.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -77.2 -28.86 54.06 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.617 -2.083 . . . . 0.0 110.863 -176.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 -80.07 -43.3 22.06 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 123.92 0.888 . . . . 0.0 108.63 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 16.7 t-160 -61.36 -51.71 67.67 Favored 'General case' 0 N--CA 1.428 -1.536 0 C-N-CA 127.149 2.179 . . . . 0.0 112.753 -175.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -86.33 -34.61 11.93 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 124.453 1.025 . . . . 0.0 111.551 -172.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 58.7 mm-40 66.01 81.04 0.21 Allowed 'General case' 0 C--N 1.36 1.046 0 C-N-CA 125.86 1.664 . . . . 0.0 109.491 -172.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 28.9 m80 -90.51 125.16 35.51 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 -174.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.2 mm -87.63 -83.78 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.61 0 C-N-CA 125.02 1.328 . . . . 0.0 107.467 -170.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -91.05 -58.19 2.55 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 106.722 -1.585 . . . . 0.0 106.722 178.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 . . . . . 0 C--O 1.26 1.654 0 C-N-CA 124.656 1.182 . . . . 0.0 107.819 -178.031 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 88.39 -65.94 0.02 OUTLIER 'General case' 0 CA--C 1.496 -1.119 0 C-N-CA 129.501 3.121 . . . . 0.0 109.305 171.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -165.12 106.24 0.79 Allowed 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 105.454 -2.054 . . . . 0.0 105.454 -178.175 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -150.03 167.0 13.89 Favored Pre-proline 0 N--CA 1.44 -0.945 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -76.02 -172.01 1.23 Allowed 'Trans proline' 0 CA--C 1.497 -1.334 0 C-N-CA 122.748 2.299 . . . . 0.0 112.293 -171.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.1 m-80 -63.23 -47.62 81.71 Favored 'General case' 0 CA--C 1.505 -0.767 0 C-N-CA 126.944 2.098 . . . . 0.0 111.261 -175.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -84.95 -10.96 56.53 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.546 1.138 . . . . 0.0 109.845 178.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.62 -22.98 78.59 Favored Glycine 0 C--N 1.355 1.628 0 C-N-CA 125.162 1.363 . . . . 0.0 111.877 178.262 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -71.12 -40.79 71.21 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 117.934 0.867 . . . . 0.0 111.08 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.8 mp -76.05 -36.51 31.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 C-N-CA 124.925 1.29 . . . . 0.0 110.558 -170.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -81.24 -3.8 53.51 Favored 'General case' 0 N--CA 1.446 -0.664 0 O-C-N 121.828 -0.545 . . . . 0.0 112.374 -176.465 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.5 t -112.2 -26.13 3.21 Favored 'Isoleucine or valine' 0 C--N 1.358 0.969 0 C-N-CA 124.424 1.09 . . . . 0.0 108.486 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.73 -20.59 49.64 Favored 'General case' 0 CA--C 1.471 -2.09 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -173.62 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.3 p -64.47 -35.71 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.327 0 C-N-CA 125.009 1.324 . . . . 0.0 110.619 174.004 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -83.01 -24.78 32.72 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-N 112.898 -1.955 . . . . 0.0 109.939 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.2 t-20 -72.25 -43.31 64.55 Favored 'General case' 0 C--N 1.356 0.888 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.5 m170 -78.17 -170.25 1.9 Allowed 'General case' 0 N--CA 1.421 -1.896 0 C-N-CA 126.634 1.974 . . . . 0.0 110.215 176.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -128.18 50.78 0.87 Allowed Glycine 0 C--N 1.352 1.437 0 N-CA-C 106.138 -2.785 . . . . 0.0 106.138 175.141 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -107.38 70.26 0.78 Allowed 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -120.91 -107.19 0.36 Allowed 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 103.868 -2.642 . . . . 0.0 103.868 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.8 pp -86.0 164.42 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 170.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -140.07 32.07 1.96 Allowed 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 61.9 m80 . . . . . 0 C--O 1.259 1.603 0 C-N-CA 125.966 1.706 . . . . 0.0 111.152 175.808 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 121.583 0.706 . . . . 0.0 110.677 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -90.61 -84.67 0.24 Allowed 'General case' 0 N--CA 1.44 -0.945 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 -179.205 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -158.98 105.54 1.77 Allowed 'General case' 0 N--CA 1.432 -1.369 0 N-CA-C 104.064 -2.569 . . . . 0.0 104.064 176.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 85.6 mt -96.26 163.55 20.5 Favored Pre-proline 0 N--CA 1.442 -0.853 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -77.38 -174.84 2.37 Favored 'Trans proline' 0 CA--C 1.499 -1.259 0 C-N-CA 123.192 2.594 . . . . 0.0 110.328 179.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -66.43 -39.46 88.94 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 125.792 1.637 . . . . 0.0 110.741 -178.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -83.92 -14.99 49.61 Favored 'General case' 0 C--N 1.352 0.713 0 C-N-CA 124.796 1.239 . . . . 0.0 110.159 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.57 -2.83 72.35 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -93.84 -11.35 31.38 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 118.007 0.903 . . . . 0.0 108.983 174.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 47.8 mm -77.09 -36.21 24.31 Favored 'Isoleucine or valine' 0 C--N 1.356 0.861 0 C-N-CA 125.008 1.323 . . . . 0.0 108.842 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.39 0.65 40.99 Favored 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 122.896 0.478 . . . . 0.0 111.436 -179.089 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.78 -40.59 9.26 Favored 'Isoleucine or valine' 0 C--N 1.358 0.94 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 171.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.25 -17.58 58.3 Favored 'General case' 0 CA--C 1.47 -2.106 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -167.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -63.67 -34.41 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 C-N-CA 125.402 1.481 . . . . 0.0 110.826 176.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -80.44 -29.81 37.58 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 112.724 -2.035 . . . . 0.0 110.357 -177.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.5 t30 -73.05 -40.99 64.64 Favored 'General case' 0 C--N 1.354 0.774 0 C-N-CA 124.216 1.007 . . . . 0.0 108.609 176.449 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -71.96 158.73 35.48 Favored 'General case' 0 N--CA 1.418 -2.026 0 C-N-CA 127.462 2.305 . . . . 0.0 110.266 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -150.36 -85.28 0.05 OUTLIER Glycine 0 CA--C 1.489 -1.558 0 N-CA-C 105.42 -3.072 . . . . 0.0 105.42 179.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 58.07 96.83 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.027 0 C-N-CA 127.247 2.219 . . . . 0.0 114.343 177.704 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -96.6 -105.55 0.17 Allowed 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 19.3 pt -87.42 156.81 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 C-N-CA 124.178 0.991 . . . . 0.0 108.518 177.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 57.5 t-80 -93.73 -59.12 2.07 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 105.894 -1.891 . . . . 0.0 105.894 175.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 62.6 t-80 . . . . . 0 C--O 1.26 1.617 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 179.119 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 . . . . . 0 N--CA 1.487 1.418 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 61.94 6.28 1.65 Allowed 'General case' 0 C--N 1.356 0.86 0 C-N-CA 126.603 1.961 . . . . 0.0 114.141 -172.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 71.37 99.25 0.07 Allowed 'General case' 0 N--CA 1.438 -1.055 0 C-N-CA 129.361 3.064 . . . . 0.0 109.174 -166.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 95.1 mt -82.63 157.53 67.05 Favored Pre-proline 0 N--CA 1.444 -0.774 0 C-N-CA 124.395 1.078 . . . . 0.0 108.58 178.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -78.35 -176.73 3.42 Favored 'Trans proline' 0 CA--C 1.501 -1.132 0 C-N-CA 122.864 2.376 . . . . 0.0 111.315 -172.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -110.02 -67.68 0.97 Allowed 'General case' 0 CA--C 1.498 -1.023 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 177.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -88.94 1.31 55.63 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.681 1.192 . . . . 0.0 110.784 -174.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.95 -10.44 80.85 Favored Glycine 0 C--N 1.356 1.666 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 176.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.4 m-70 -95.04 -31.22 13.7 Favored 'General case' 0 CA--C 1.502 -0.876 0 C-N-CA 124.122 0.969 . . . . 0.0 108.701 173.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.2 mt -75.82 -33.39 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 C-N-CA 125.508 1.523 . . . . 0.0 110.6 -171.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -74.1 -13.14 60.79 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 123.506 0.722 . . . . 0.0 112.163 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.14 -33.18 3.93 Favored 'Isoleucine or valine' 0 C--N 1.357 0.915 0 C-N-CA 124.766 1.226 . . . . 0.0 108.957 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.74 -19.78 47.94 Favored 'General case' 0 CA--C 1.476 -1.883 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -164.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 m -68.98 -30.24 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 C-N-CA 125.207 1.403 . . . . 0.0 110.822 175.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -87.08 -20.7 26.75 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.472 -2.149 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -75.7 -31.25 59.61 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.174 0.99 . . . . 0.0 109.056 177.167 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 56.5 m170 -57.85 142.74 44.86 Favored 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 125.704 1.602 . . . . 0.0 112.379 177.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -106.83 -119.95 4.55 Favored Glycine 0 C--N 1.354 1.562 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -173.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -104.47 67.52 0.83 Allowed 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 -174.302 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 24.0 p80 -147.67 171.4 15.69 Favored 'General case' 0 N--CA 1.437 -1.086 0 N-CA-C 105.96 -1.866 . . . . 0.0 105.96 173.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 20.4 pt -83.67 151.61 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 123.957 0.903 . . . . 0.0 109.665 -176.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 65.6 t60 -153.13 62.07 0.77 Allowed 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 104.662 -2.347 . . . . 0.0 104.662 176.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 68.3 m80 . . . . . 0 C--O 1.261 1.685 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 179.718 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.631 0.729 . . . . 0.0 110.978 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 62.7 mm-40 -103.3 -55.41 2.41 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -165.59 110.62 0.87 Allowed 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 -177.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 5.3 mp -76.96 154.6 82.94 Favored Pre-proline 0 N--CA 1.444 -0.725 0 C-N-CA 124.504 1.122 . . . . 0.0 108.897 -178.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -78.21 -176.57 3.32 Favored 'Trans proline' 0 CA--C 1.5 -1.185 0 C-N-CA 122.826 2.35 . . . . 0.0 111.304 -172.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 -128.82 -60.09 1.11 Allowed 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 104.538 -2.393 . . . . 0.0 104.538 176.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -86.68 -1.09 57.42 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.862 1.265 . . . . 0.0 110.898 -174.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.04 -30.02 39.65 Favored Glycine 0 C--N 1.355 1.633 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.1 m80 -76.81 -30.42 56.41 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 124.605 1.162 . . . . 0.0 110.363 177.016 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -73.58 -31.1 31.34 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 C-N-CA 126.029 1.731 . . . . 0.0 109.61 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.38 -27.84 64.63 Favored 'General case' 0 N--CA 1.437 -1.114 0 C-N-CA 125.441 1.497 . . . . 0.0 111.261 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 83.9 t -85.77 -44.87 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.864 0 C-N-CA 123.287 0.635 . . . . 0.0 109.502 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 pptp? -66.69 -21.28 66.09 Favored 'General case' 0 CA--C 1.483 -1.628 0 N-CA-C 116.191 1.922 . . . . 0.0 116.191 -160.279 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -55.39 -30.66 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 C-N-CA 127.953 2.501 . . . . 0.0 113.127 176.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.19 -37.24 71.86 Favored 'General case' 0 CA--C 1.509 -0.629 0 C-N-CA 127.903 2.481 . . . . 0.0 112.974 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -75.61 -47.3 27.17 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 126.007 1.723 . . . . 0.0 108.474 -177.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 44.0 m170 -59.91 -43.34 94.94 Favored 'General case' 0 N--CA 1.432 -1.346 0 C-N-CA 126.22 1.808 . . . . 0.0 113.216 -175.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -168.64 -111.93 0.25 Allowed Glycine 0 N--CA 1.434 -1.458 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 66.5 83.04 0.17 Allowed 'General case' 0 C--N 1.356 0.89 0 C-N-CA 126.89 2.076 . . . . 0.0 109.208 -166.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 65.1 m80 70.63 -110.6 0.07 Allowed 'General case' 0 C--N 1.358 0.952 0 C-N-CA 126.217 1.807 . . . . 0.0 108.497 -173.167 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 24.6 pt -88.38 173.46 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 124.634 1.174 . . . . 0.0 108.263 176.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 86.7 t60 -83.5 -40.67 18.9 Favored 'General case' 0 CA--C 1.501 -0.915 0 C-N-CA 123.859 0.864 . . . . 0.0 109.688 -177.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 63.6 t-80 . . . . . 0 C--O 1.261 1.664 0 C-N-CA 124.527 1.131 . . . . 0.0 109.65 -174.588 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 26.6 t80 . . . . . 0 N--CA 1.483 1.196 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -114.39 -68.14 0.95 Allowed 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 105.811 -1.922 . . . . 0.0 105.811 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -156.56 104.66 2.19 Favored 'General case' 0 N--CA 1.433 -1.322 0 N-CA-C 104.534 -2.395 . . . . 0.0 104.534 177.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 91.0 mt -102.73 159.46 29.25 Favored Pre-proline 0 N--CA 1.442 -0.859 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 179.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -78.17 -177.9 4.22 Favored 'Trans proline' 0 CA--C 1.501 -1.173 0 C-N-CA 122.879 2.386 . . . . 0.0 111.124 -172.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -119.36 -62.35 1.52 Allowed 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -82.69 -5.19 58.73 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.928 1.291 . . . . 0.0 111.371 -173.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -84.93 2.35 88.31 Favored Glycine 0 C--N 1.356 1.644 0 C-N-CA 124.064 0.84 . . . . 0.0 111.288 176.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -112.3 -26.62 8.67 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.207 1.403 . . . . 0.0 108.302 175.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.7 mt -75.73 -34.44 28.49 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 125.503 1.521 . . . . 0.0 109.888 -176.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.33 -11.06 59.79 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 123.799 0.84 . . . . 0.0 111.994 -179.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.7 t -98.17 -31.35 3.71 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 124.696 1.198 . . . . 0.0 108.93 -175.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.58 -19.25 58.07 Favored 'General case' 0 CA--C 1.475 -1.92 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -167.475 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.3 m -63.86 -31.37 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 C-N-CA 126.31 1.844 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -77.07 -34.72 56.99 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.252 -2.249 . . . . 0.0 109.972 -176.168 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 37.4 t30 -74.67 -43.39 55.5 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 124.369 1.068 . . . . 0.0 108.85 177.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.1 t-80 -60.06 146.64 42.19 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 127.124 2.17 . . . . 0.0 112.637 -175.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.11 -32.41 0.19 Allowed Glycine 0 N--CA 1.435 -1.422 0 N-CA-C 106.775 -2.53 . . . . 0.0 106.775 -177.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 47.5 mm-40 68.86 85.18 0.14 Allowed 'General case' 0 C--N 1.359 1.021 0 C-N-CA 126.839 2.056 . . . . 0.0 109.856 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.475 ' H ' ' CE1' ' A' ' 23' ' ' HIS . 66.0 m-70 -103.28 -167.63 1.41 Allowed 'General case' 0 N--CA 1.437 -1.099 0 C-N-CA 124.412 1.085 . . . . 0.0 108.351 -170.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.508 HD13 ' H ' ' A' ' 21' ' ' ILE . 0.1 OUTLIER -91.34 170.9 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.331 0 C-N-CA 125.008 1.323 . . . . 0.0 108.17 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 58.5 t60 72.92 17.01 4.34 Favored 'General case' 0 C--N 1.357 0.924 0 C-N-CA 126.722 2.009 . . . . 0.0 110.791 -176.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . 0.475 ' CE1' ' H ' ' A' ' 20' ' ' HIS . 38.6 m170 . . . . . 0 C--O 1.259 1.598 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 177.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 61.5 mm-40 -108.11 13.9 25.55 Favored 'General case' 0 C--N 1.353 0.747 0 C-N-CA 125.331 1.453 . . . . 0.0 107.783 174.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . 0.447 2.3 p30 73.22 112.25 0.06 Allowed 'General case' 0 C--N 1.356 0.851 0 C-N-CA 129.668 3.187 . . . . 0.0 110.164 -171.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 79.7 mt -101.06 163.82 17.23 Favored Pre-proline 0 N--CA 1.441 -0.898 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -172.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -77.58 -179.52 5.52 Favored 'Trans proline' 0 CA--C 1.499 -1.247 0 C-N-CA 123.076 2.517 . . . . 0.0 110.314 -176.018 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -65.2 -53.26 47.36 Favored 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 126.295 1.838 . . . . 0.0 110.085 -174.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -79.05 -17.06 55.92 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 124.511 1.125 . . . . 0.0 110.247 -178.569 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.56 29.67 7.6 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.107 0.861 . . . . 0.0 111.078 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 55.3 m-70 -112.64 -35.11 5.61 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 168.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mp -73.06 -44.75 56.05 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 109.243 -173.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 3.2 pp0? -78.69 -6.48 55.87 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.529 0.732 . . . . 0.0 112.22 -176.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.91 -28.2 3.82 Favored 'Isoleucine or valine' 0 C--N 1.358 0.949 0 C-N-CA 124.325 1.05 . . . . 0.0 109.171 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.69 -21.7 54.99 Favored 'General case' 0 CA--C 1.473 -2.006 0 N-CA-C 114.181 1.178 . . . . 0.0 114.181 -169.427 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.4 m -64.98 -28.78 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 126.629 1.971 . . . . 0.0 111.428 -176.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -71.6 -41.5 68.87 Favored 'General case' 0 CA--C 1.506 -0.746 0 CA-C-N 111.84 -2.436 . . . . 0.0 109.947 -175.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -80.94 -41.82 22.3 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.463 1.105 . . . . 0.0 109.594 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 71.0 t60 -62.5 -63.86 1.1 Allowed 'General case' 0 N--CA 1.426 -1.634 0 C-N-CA 127.933 2.493 . . . . 0.0 112.452 -170.065 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.23 -116.52 3.0 Favored Glycine 0 CA--C 1.492 -1.373 0 N-CA-C 107.631 -2.188 . . . . 0.0 107.631 -178.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -150.5 48.63 0.88 Allowed 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 -178.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 16.2 m80 72.91 156.27 0.17 Allowed 'General case' 0 C--N 1.354 0.79 0 C-N-CA 126.838 2.055 . . . . 0.0 112.524 175.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 24.3 pt -100.62 -165.82 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 176.573 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 56.7 m170 -82.88 -39.53 21.46 Favored 'General case' 0 CA--C 1.501 -0.905 0 C-N-CA 124.315 1.046 . . . . 0.0 110.06 -177.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 82.7 t60 . . . . . 0 C--O 1.26 1.62 0 CA-C-O 117.796 -1.097 . . . . 0.0 109.534 -177.215 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 . . . . . 0 N--CA 1.488 1.463 0 CA-C-O 122.058 0.932 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -85.46 -36.22 20.74 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 173.574 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 40.6 m-20 76.03 99.69 0.07 Allowed 'General case' 0 CA--C 1.498 -1.045 0 C-N-CA 127.768 2.427 . . . . 0.0 108.775 -177.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 5.7 mp -101.04 159.21 30.14 Favored Pre-proline 0 N--CA 1.438 -1.052 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 -171.083 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -77.9 -176.72 3.38 Favored 'Trans proline' 0 CA--C 1.5 -1.219 0 C-N-CA 122.87 2.38 . . . . 0.0 111.302 -173.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -118.19 -65.88 1.13 Allowed 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 178.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -81.13 -12.46 59.24 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.445 1.098 . . . . 0.0 110.004 -178.028 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.27 9.32 61.42 Favored Glycine 0 C--N 1.356 1.694 0 C-N-CA 123.652 0.644 . . . . 0.0 112.145 178.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -109.43 -32.02 7.31 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 168.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.3 -34.55 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.827 0 C-N-CA 125.933 1.693 . . . . 0.0 110.956 -170.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -80.12 -24.66 40.33 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.149 0.58 . . . . 0.0 110.608 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t -81.92 -28.34 9.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.813 0 C-N-CA 125.224 1.41 . . . . 0.0 109.803 -175.283 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.85 -19.17 57.81 Favored 'General case' 0 CA--C 1.477 -1.846 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 -171.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 82.1 t -67.55 -36.02 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.227 0 C-N-CA 125.454 1.502 . . . . 0.0 108.67 176.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -85.76 -23.86 27.11 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.659 -1.609 . . . . 0.0 108.808 -175.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -73.95 -35.23 64.53 Favored 'General case' 0 N--CA 1.44 -0.948 0 C-N-CA 123.922 0.889 . . . . 0.0 108.776 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.94 137.09 53.5 Favored 'General case' 0 N--CA 1.427 -1.602 0 C-N-CA 124.5 1.12 . . . . 0.0 109.437 174.801 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.26 -16.12 61.32 Favored Glycine 0 C--N 1.354 1.547 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -174.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 57.4 mm-40 64.68 64.81 0.65 Allowed 'General case' 0 C--N 1.359 0.992 0 C-N-CA 127.254 2.222 . . . . 0.0 111.129 179.325 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 -94.8 -66.5 0.91 Allowed 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 176.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 13.3 pt -89.41 161.5 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.332 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 164.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -131.14 -48.74 1.01 Allowed 'General case' 0 CA--C 1.493 -1.239 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -174.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 56.4 m170 . . . . . 0 C--O 1.26 1.614 0 C-N-CA 126.151 1.78 . . . . 0.0 111.084 -178.735 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 25.6 t80 . . . . . 0 N--CA 1.483 1.208 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 66.4 mm-40 -124.69 -70.61 0.75 Allowed 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 105.026 -2.213 . . . . 0.0 105.026 -177.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 43.4 m-20 -149.64 106.09 3.51 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 103.076 -2.935 . . . . 0.0 103.076 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 90.0 mt -90.26 160.69 39.32 Favored Pre-proline 0 N--CA 1.443 -0.796 0 C-N-CA 125.097 1.359 . . . . 0.0 107.691 176.094 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -77.1 -179.78 5.76 Favored 'Trans proline' 0 CA--C 1.5 -1.206 0 C-N-CA 123.199 2.599 . . . . 0.0 110.499 -176.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -70.83 -47.42 59.48 Favored 'General case' 0 CA--C 1.501 -0.922 0 C-N-CA 125.652 1.581 . . . . 0.0 110.284 -173.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -79.66 -18.04 52.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 C-N-CA 124.585 1.154 . . . . 0.0 109.877 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.41 28.82 6.54 Favored Glycine 0 C--N 1.357 1.718 0 C-N-CA 124.376 0.989 . . . . 0.0 111.241 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -115.22 -32.43 5.67 Favored 'General case' 0 CA--C 1.501 -0.916 0 C-N-CA 124.654 1.182 . . . . 0.0 108.08 171.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.0 mp -80.59 -37.95 17.16 Favored 'Isoleucine or valine' 0 C--N 1.354 0.774 0 C-N-CA 125.19 1.396 . . . . 0.0 109.005 -172.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -83.32 11.53 6.6 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.435 0.694 . . . . 0.0 111.378 179.16 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 82.0 t -118.16 -33.34 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 C-N-CA 125.253 1.421 . . . . 0.0 107.713 178.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.87 -21.65 40.5 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -170.731 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 p -65.93 -33.72 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 C-N-CA 125.317 1.447 . . . . 0.0 110.751 175.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -81.68 -24.97 35.92 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 112.797 -2.001 . . . . 0.0 110.052 -178.595 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -71.78 -46.7 57.49 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 54.3 m-70 -72.26 160.76 31.85 Favored 'General case' 0 N--CA 1.424 -1.767 0 C-N-CA 124.701 1.201 . . . . 0.0 112.126 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -119.48 -9.53 8.46 Favored Glycine 0 C--N 1.351 1.38 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 174.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -104.33 44.44 1.02 Allowed 'General case' 0 C--N 1.359 1.017 0 CA-C-O 122.7 1.238 . . . . 0.0 108.83 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -161.73 144.04 11.69 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 104.0 -2.592 . . . . 0.0 104.0 177.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 16.8 pt -86.38 149.1 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 178.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 58.3 m170 -91.97 -36.67 13.29 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -176.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 22.9 p80 . . . . . 0 C--O 1.261 1.683 0 C-N-CA 124.785 1.234 . . . . 0.0 110.965 177.67 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 . . . . . 0 N--CA 1.488 1.468 0 CA-C-O 121.982 0.896 . . . . 0.0 111.023 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 59.0 mm-40 -89.67 -21.39 22.78 Favored 'General case' 0 N--CA 1.443 -0.812 0 C-N-CA 124.703 1.201 . . . . 0.0 108.583 175.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 44.1 m-20 77.8 102.6 0.07 Allowed 'General case' 0 C--N 1.359 0.986 0 C-N-CA 127.877 2.471 . . . . 0.0 108.347 -176.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 64.7 mt -96.41 157.06 36.1 Favored Pre-proline 0 N--CA 1.44 -0.944 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 -169.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -79.37 179.12 6.67 Favored 'Trans proline' 0 CA--C 1.501 -1.148 0 C-N-CA 122.767 2.311 . . . . 0.0 110.902 -170.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -121.0 -56.83 1.91 Allowed 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -85.05 -1.29 56.66 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.733 1.213 . . . . 0.0 110.773 -177.005 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -88.79 8.42 79.53 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.236 0.922 . . . . 0.0 110.929 175.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.1 t60 -106.84 -31.21 8.48 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 173.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -74.83 -38.46 44.1 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.889 0 C-N-CA 125.127 1.371 . . . . 0.0 108.798 -174.069 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.0 4.59 11.82 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 179.123 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -105.79 -38.36 4.45 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 C-N-CA 124.909 1.284 . . . . 0.0 108.411 173.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.63 -21.75 51.78 Favored 'General case' 0 CA--C 1.476 -1.868 0 N-CA-C 115.122 1.527 . . . . 0.0 115.122 -163.756 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.9 m -69.35 -29.66 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 C-N-CA 125.468 1.507 . . . . 0.0 110.99 176.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -86.87 -24.74 24.79 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 112.513 -2.131 . . . . 0.0 109.866 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -72.21 -41.09 67.32 Favored 'General case' 0 C--N 1.356 0.868 0 C-N-CA 124.378 1.071 . . . . 0.0 108.202 176.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 57.2 m170 -62.87 -50.2 71.86 Favored 'General case' 0 N--CA 1.428 -1.542 0 C-N-CA 126.301 1.841 . . . . 0.0 110.618 174.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.85 100.97 2.68 Favored Glycine 0 CA--C 1.491 -1.435 0 N-CA-C 107.441 -2.264 . . . . 0.0 107.441 175.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -100.4 64.89 1.18 Allowed 'General case' 0 C--N 1.355 0.819 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 176.245 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -81.48 -67.87 0.74 Allowed 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 21.0 pt -85.19 158.73 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 125.28 1.432 . . . . 0.0 108.017 174.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -137.09 59.72 1.68 Allowed 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 104.497 -2.408 . . . . 0.0 104.497 177.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 26.8 p80 . . . . . 0 C--O 1.258 1.545 0 C-N-CA 126.928 2.091 . . . . 0.0 112.835 -179.016 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 5.9 t80 . . . . . 0 N--CA 1.487 1.424 0 N-CA-C 110.683 -0.118 . . . . 0.0 110.683 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 76.54 -4.34 2.37 Favored 'General case' 0 N--CA 1.441 -0.901 0 C-N-CA 127.729 2.412 . . . . 0.0 113.224 -176.679 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 72.0 99.43 0.07 Allowed 'General case' 0 CA--C 1.496 -1.11 0 C-N-CA 127.663 2.385 . . . . 0.0 110.878 178.411 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -145.51 159.34 48.41 Favored Pre-proline 0 N--CA 1.441 -0.876 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 176.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -78.69 -178.42 4.62 Favored 'Trans proline' 0 CA--C 1.5 -1.193 0 C-N-CA 122.518 2.145 . . . . 0.0 111.215 -172.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -77.71 -40.71 40.41 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 125.748 1.619 . . . . 0.0 108.407 -178.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -77.88 -13.87 59.74 Favored 'General case' 0 C--N 1.356 0.863 0 C-N-CA 124.557 1.143 . . . . 0.0 109.872 178.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -79.57 0.33 81.65 Favored Glycine 0 C--N 1.357 1.734 0 C-N-CA 124.124 0.868 . . . . 0.0 112.29 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -96.81 -36.23 10.69 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 172.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.2 mt -73.94 -48.47 38.59 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.929 0 C-N-CA 126.073 1.749 . . . . 0.0 110.94 -169.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -75.94 -23.09 55.4 Favored 'General case' 0 CA--C 1.508 -0.671 0 C-N-CA 124.317 1.047 . . . . 0.0 112.397 -171.053 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 84.3 t -81.19 -25.5 10.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 C-N-CA 125.099 1.36 . . . . 0.0 109.658 -175.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 24.9 tptp -84.57 -20.3 31.72 Favored 'General case' 0 N--CA 1.429 -1.501 0 C-N-CA 125.858 1.663 . . . . 0.0 111.454 -171.478 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 58.8 t -60.33 -37.54 74.43 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.927 0 C-N-CA 126.599 1.96 . . . . 0.0 109.563 168.377 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -86.52 -12.35 49.07 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.196 -175.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -80.46 -28.66 37.57 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.38 1.072 . . . . 0.0 108.57 173.263 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 46.3 m170 -60.69 164.49 4.61 Favored 'General case' 0 C--N 1.365 1.276 0 C-N-CA 125.36 1.464 . . . . 0.0 112.754 177.703 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -101.15 70.88 0.4 Allowed Glycine 0 C--N 1.354 1.551 0 N-CA-C 106.122 -2.791 . . . . 0.0 106.122 176.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -95.27 62.11 2.46 Favored 'General case' 0 N--CA 1.442 -0.858 0 C-N-CA 125.575 1.55 . . . . 0.0 108.668 -176.726 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 71.6 m80 -93.49 165.42 12.76 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 31.5 pt -88.92 173.65 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.187 0 C-N-CA 124.446 1.098 . . . . 0.0 108.874 -179.09 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 17.9 p80 -84.88 -32.88 22.95 Favored 'General case' 0 N--CA 1.442 -0.843 0 C-N-CA 124.483 1.113 . . . . 0.0 109.092 177.726 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 70.8 t60 . . . . . 0 C--O 1.261 1.666 0 C-N-CA 126.145 1.778 . . . . 0.0 111.084 177.272 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 CA--C 1.505 -0.755 0 N-CA-C 110.641 -0.133 . . . . 0.0 110.641 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -81.96 -13.12 57.91 Favored 'General case' 0 C--N 1.356 0.862 0 C-N-CA 123.847 0.859 . . . . 0.0 110.125 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -69.95 -28.87 71.27 Favored Glycine 0 C--N 1.356 1.642 0 C-N-CA 123.823 0.725 . . . . 0.0 111.745 178.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.4 t-80 -74.35 -39.54 62.72 Favored 'General case' 0 N--CA 1.434 -1.252 0 C-N-CA 124.778 1.231 . . . . 0.0 111.249 175.137 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.3 mt -73.41 -36.65 49.12 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.731 0 C-N-CA 125.979 1.712 . . . . 0.0 111.435 -169.733 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 19.8 pt20 -77.07 -7.84 56.41 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 123.693 0.797 . . . . 0.0 112.197 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.35 -35.17 3.46 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.766 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.54 -21.23 52.93 Favored 'General case' 0 CA--C 1.47 -2.115 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -169.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -62.07 -32.51 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.272 0 C-N-CA 125.929 1.692 . . . . 0.0 111.529 178.145 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -75.64 -41.52 53.9 Favored 'General case' 0 CA--C 1.503 -0.844 0 CA-C-N 112.658 -2.064 . . . . 0.0 109.959 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.4 t30 -71.37 -32.5 68.56 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.987 1.315 . . . . 0.0 110.386 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.0 t60 . . . . . 0 N--CA 1.421 -1.882 0 C-N-CA 127.701 2.4 . . . . 0.0 110.98 179.896 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 . . . . . 0 CA--C 1.506 -0.712 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -79.66 -23.33 42.57 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.73 1.212 . . . . 0.0 108.866 174.643 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -77.76 -14.4 82.43 Favored Glycine 0 C--N 1.355 1.633 0 C-N-CA 124.39 0.995 . . . . 0.0 111.504 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 32.3 m170 -89.49 -35.52 15.92 Favored 'General case' 0 CA--C 1.502 -0.896 0 C-N-CA 124.244 1.018 . . . . 0.0 108.56 174.417 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -72.57 -30.93 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 C-N-CA 125.898 1.679 . . . . 0.0 111.74 -171.763 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 5.4 pp0? -78.31 -5.96 53.67 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 124.13 0.972 . . . . 0.0 111.927 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.9 t -83.95 -41.18 16.31 Favored 'Isoleucine or valine' 0 C--N 1.357 0.919 0 C-N-CA 124.023 0.929 . . . . 0.0 108.558 174.795 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -72.06 -16.23 62.03 Favored 'General case' 0 CA--C 1.491 -1.306 0 C-N-CA 127.426 2.29 . . . . 0.0 113.009 -165.04 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.1 t -49.55 -37.32 11.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 C-N-CA 129.07 2.948 . . . . 0.0 111.368 170.078 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -55.97 -36.38 67.78 Favored 'General case' 0 C--N 1.349 0.571 0 C-N-CA 126.886 2.074 . . . . 0.0 113.158 -175.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -86.32 -48.59 8.35 Favored 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 126.089 1.756 . . . . 0.0 107.697 -178.292 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 . . . . . 0 N--CA 1.431 -1.376 0 C-N-CA 126.722 2.009 . . . . 0.0 112.706 -175.655 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -80.24 -11.06 59.77 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.474 1.109 . . . . 0.0 110.151 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -73.02 -18.52 79.18 Favored Glycine 0 C--N 1.357 1.712 0 C-N-CA 124.205 0.907 . . . . 0.0 111.857 178.145 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.2 m170 -85.03 -40.63 16.63 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.365 1.066 . . . . 0.0 109.204 175.54 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.2 mt -68.18 -34.69 67.88 Favored 'Isoleucine or valine' 0 C--N 1.352 0.708 0 C-N-CA 127.185 2.194 . . . . 0.0 111.73 -171.202 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -80.25 12.6 2.8 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 124.595 1.158 . . . . 0.0 112.719 -176.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -107.32 -32.7 2.57 Favored 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.1 mmmt -86.65 -9.73 55.37 Favored 'General case' 0 CA--C 1.485 -1.551 0 C-N-CA 124.508 1.123 . . . . 0.0 110.647 -170.178 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.5 p -61.14 -36.74 74.68 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 C-N-CA 126.094 1.758 . . . . 0.0 110.595 170.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -77.37 -29.35 53.25 Favored 'General case' 0 CA--C 1.506 -0.714 0 C-N-CA 126.613 1.965 . . . . 0.0 110.209 -178.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -73.83 -41.07 62.83 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.368 1.067 . . . . 0.0 109.091 177.291 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 35.5 m-70 . . . . . 0 N--CA 1.428 -1.552 0 C-N-CA 125.357 1.463 . . . . 0.0 110.222 178.245 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.5 m120 . . . . . 0 CA--C 1.503 -0.827 0 CA-C-O 120.354 0.121 . . . . 0.0 111.247 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -84.8 -10.23 57.4 Favored 'General case' 0 CA--C 1.505 -0.76 0 C-N-CA 124.452 1.101 . . . . 0.0 110.045 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.7 5.36 83.92 Favored Glycine 0 C--N 1.355 1.585 0 C-N-CA 124.09 0.852 . . . . 0.0 111.966 179.015 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.2 m-70 -91.37 -40.33 11.51 Favored 'General case' 0 CA--C 1.501 -0.908 0 C-N-CA 123.893 0.877 . . . . 0.0 108.645 175.485 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.3 mp -72.51 -32.7 42.71 Favored 'Isoleucine or valine' 0 C--N 1.352 0.694 0 C-N-CA 126.476 1.91 . . . . 0.0 110.488 -171.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 4.4 pp0? -80.75 9.07 6.76 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.884 0.873 . . . . 0.0 112.493 -177.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -97.65 -33.27 4.26 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 171.115 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 mmmt -89.63 -8.75 51.84 Favored 'General case' 0 CA--C 1.483 -1.608 0 C-N-CA 124.843 1.257 . . . . 0.0 111.208 -166.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.9 p -64.23 -37.35 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 C-N-CA 125.295 1.438 . . . . 0.0 110.315 168.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -79.1 -26.87 42.9 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.898 -178.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -75.71 -40.36 55.82 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.263 1.025 . . . . 0.0 109.219 178.106 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.432 -1.355 0 C-N-CA 124.909 1.284 . . . . 0.0 113.072 -172.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 . . . . . 0 CA--C 1.498 -1.03 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 35.4 t80 -80.97 -10.17 59.75 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.489 1.115 . . . . 0.0 110.313 -177.23 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.06 3.32 77.21 Favored Glycine 0 C--N 1.356 1.686 0 C-N-CA 123.908 0.765 . . . . 0.0 112.005 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 58.5 m170 -109.04 -31.9 7.44 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.174 1.389 . . . . 0.0 107.782 174.164 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -76.71 -33.53 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.742 0 C-N-CA 125.827 1.651 . . . . 0.0 110.563 -172.526 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.53 -16.98 58.36 Favored 'General case' 0 N--CA 1.445 -0.695 0 C-N-CA 123.495 0.718 . . . . 0.0 111.515 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -91.1 -43.04 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 C-N-CA 124.15 0.98 . . . . 0.0 109.072 -176.594 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -19.68 65.11 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -163.685 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.4 m -57.28 -29.42 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.268 0 C-N-CA 127.916 2.487 . . . . 0.0 113.191 177.429 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.12 -36.77 71.05 Favored 'General case' 0 CA--C 1.511 -0.533 0 C-N-CA 127.745 2.418 . . . . 0.0 112.661 -176.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -70.07 -53.84 15.69 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 126.49 1.916 . . . . 0.0 108.98 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 . . . . . 0 N--CA 1.428 -1.539 0 C-N-CA 125.172 1.389 . . . . 0.0 112.897 -173.706 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 4.0 p30 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -82.46 -5.78 58.9 Favored 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 173.724 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.72 24.94 9.14 Favored Glycine 0 C--N 1.356 1.666 0 C-N-CA 124.506 1.051 . . . . 0.0 110.803 175.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.7 m-70 -114.29 -40.48 3.65 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 168.346 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.6 mp -76.71 -42.82 34.17 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.98 0 C-N-CA 125.91 1.684 . . . . 0.0 110.173 -172.452 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -76.78 -26.25 54.28 Favored 'General case' 0 CA--C 1.508 -0.649 0 O-C-N 121.956 -0.465 . . . . 0.0 110.71 -177.378 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.9 t -78.23 -24.26 13.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 C-N-CA 125.345 1.458 . . . . 0.0 109.976 -175.662 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.67 -25.56 53.83 Favored 'General case' 0 CA--C 1.475 -1.923 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -176.422 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.7 -33.06 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 C-N-CA 125.207 1.403 . . . . 0.0 108.286 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 15.8 m-30 -81.45 -28.5 34.15 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 113.317 -1.765 . . . . 0.0 108.787 -172.413 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -75.89 -46.0 32.45 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.06 1.344 . . . . 0.0 108.521 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 . . . . . 0 N--CA 1.425 -1.677 0 C-N-CA 126.466 1.906 . . . . 0.0 111.649 -175.698 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.3 m-80 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -83.6 2.2 38.48 Favored 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.604 1.161 . . . . 0.0 110.83 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 12.68 66.48 Favored Glycine 0 C--N 1.355 1.62 0 C-N-CA 124.37 0.986 . . . . 0.0 110.745 173.268 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -118.44 -27.23 6.02 Favored 'General case' 0 C--N 1.355 0.845 0 C-N-CA 124.93 1.292 . . . . 0.0 108.834 174.002 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -76.85 -40.26 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.997 0 C-N-CA 125.198 1.399 . . . . 0.0 108.062 -177.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -66.23 -25.17 66.78 Favored 'General case' 0 C--N 1.348 0.514 0 C-N-CA 123.834 0.854 . . . . 0.0 112.375 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 66.5 t -73.81 -29.19 25.62 Favored 'Isoleucine or valine' 0 C--N 1.357 0.914 0 C-N-CA 125.464 1.506 . . . . 0.0 110.132 -176.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.08 -25.7 52.63 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -174.416 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 88.5 t -68.63 -33.32 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 125.163 1.385 . . . . 0.0 108.149 179.228 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.4 m-30 -80.29 -28.29 38.34 Favored 'General case' 0 CA--C 1.504 -0.801 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.351 -172.007 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -76.07 -43.13 45.07 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.838 1.255 . . . . 0.0 108.211 176.239 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 81.4 t60 . . . . . 0 N--CA 1.421 -1.912 0 C-N-CA 127.268 2.227 . . . . 0.0 110.913 -178.319 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 . . . . . 0 N--CA 1.446 -0.65 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -77.02 -34.22 57.37 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 125.175 1.39 . . . . 0.0 111.029 -178.572 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.84 14.2 62.4 Favored Glycine 0 C--N 1.35 1.358 0 C-N-CA 124.07 0.843 . . . . 0.0 111.96 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 t60 -102.59 -38.24 7.6 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.855 -1.905 . . . . 0.0 105.855 170.001 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.7 mt -71.2 -31.39 44.09 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 C-N-CA 125.697 1.599 . . . . 0.0 110.249 -175.689 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -71.72 -26.82 62.64 Favored 'General case' 0 N--CA 1.422 -1.857 0 C-N-CA 127.557 2.343 . . . . 0.0 110.476 -178.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.7 t -94.01 -34.56 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 C-N-CA 124.382 1.073 . . . . 0.0 109.457 -177.013 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.2 pptp? -79.22 -19.83 49.75 Favored 'General case' 0 CA--C 1.469 -2.159 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -166.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.1 p -64.6 -32.84 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-O 123.293 1.521 . . . . 0.0 111.006 177.434 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -78.86 -30.52 45.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.669 -2.06 . . . . 0.0 109.921 -178.491 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -80.42 -36.88 33.09 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 124.073 0.949 . . . . 0.0 110.056 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.43 -1.453 0 C-N-CA 125.616 1.566 . . . . 0.0 113.935 -168.485 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 . . . . . 0 CA--C 1.498 -1.021 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -82.62 -13.48 56.43 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 124.298 1.039 . . . . 0.0 110.139 -175.891 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.09 7.88 65.52 Favored Glycine 0 C--N 1.355 1.618 0 C-N-CA 123.702 0.668 . . . . 0.0 111.784 178.362 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 66.9 m170 -102.99 -30.68 10.63 Favored 'General case' 0 CA--C 1.503 -0.858 0 C-N-CA 124.975 1.31 . . . . 0.0 107.775 171.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 31.9 mm -75.14 -38.74 42.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 C-N-CA 125.832 1.653 . . . . 0.0 110.27 -170.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -77.97 -8.49 58.21 Favored 'General case' 0 N--CA 1.441 -0.915 0 C-N-CA 123.507 0.723 . . . . 0.0 111.435 -176.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -101.48 -31.05 3.12 Favored 'Isoleucine or valine' 0 C--N 1.357 0.899 0 C-N-CA 125.139 1.376 . . . . 0.0 108.679 -177.511 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.9 pptp? -79.49 -19.13 50.49 Favored 'General case' 0 CA--C 1.472 -2.023 0 N-CA-C 115.107 1.521 . . . . 0.0 115.107 -166.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 28.7 m -67.87 -32.09 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 C-N-CA 125.077 1.351 . . . . 0.0 110.72 175.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -84.58 -24.26 29.28 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-N 112.6 -2.091 . . . . 0.0 109.912 -177.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -73.19 -45.45 56.35 Favored 'General case' 0 C--N 1.356 0.865 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 43.2 m170 . . . . . 0 N--CA 1.425 -1.707 0 C-N-CA 125.869 1.668 . . . . 0.0 111.527 179.865 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 36.1 m120 . . . . . 0 CA--C 1.504 -0.801 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -82.57 -12.65 57.57 Favored 'General case' 0 C--N 1.354 0.792 0 C-N-CA 125.149 1.38 . . . . 0.0 109.913 177.327 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.03 8.42 76.51 Favored Glycine 0 C--N 1.356 1.655 0 C-N-CA 124.253 0.93 . . . . 0.0 111.873 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -92.94 -32.45 14.55 Favored 'General case' 0 CA--C 1.503 -0.858 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.1 mp -76.82 -32.75 20.53 Favored 'Isoleucine or valine' 0 C--N 1.354 0.785 0 C-N-CA 125.734 1.613 . . . . 0.0 109.811 -174.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -71.94 -16.47 62.1 Favored 'General case' 0 C--N 1.35 0.628 0 C-N-CA 123.342 0.657 . . . . 0.0 112.384 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.9 t -98.92 -36.85 5.79 Favored 'Isoleucine or valine' 0 C--N 1.358 0.96 0 C-N-CA 124.103 0.961 . . . . 0.0 108.718 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.57 -19.35 57.99 Favored 'General case' 0 CA--C 1.471 -2.069 0 N-CA-C 114.505 1.298 . . . . 0.0 114.505 -168.057 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.87 -33.61 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.187 0 C-N-CA 125.771 1.628 . . . . 0.0 111.226 177.555 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -77.2 -28.86 54.06 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.617 -2.083 . . . . 0.0 110.863 -176.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 -80.07 -43.3 22.06 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 123.92 0.888 . . . . 0.0 108.63 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 16.7 t-160 . . . . . 0 N--CA 1.428 -1.536 0 C-N-CA 127.149 2.179 . . . . 0.0 112.753 -175.434 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.1 m-80 . . . . . 0 CA--C 1.505 -0.767 0 CA-C-O 120.405 0.145 . . . . 0.0 111.261 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -84.95 -10.96 56.53 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.546 1.138 . . . . 0.0 109.845 178.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.62 -22.98 78.59 Favored Glycine 0 C--N 1.355 1.628 0 C-N-CA 125.162 1.363 . . . . 0.0 111.877 178.262 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -71.12 -40.79 71.21 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 117.934 0.867 . . . . 0.0 111.08 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.8 mp -76.05 -36.51 31.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 C-N-CA 124.925 1.29 . . . . 0.0 110.558 -170.162 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -81.24 -3.8 53.51 Favored 'General case' 0 N--CA 1.446 -0.664 0 O-C-N 121.828 -0.545 . . . . 0.0 112.374 -176.465 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.5 t -112.2 -26.13 3.21 Favored 'Isoleucine or valine' 0 C--N 1.358 0.969 0 C-N-CA 124.424 1.09 . . . . 0.0 108.486 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.73 -20.59 49.64 Favored 'General case' 0 CA--C 1.471 -2.09 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -173.62 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.3 p -64.47 -35.71 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.327 0 C-N-CA 125.009 1.324 . . . . 0.0 110.619 174.004 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -83.01 -24.78 32.72 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-N 112.898 -1.955 . . . . 0.0 109.939 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.2 t-20 -72.25 -43.31 64.55 Favored 'General case' 0 C--N 1.356 0.888 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.5 m170 . . . . . 0 N--CA 1.421 -1.896 0 C-N-CA 126.634 1.974 . . . . 0.0 110.215 176.807 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 . . . . . 0 CA--C 1.507 -0.707 0 CA-C-O 120.576 0.227 . . . . 0.0 110.741 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -83.92 -14.99 49.61 Favored 'General case' 0 C--N 1.352 0.713 0 C-N-CA 124.796 1.239 . . . . 0.0 110.159 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.57 -2.83 72.35 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.216 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -93.84 -11.35 31.38 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 118.007 0.903 . . . . 0.0 108.983 174.228 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 47.8 mm -77.09 -36.21 24.31 Favored 'Isoleucine or valine' 0 C--N 1.356 0.861 0 C-N-CA 125.008 1.323 . . . . 0.0 108.842 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.39 0.65 40.99 Favored 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 122.896 0.478 . . . . 0.0 111.436 -179.089 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.78 -40.59 9.26 Favored 'Isoleucine or valine' 0 C--N 1.358 0.94 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 171.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.25 -17.58 58.3 Favored 'General case' 0 CA--C 1.47 -2.106 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -167.448 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -63.67 -34.41 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 C-N-CA 125.402 1.481 . . . . 0.0 110.826 176.01 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -80.44 -29.81 37.58 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 112.724 -2.035 . . . . 0.0 110.357 -177.553 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.5 t30 -73.05 -40.99 64.64 Favored 'General case' 0 C--N 1.354 0.774 0 C-N-CA 124.216 1.007 . . . . 0.0 108.609 176.449 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.2 t60 . . . . . 0 N--CA 1.418 -2.026 0 C-N-CA 127.462 2.305 . . . . 0.0 110.266 179.905 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 . . . . . 0 CA--C 1.498 -1.023 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -88.94 1.31 55.63 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.681 1.192 . . . . 0.0 110.784 -174.79 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.95 -10.44 80.85 Favored Glycine 0 C--N 1.356 1.666 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 176.756 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.4 m-70 -95.04 -31.22 13.7 Favored 'General case' 0 CA--C 1.502 -0.876 0 C-N-CA 124.122 0.969 . . . . 0.0 108.701 173.779 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.2 mt -75.82 -33.39 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 C-N-CA 125.508 1.523 . . . . 0.0 110.6 -171.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -74.1 -13.14 60.79 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 123.506 0.722 . . . . 0.0 112.163 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.14 -33.18 3.93 Favored 'Isoleucine or valine' 0 C--N 1.357 0.915 0 C-N-CA 124.766 1.226 . . . . 0.0 108.957 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.74 -19.78 47.94 Favored 'General case' 0 CA--C 1.476 -1.883 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -164.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 m -68.98 -30.24 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 C-N-CA 125.207 1.403 . . . . 0.0 110.822 175.89 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -87.08 -20.7 26.75 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.472 -2.149 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -75.7 -31.25 59.61 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.174 0.99 . . . . 0.0 109.056 177.167 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 56.5 m170 . . . . . 0 N--CA 1.434 -1.272 0 C-N-CA 125.704 1.602 . . . . 0.0 112.379 177.092 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 . . . . . 0 N--CA 1.435 -1.215 0 N-CA-C 104.538 -2.393 . . . . 0.0 104.538 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -86.68 -1.09 57.42 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.862 1.265 . . . . 0.0 110.898 -174.805 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.04 -30.02 39.65 Favored Glycine 0 C--N 1.355 1.633 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.1 m80 -76.81 -30.42 56.41 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 124.605 1.162 . . . . 0.0 110.363 177.016 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -73.58 -31.1 31.34 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 C-N-CA 126.029 1.731 . . . . 0.0 109.61 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.38 -27.84 64.63 Favored 'General case' 0 N--CA 1.437 -1.114 0 C-N-CA 125.441 1.497 . . . . 0.0 111.261 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 83.9 t -85.77 -44.87 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.864 0 C-N-CA 123.287 0.635 . . . . 0.0 109.502 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 pptp? -66.69 -21.28 66.09 Favored 'General case' 0 CA--C 1.483 -1.628 0 N-CA-C 116.191 1.922 . . . . 0.0 116.191 -160.279 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -55.39 -30.66 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 C-N-CA 127.953 2.501 . . . . 0.0 113.127 176.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.19 -37.24 71.86 Favored 'General case' 0 CA--C 1.509 -0.629 0 C-N-CA 127.903 2.481 . . . . 0.0 112.974 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -75.61 -47.3 27.17 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 126.007 1.723 . . . . 0.0 108.474 -177.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 44.0 m170 . . . . . 0 N--CA 1.432 -1.346 0 C-N-CA 126.22 1.808 . . . . 0.0 113.216 -175.1 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 . . . . . 0 N--CA 1.435 -1.219 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -82.69 -5.19 58.73 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.928 1.291 . . . . 0.0 111.371 -173.693 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -84.93 2.35 88.31 Favored Glycine 0 C--N 1.356 1.644 0 C-N-CA 124.064 0.84 . . . . 0.0 111.288 176.687 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -112.3 -26.62 8.67 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.207 1.403 . . . . 0.0 108.302 175.455 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.7 mt -75.73 -34.44 28.49 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 125.503 1.521 . . . . 0.0 109.888 -176.259 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.33 -11.06 59.79 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 123.799 0.84 . . . . 0.0 111.994 -179.31 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.7 t -98.17 -31.35 3.71 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 124.696 1.198 . . . . 0.0 108.93 -175.627 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.58 -19.25 58.07 Favored 'General case' 0 CA--C 1.475 -1.92 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -167.475 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.3 m -63.86 -31.37 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 C-N-CA 126.31 1.844 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -77.07 -34.72 56.99 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.252 -2.249 . . . . 0.0 109.972 -176.168 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 37.4 t30 -74.67 -43.39 55.5 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 124.369 1.068 . . . . 0.0 108.85 177.249 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.1 t-80 . . . . . 0 N--CA 1.429 -1.499 0 C-N-CA 127.124 2.17 . . . . 0.0 112.637 -175.874 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 41.0 t30 . . . . . 0 N--CA 1.444 -0.739 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -79.05 -17.06 55.92 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 124.511 1.125 . . . . 0.0 110.247 -178.569 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.56 29.67 7.6 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.107 0.861 . . . . 0.0 111.078 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 55.3 m-70 -112.64 -35.11 5.61 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 168.056 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mp -73.06 -44.75 56.05 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 109.243 -173.202 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 3.2 pp0? -78.69 -6.48 55.87 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.529 0.732 . . . . 0.0 112.22 -176.459 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.91 -28.2 3.82 Favored 'Isoleucine or valine' 0 C--N 1.358 0.949 0 C-N-CA 124.325 1.05 . . . . 0.0 109.171 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.69 -21.7 54.99 Favored 'General case' 0 CA--C 1.473 -2.006 0 N-CA-C 114.181 1.178 . . . . 0.0 114.181 -169.427 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.4 m -64.98 -28.78 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 126.629 1.971 . . . . 0.0 111.428 -176.06 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -71.6 -41.5 68.87 Favored 'General case' 0 CA--C 1.506 -0.746 0 CA-C-N 111.84 -2.436 . . . . 0.0 109.947 -175.585 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -80.94 -41.82 22.3 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.463 1.105 . . . . 0.0 109.594 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 71.0 t60 . . . . . 0 N--CA 1.426 -1.634 0 C-N-CA 127.933 2.493 . . . . 0.0 112.452 -170.065 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.7 m120 . . . . . 0 CA--C 1.496 -1.13 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -81.13 -12.46 59.24 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.445 1.098 . . . . 0.0 110.004 -178.028 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.27 9.32 61.42 Favored Glycine 0 C--N 1.356 1.694 0 C-N-CA 123.652 0.644 . . . . 0.0 112.145 178.866 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -109.43 -32.02 7.31 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 168.683 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.3 -34.55 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.827 0 C-N-CA 125.933 1.693 . . . . 0.0 110.956 -170.699 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -80.12 -24.66 40.33 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.149 0.58 . . . . 0.0 110.608 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t -81.92 -28.34 9.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.813 0 C-N-CA 125.224 1.41 . . . . 0.0 109.803 -175.283 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.85 -19.17 57.81 Favored 'General case' 0 CA--C 1.477 -1.846 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 -171.546 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 82.1 t -67.55 -36.02 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.227 0 C-N-CA 125.454 1.502 . . . . 0.0 108.67 176.49 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -85.76 -23.86 27.11 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.659 -1.609 . . . . 0.0 108.808 -175.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -73.95 -35.23 64.53 Favored 'General case' 0 N--CA 1.44 -0.948 0 C-N-CA 123.922 0.889 . . . . 0.0 108.776 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.427 -1.602 0 C-N-CA 124.5 1.12 . . . . 0.0 109.437 174.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 . . . . . 0 CA--C 1.501 -0.922 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -79.66 -18.04 52.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 C-N-CA 124.585 1.154 . . . . 0.0 109.877 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.41 28.82 6.54 Favored Glycine 0 C--N 1.357 1.718 0 C-N-CA 124.376 0.989 . . . . 0.0 111.241 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -115.22 -32.43 5.67 Favored 'General case' 0 CA--C 1.501 -0.916 0 C-N-CA 124.654 1.182 . . . . 0.0 108.08 171.256 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.0 mp -80.59 -37.95 17.16 Favored 'Isoleucine or valine' 0 C--N 1.354 0.774 0 C-N-CA 125.19 1.396 . . . . 0.0 109.005 -172.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -83.32 11.53 6.6 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.435 0.694 . . . . 0.0 111.378 179.16 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 82.0 t -118.16 -33.34 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 C-N-CA 125.253 1.421 . . . . 0.0 107.713 178.413 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.87 -21.65 40.5 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -170.731 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 p -65.93 -33.72 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 C-N-CA 125.317 1.447 . . . . 0.0 110.751 175.257 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -81.68 -24.97 35.92 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 112.797 -2.001 . . . . 0.0 110.052 -178.595 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -71.78 -46.7 57.49 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 54.3 m-70 . . . . . 0 N--CA 1.424 -1.767 0 C-N-CA 124.701 1.201 . . . . 0.0 112.126 -179.99 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 . . . . . 0 CA--C 1.494 -1.184 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -85.05 -1.29 56.66 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.733 1.213 . . . . 0.0 110.773 -177.005 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -88.79 8.42 79.53 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.236 0.922 . . . . 0.0 110.929 175.516 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.1 t60 -106.84 -31.21 8.48 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 173.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -74.83 -38.46 44.1 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.889 0 C-N-CA 125.127 1.371 . . . . 0.0 108.798 -174.069 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.0 4.59 11.82 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 179.123 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -105.79 -38.36 4.45 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 C-N-CA 124.909 1.284 . . . . 0.0 108.411 173.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.63 -21.75 51.78 Favored 'General case' 0 CA--C 1.476 -1.868 0 N-CA-C 115.122 1.527 . . . . 0.0 115.122 -163.756 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.9 m -69.35 -29.66 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 C-N-CA 125.468 1.507 . . . . 0.0 110.99 176.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -86.87 -24.74 24.79 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 112.513 -2.131 . . . . 0.0 109.866 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -72.21 -41.09 67.32 Favored 'General case' 0 C--N 1.356 0.868 0 C-N-CA 124.378 1.071 . . . . 0.0 108.202 176.448 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 57.2 m170 . . . . . 0 N--CA 1.428 -1.542 0 C-N-CA 126.301 1.841 . . . . 0.0 110.618 174.617 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 . . . . . 0 N--CA 1.443 -0.811 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -77.88 -13.87 59.74 Favored 'General case' 0 C--N 1.356 0.863 0 C-N-CA 124.557 1.143 . . . . 0.0 109.872 178.045 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -79.57 0.33 81.65 Favored Glycine 0 C--N 1.357 1.734 0 C-N-CA 124.124 0.868 . . . . 0.0 112.29 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -96.81 -36.23 10.69 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 172.468 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.2 mt -73.94 -48.47 38.59 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.929 0 C-N-CA 126.073 1.749 . . . . 0.0 110.94 -169.843 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -75.94 -23.09 55.4 Favored 'General case' 0 CA--C 1.508 -0.671 0 C-N-CA 124.317 1.047 . . . . 0.0 112.397 -171.053 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 84.3 t -81.19 -25.5 10.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 C-N-CA 125.099 1.36 . . . . 0.0 109.658 -175.832 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 24.9 tptp -84.57 -20.3 31.72 Favored 'General case' 0 N--CA 1.429 -1.501 0 C-N-CA 125.858 1.663 . . . . 0.0 111.454 -171.478 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 58.8 t -60.33 -37.54 74.43 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.927 0 C-N-CA 126.599 1.96 . . . . 0.0 109.563 168.377 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -86.52 -12.35 49.07 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.196 -175.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -80.46 -28.66 37.57 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.38 1.072 . . . . 0.0 108.57 173.263 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 46.3 m170 . . . . . 0 C--N 1.365 1.276 0 C-N-CA 125.36 1.464 . . . . 0.0 112.754 177.703 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 50.2 p90 . . . . . 0 N--CA 1.489 1.493 0 CA-C-O 121.379 0.609 . . . . 0.0 111.788 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -88.85 -83.1 0.23 Allowed 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -154.66 101.53 2.32 Favored 'General case' 0 N--CA 1.433 -1.299 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 177.094 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 94.8 mt -101.01 159.27 29.96 Favored Pre-proline 0 CA--C 1.501 -0.93 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -75.85 -173.81 1.8 Allowed 'Trans proline' 0 CA--C 1.501 -1.144 0 C-N-CA 123.159 2.573 . . . . 0.0 110.945 177.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 -65.17 -51.3 61.97 Favored 'General case' 0 CA--C 1.505 -0.755 0 C-N-CA 125.806 1.643 . . . . 0.0 110.641 -176.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -81.96 -13.12 57.91 Favored 'General case' 0 C--N 1.356 0.862 0 C-N-CA 123.847 0.859 . . . . 0.0 110.125 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -69.95 -28.87 71.27 Favored Glycine 0 C--N 1.356 1.642 0 C-N-CA 123.823 0.725 . . . . 0.0 111.745 178.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.4 t-80 -74.35 -39.54 62.72 Favored 'General case' 0 N--CA 1.434 -1.252 0 C-N-CA 124.778 1.231 . . . . 0.0 111.249 175.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.3 mt -73.41 -36.65 49.12 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.731 0 C-N-CA 125.979 1.712 . . . . 0.0 111.435 -169.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 19.8 pt20 -77.07 -7.84 56.41 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 123.693 0.797 . . . . 0.0 112.197 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.35 -35.17 3.46 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.54 -21.23 52.93 Favored 'General case' 0 CA--C 1.47 -2.115 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -169.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -62.07 -32.51 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.272 0 C-N-CA 125.929 1.692 . . . . 0.0 111.529 178.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -75.64 -41.52 53.9 Favored 'General case' 0 CA--C 1.503 -0.844 0 CA-C-N 112.658 -2.064 . . . . 0.0 109.959 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.4 t30 -71.37 -32.5 68.56 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.987 1.315 . . . . 0.0 110.386 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -67.4 -31.9 72.43 Favored 'General case' 0 N--CA 1.421 -1.882 0 C-N-CA 127.701 2.4 . . . . 0.0 110.98 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -80.85 -97.38 0.38 Allowed Glycine 0 C--N 1.353 1.484 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 177.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 48.5 mm-40 63.29 42.41 6.99 Favored 'General case' 0 C--N 1.357 0.902 0 C-N-CA 126.199 1.8 . . . . 0.0 111.428 -176.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 72.6 m80 -152.81 -95.13 0.05 OUTLIER 'General case' 0 CA--C 1.493 -1.249 1 N-CA-C 100.17 -4.011 . . . . 0.0 100.17 177.247 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.3 pp -92.88 155.18 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 105.518 -2.03 . . . . 0.0 105.518 157.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 18.8 t-80 61.49 47.39 6.68 Favored 'General case' 0 C--N 1.356 0.858 0 C-N-CA 125.565 1.546 . . . . 0.0 109.123 -167.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 85.3 t60 . . . . . 0 C--O 1.26 1.62 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.155 -175.55 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 52.9 p90 . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 121.491 0.662 . . . . 0.0 111.993 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -93.19 -71.23 0.66 Allowed 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 177.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -160.26 106.51 1.55 Allowed 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 104.475 -2.417 . . . . 0.0 104.475 175.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -89.13 162.74 36.7 Favored Pre-proline 0 N--CA 1.445 -0.7 0 C-N-CA 124.601 1.16 . . . . 0.0 108.447 177.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -76.7 -168.49 0.58 Allowed 'Trans proline' 0 CA--C 1.498 -1.28 0 C-N-CA 122.583 2.189 . . . . 0.0 112.901 -169.332 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 -72.19 -30.81 65.32 Favored 'General case' 0 CA--C 1.506 -0.712 0 C-N-CA 126.334 1.854 . . . . 0.0 110.039 175.636 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -79.66 -23.33 42.57 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.73 1.212 . . . . 0.0 108.866 174.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -77.76 -14.4 82.43 Favored Glycine 0 C--N 1.355 1.633 0 C-N-CA 124.39 0.995 . . . . 0.0 111.504 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 32.3 m170 -89.49 -35.52 15.92 Favored 'General case' 0 CA--C 1.502 -0.896 0 C-N-CA 124.244 1.018 . . . . 0.0 108.56 174.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -72.57 -30.93 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 C-N-CA 125.898 1.679 . . . . 0.0 111.74 -171.763 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 5.4 pp0? -78.31 -5.96 53.67 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 124.13 0.972 . . . . 0.0 111.927 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.9 t -83.95 -41.18 16.31 Favored 'Isoleucine or valine' 0 C--N 1.357 0.919 0 C-N-CA 124.023 0.929 . . . . 0.0 108.558 174.795 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -72.06 -16.23 62.03 Favored 'General case' 0 CA--C 1.491 -1.306 0 C-N-CA 127.426 2.29 . . . . 0.0 113.009 -165.04 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.1 t -49.55 -37.32 11.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 C-N-CA 129.07 2.948 . . . . 0.0 111.368 170.078 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -55.97 -36.38 67.78 Favored 'General case' 0 C--N 1.349 0.571 0 C-N-CA 126.886 2.074 . . . . 0.0 113.158 -175.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -86.32 -48.59 8.35 Favored 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 126.089 1.756 . . . . 0.0 107.697 -178.292 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -59.57 148.08 34.75 Favored 'General case' 0 N--CA 1.431 -1.376 0 C-N-CA 126.722 2.009 . . . . 0.0 112.706 -175.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -171.29 31.11 0.13 Allowed Glycine 0 N--CA 1.436 -1.36 0 N-CA-C 108.056 -2.018 . . . . 0.0 108.056 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -116.15 64.94 0.7 Allowed 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 178.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 71.7 m-70 -91.27 -97.71 0.12 Allowed 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 -177.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 12.2 pt -86.89 157.01 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.212 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 173.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -141.7 -50.92 0.41 Allowed 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 -177.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 81.0 m-70 . . . . . 0 C--O 1.261 1.659 0 C-N-CA 126.251 1.82 . . . . 0.0 110.785 -177.678 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 16.1 t80 . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 121.543 0.687 . . . . 0.0 109.753 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 53.8 mm-40 -79.69 -49.89 11.42 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 125.155 1.382 . . . . 0.0 109.985 -173.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -147.34 98.73 3.05 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 -177.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 6.6 mp -78.98 152.59 77.14 Favored Pre-proline 0 N--CA 1.44 -0.933 0 C-N-CA 125.431 1.493 . . . . 0.0 108.358 -176.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -78.57 176.93 9.33 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 123.112 2.542 . . . . 0.0 109.821 -174.298 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -81.04 -49.78 10.48 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 124.878 1.271 . . . . 0.0 108.531 -176.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -80.24 -11.06 59.77 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.474 1.109 . . . . 0.0 110.151 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -73.02 -18.52 79.18 Favored Glycine 0 C--N 1.357 1.712 0 C-N-CA 124.205 0.907 . . . . 0.0 111.857 178.145 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.2 m170 -85.03 -40.63 16.63 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.365 1.066 . . . . 0.0 109.204 175.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.2 mt -68.18 -34.69 67.88 Favored 'Isoleucine or valine' 0 C--N 1.352 0.708 0 C-N-CA 127.185 2.194 . . . . 0.0 111.73 -171.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -80.25 12.6 2.8 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 124.595 1.158 . . . . 0.0 112.719 -176.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -107.32 -32.7 2.57 Favored 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.1 mmmt -86.65 -9.73 55.37 Favored 'General case' 0 CA--C 1.485 -1.551 0 C-N-CA 124.508 1.123 . . . . 0.0 110.647 -170.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.5 p -61.14 -36.74 74.68 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 C-N-CA 126.094 1.758 . . . . 0.0 110.595 170.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -77.37 -29.35 53.25 Favored 'General case' 0 CA--C 1.506 -0.714 0 C-N-CA 126.613 1.965 . . . . 0.0 110.209 -178.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -73.83 -41.07 62.83 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.368 1.067 . . . . 0.0 109.091 177.291 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 35.5 m-70 -67.83 127.63 33.52 Favored 'General case' 0 N--CA 1.428 -1.552 0 C-N-CA 125.357 1.463 . . . . 0.0 110.222 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.55 -43.58 1.73 Allowed Glycine 0 C--N 1.354 1.547 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -175.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 80.21 116.58 0.06 Allowed 'General case' 0 CA--C 1.495 -1.139 0 C-N-CA 127.957 2.503 . . . . 0.0 110.225 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 59.9 m170 -80.02 -75.86 0.24 Allowed 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 173.639 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 15.6 pt -89.9 150.91 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 N-CA-C 106.814 -1.551 . . . . 0.0 106.814 167.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 39.0 m80 -112.83 -37.06 4.96 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 -179.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 43.4 p-80 . . . . . 0 C--O 1.259 1.593 0 C-N-CA 125.1 1.36 . . . . 0.0 109.312 175.931 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 121.613 0.72 . . . . 0.0 111.037 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -99.4 -54.39 2.96 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 176.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -164.22 113.65 1.2 Allowed 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 102.673 -3.084 . . . . 0.0 102.673 -178.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 5.4 mp -76.13 156.26 84.02 Favored Pre-proline 0 N--CA 1.443 -0.822 0 C-N-CA 124.624 1.169 . . . . 0.0 109.088 -178.003 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -76.26 -178.31 4.33 Favored 'Trans proline' 0 CA--C 1.501 -1.158 0 C-N-CA 123.107 2.538 . . . . 0.0 110.795 -176.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.5 m120 -64.23 -53.39 49.85 Favored 'General case' 0 CA--C 1.503 -0.827 0 C-N-CA 126.238 1.815 . . . . 0.0 111.247 -171.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -84.8 -10.23 57.4 Favored 'General case' 0 CA--C 1.505 -0.76 0 C-N-CA 124.452 1.101 . . . . 0.0 110.045 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.7 5.36 83.92 Favored Glycine 0 C--N 1.355 1.585 0 C-N-CA 124.09 0.852 . . . . 0.0 111.966 179.015 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.2 m-70 -91.37 -40.33 11.51 Favored 'General case' 0 CA--C 1.501 -0.908 0 C-N-CA 123.893 0.877 . . . . 0.0 108.645 175.485 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.3 mp -72.51 -32.7 42.71 Favored 'Isoleucine or valine' 0 C--N 1.352 0.694 0 C-N-CA 126.476 1.91 . . . . 0.0 110.488 -171.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 4.4 pp0? -80.75 9.07 6.76 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.884 0.873 . . . . 0.0 112.493 -177.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -97.65 -33.27 4.26 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 171.115 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 mmmt -89.63 -8.75 51.84 Favored 'General case' 0 CA--C 1.483 -1.608 0 C-N-CA 124.843 1.257 . . . . 0.0 111.208 -166.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.9 p -64.23 -37.35 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 C-N-CA 125.295 1.438 . . . . 0.0 110.315 168.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -79.1 -26.87 42.9 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.898 -178.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -75.71 -40.36 55.82 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.263 1.025 . . . . 0.0 109.219 178.106 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -65.47 160.81 21.33 Favored 'General case' 0 N--CA 1.432 -1.355 0 C-N-CA 124.909 1.284 . . . . 0.0 113.072 -172.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.02 36.84 17.25 Favored Glycine 0 C--N 1.353 1.475 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -177.524 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -106.53 58.78 0.64 Allowed 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 -176.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 63.8 m80 67.13 -118.03 0.23 Allowed 'General case' 0 C--N 1.357 0.923 0 C-N-CA 126.38 1.872 . . . . 0.0 109.434 -177.107 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 23.6 pt -87.52 166.5 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 C-N-CA 124.723 1.209 . . . . 0.0 108.741 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 59.1 t-80 -89.87 -44.33 10.0 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.308 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 9.9 p80 . . . . . 0 C--O 1.258 1.539 0 C-N-CA 125.596 1.558 . . . . 0.0 109.55 -176.916 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 38.5 p90 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 121.324 0.583 . . . . 0.0 112.024 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -83.12 -81.47 0.16 Allowed 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -151.85 100.87 2.71 Favored 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 105.861 -1.903 . . . . 0.0 105.861 175.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 89.8 mt -124.29 161.02 50.01 Favored Pre-proline 0 N--CA 1.44 -0.964 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 176.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -79.4 176.82 9.23 Favored 'Trans proline' 0 CA--C 1.502 -1.08 0 C-N-CA 122.764 2.309 . . . . 0.0 110.085 -171.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -93.85 -56.34 2.92 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -175.389 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 35.4 t80 -80.97 -10.17 59.75 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.489 1.115 . . . . 0.0 110.313 -177.23 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.06 3.32 77.21 Favored Glycine 0 C--N 1.356 1.686 0 C-N-CA 123.908 0.765 . . . . 0.0 112.005 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 58.5 m170 -109.04 -31.9 7.44 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.174 1.389 . . . . 0.0 107.782 174.164 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -76.71 -33.53 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.742 0 C-N-CA 125.827 1.651 . . . . 0.0 110.563 -172.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.53 -16.98 58.36 Favored 'General case' 0 N--CA 1.445 -0.695 0 C-N-CA 123.495 0.718 . . . . 0.0 111.515 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -91.1 -43.04 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 C-N-CA 124.15 0.98 . . . . 0.0 109.072 -176.594 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -19.68 65.11 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -163.685 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.4 m -57.28 -29.42 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.268 0 C-N-CA 127.916 2.487 . . . . 0.0 113.191 177.429 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.12 -36.77 71.05 Favored 'General case' 0 CA--C 1.511 -0.533 0 C-N-CA 127.745 2.418 . . . . 0.0 112.661 -176.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -70.07 -53.84 15.69 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 126.49 1.916 . . . . 0.0 108.98 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 -66.17 150.27 49.03 Favored 'General case' 0 N--CA 1.428 -1.539 0 C-N-CA 125.172 1.389 . . . . 0.0 112.897 -173.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.63 -50.71 0.42 Allowed Glycine 0 CA--C 1.492 -1.398 0 N-CA-C 105.501 -3.04 . . . . 0.0 105.501 -175.159 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 9.7 mp0 66.0 70.91 0.42 Allowed 'General case' 0 C--N 1.358 0.956 0 C-N-CA 126.573 1.949 . . . . 0.0 110.202 178.121 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 74.3 t60 -103.47 169.74 8.36 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 178.39 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 19.3 pt -83.08 161.38 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 C-N-CA 124.416 1.086 . . . . 0.0 109.279 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -95.35 -60.74 1.6 Allowed 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 175.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 84.2 t60 . . . . . 0 C--O 1.261 1.673 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 179.942 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 . . . . . 0 N--CA 1.488 1.447 0 CA-C-O 121.751 0.786 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 62.1 mm-40 -102.81 -44.34 5.31 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 173.077 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -142.9 105.14 4.43 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 101.31 -3.589 . . . . 0.0 101.31 176.576 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -75.94 154.26 84.87 Favored Pre-proline 0 N--CA 1.443 -0.82 0 C-N-CA 125.323 1.449 . . . . 0.0 110.781 -174.376 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -77.38 -179.45 5.44 Favored 'Trans proline' 0 CA--C 1.501 -1.167 0 C-N-CA 122.605 2.204 . . . . 0.0 112.016 -168.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -82.04 -45.18 15.63 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 125.905 1.682 . . . . 0.0 110.248 -173.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -82.46 -5.78 58.9 Favored 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 173.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.72 24.94 9.14 Favored Glycine 0 C--N 1.356 1.666 0 C-N-CA 124.506 1.051 . . . . 0.0 110.803 175.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.7 m-70 -114.29 -40.48 3.65 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 168.346 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.6 mp -76.71 -42.82 34.17 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.98 0 C-N-CA 125.91 1.684 . . . . 0.0 110.173 -172.452 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -76.78 -26.25 54.28 Favored 'General case' 0 CA--C 1.508 -0.649 0 O-C-N 121.956 -0.465 . . . . 0.0 110.71 -177.378 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.9 t -78.23 -24.26 13.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 C-N-CA 125.345 1.458 . . . . 0.0 109.976 -175.662 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.67 -25.56 53.83 Favored 'General case' 0 CA--C 1.475 -1.923 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -176.422 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.7 -33.06 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 C-N-CA 125.207 1.403 . . . . 0.0 108.286 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 15.8 m-30 -81.45 -28.5 34.15 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 113.317 -1.765 . . . . 0.0 108.787 -172.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -75.89 -46.0 32.45 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.06 1.344 . . . . 0.0 108.521 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 -64.1 -65.37 0.69 Allowed 'General case' 0 N--CA 1.425 -1.677 0 C-N-CA 126.466 1.906 . . . . 0.0 111.649 -175.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 103.4 76.63 1.14 Allowed Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 106.157 -2.777 . . . . 0.0 106.157 -177.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -100.44 67.45 1.32 Allowed 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 -178.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 73.0 m80 -99.05 -93.93 0.25 Allowed 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 104.826 -2.287 . . . . 0.0 104.826 178.377 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 20.2 pt -86.34 159.04 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.284 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 170.292 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -135.74 59.21 1.72 Allowed 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 104.626 -2.361 . . . . 0.0 104.626 177.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 36.4 m170 . . . . . 0 C--O 1.259 1.575 0 C-N-CA 125.926 1.69 . . . . 0.0 110.631 -179.873 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 42.8 p90 . . . . . 0 N--CA 1.488 1.473 0 CA-C-O 121.279 0.562 . . . . 0.0 111.758 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -89.39 -84.51 0.22 Allowed 'General case' 0 CA--C 1.503 -0.827 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -152.93 102.58 2.68 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 104.773 -2.306 . . . . 0.0 104.773 176.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 95.0 mt -121.61 160.32 46.89 Favored Pre-proline 0 N--CA 1.44 -0.951 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -77.13 -179.1 5.1 Favored 'Trans proline' 0 CA--C 1.5 -1.179 0 C-N-CA 123.296 2.664 . . . . 0.0 109.971 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.3 m-80 -68.26 -50.04 56.51 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 125.435 1.494 . . . . 0.0 109.967 -176.015 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -83.6 2.2 38.48 Favored 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.604 1.161 . . . . 0.0 110.83 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 12.68 66.48 Favored Glycine 0 C--N 1.355 1.62 0 C-N-CA 124.37 0.986 . . . . 0.0 110.745 173.268 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 36.9 m80 -118.44 -27.23 6.02 Favored 'General case' 0 C--N 1.355 0.845 0 C-N-CA 124.93 1.292 . . . . 0.0 108.834 174.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -76.85 -40.26 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.997 0 C-N-CA 125.198 1.399 . . . . 0.0 108.062 -177.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -66.23 -25.17 66.78 Favored 'General case' 0 C--N 1.348 0.514 0 C-N-CA 123.834 0.854 . . . . 0.0 112.375 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 66.5 t -73.81 -29.19 25.62 Favored 'Isoleucine or valine' 0 C--N 1.357 0.914 0 C-N-CA 125.464 1.506 . . . . 0.0 110.132 -176.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.08 -25.7 52.63 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -174.416 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 88.5 t -68.63 -33.32 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 125.163 1.385 . . . . 0.0 108.149 179.228 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.4 m-30 -80.29 -28.29 38.34 Favored 'General case' 0 CA--C 1.504 -0.801 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.351 -172.007 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -76.07 -43.13 45.07 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.838 1.255 . . . . 0.0 108.211 176.239 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -70.32 159.18 34.59 Favored 'General case' 0 N--CA 1.421 -1.912 0 C-N-CA 127.268 2.227 . . . . 0.0 110.913 -178.319 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -157.13 -96.14 0.12 Allowed Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 105.03 -3.228 . . . . 0.0 105.03 178.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 61.46 78.74 0.28 Allowed 'General case' 0 C--N 1.356 0.863 0 C-N-CA 126.2 1.8 . . . . 0.0 112.095 176.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 19.2 p80 -94.48 179.0 5.42 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 36.1 pt -88.0 -167.36 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 C-N-CA 124.888 1.275 . . . . 0.0 109.544 -173.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -78.83 -42.6 27.23 Favored 'General case' 0 CA--C 1.503 -0.831 0 C-N-CA 124.596 1.159 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 56.5 m80 . . . . . 0 C--O 1.26 1.623 0 C-N-CA 127.433 2.293 . . . . 0.0 109.841 -177.85 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 . . . . . 0 N--CA 1.487 1.401 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 79.57 -6.89 1.77 Allowed 'General case' 0 C--N 1.36 1.045 0 C-N-CA 128.239 2.616 . . . . 0.0 110.943 -171.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -159.27 108.17 1.86 Allowed 'General case' 0 N--CA 1.428 -1.545 0 N-CA-C 102.045 -3.317 . . . . 0.0 102.045 176.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 88.7 mt -80.15 156.7 74.06 Favored Pre-proline 0 N--CA 1.443 -0.82 0 C-N-CA 124.218 1.007 . . . . 0.0 109.582 -174.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -75.53 -177.21 3.4 Favored 'Trans proline' 0 CA--C 1.501 -1.166 0 C-N-CA 123.926 3.084 . . . . 0.0 109.764 175.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -71.07 -49.9 39.63 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 124.647 1.179 . . . . 0.0 109.15 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -77.02 -34.22 57.37 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 125.175 1.39 . . . . 0.0 111.029 -178.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.84 14.2 62.4 Favored Glycine 0 C--N 1.35 1.358 0 C-N-CA 124.07 0.843 . . . . 0.0 111.96 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 t60 -102.59 -38.24 7.6 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.855 -1.905 . . . . 0.0 105.855 170.001 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.7 mt -71.2 -31.39 44.09 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 C-N-CA 125.697 1.599 . . . . 0.0 110.249 -175.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -71.72 -26.82 62.64 Favored 'General case' 0 N--CA 1.422 -1.857 0 C-N-CA 127.557 2.343 . . . . 0.0 110.476 -178.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.7 t -94.01 -34.56 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 C-N-CA 124.382 1.073 . . . . 0.0 109.457 -177.013 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.2 pptp? -79.22 -19.83 49.75 Favored 'General case' 0 CA--C 1.469 -2.159 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -166.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.1 p -64.6 -32.84 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-O 123.293 1.521 . . . . 0.0 111.006 177.434 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -78.86 -30.52 45.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.669 -2.06 . . . . 0.0 109.921 -178.491 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -80.42 -36.88 33.09 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 124.073 0.949 . . . . 0.0 110.056 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -71.44 -174.71 1.12 Allowed 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.616 1.566 . . . . 0.0 113.935 -168.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -147.93 -50.33 0.02 OUTLIER Glycine 0 CA--C 1.491 -1.434 0 N-CA-C 106.442 -2.663 . . . . 0.0 106.442 -178.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 49.4 mm-40 65.25 56.89 0.96 Allowed 'General case' 0 C--N 1.357 0.933 0 C-N-CA 126.126 1.77 . . . . 0.0 110.946 177.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 8.7 p80 -123.61 -164.65 1.24 Allowed 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 105.22 -2.141 . . . . 0.0 105.22 178.594 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 11.8 pt -95.83 143.82 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.262 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 175.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 48.0 m80 70.39 23.99 4.79 Favored 'General case' 0 C--N 1.356 0.888 0 C-N-CA 126.15 1.78 . . . . 0.0 109.91 -169.326 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 82.3 t60 . . . . . 0 C--O 1.259 1.581 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 178.959 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.347 0.594 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -84.16 -20.34 32.58 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 125.012 1.325 . . . . 0.0 107.951 170.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 31.8 t0 -93.08 -143.13 0.22 Allowed 'General case' 0 N--CA 1.422 -1.86 0 N-CA-C 103.56 -2.755 . . . . 0.0 103.56 170.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.415 ' H ' ' HG ' ' A' ' 4' ' ' LEU . 0.8 OUTLIER -64.71 155.71 81.25 Favored Pre-proline 0 N--CA 1.445 -0.712 0 C-N-CA 127.755 2.422 . . . . 0.0 111.471 -177.382 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -79.42 -175.34 2.68 Favored 'Trans proline' 0 CA--C 1.5 -1.199 0 C-N-CA 122.241 1.961 . . . . 0.0 112.026 -169.374 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -112.4 -63.71 1.39 Allowed 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -82.62 -13.48 56.43 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 124.298 1.039 . . . . 0.0 110.139 -175.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.09 7.88 65.52 Favored Glycine 0 C--N 1.355 1.618 0 C-N-CA 123.702 0.668 . . . . 0.0 111.784 178.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 66.9 m170 -102.99 -30.68 10.63 Favored 'General case' 0 CA--C 1.503 -0.858 0 C-N-CA 124.975 1.31 . . . . 0.0 107.775 171.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 31.9 mm -75.14 -38.74 42.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 C-N-CA 125.832 1.653 . . . . 0.0 110.27 -170.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -77.97 -8.49 58.21 Favored 'General case' 0 N--CA 1.441 -0.915 0 C-N-CA 123.507 0.723 . . . . 0.0 111.435 -176.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -101.48 -31.05 3.12 Favored 'Isoleucine or valine' 0 C--N 1.357 0.899 0 C-N-CA 125.139 1.376 . . . . 0.0 108.679 -177.511 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.9 pptp? -79.49 -19.13 50.49 Favored 'General case' 0 CA--C 1.472 -2.023 0 N-CA-C 115.107 1.521 . . . . 0.0 115.107 -166.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 28.7 m -67.87 -32.09 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 C-N-CA 125.077 1.351 . . . . 0.0 110.72 175.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -84.58 -24.26 29.28 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-N 112.6 -2.091 . . . . 0.0 109.912 -177.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -73.19 -45.45 56.35 Favored 'General case' 0 C--N 1.356 0.865 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 2.6 m-70 -69.73 158.65 34.99 Favored 'General case' 0 N--CA 1.425 -1.707 0 C-N-CA 125.869 1.668 . . . . 0.0 111.527 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -178.73 55.02 0.09 OUTLIER Glycine 0 CA--C 1.491 -1.442 0 N-CA-C 107.085 -2.406 . . . . 0.0 107.085 178.43 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 67.16 100.5 0.05 OUTLIER 'General case' 0 C--N 1.358 0.937 0 C-N-CA 126.716 2.007 . . . . 0.0 111.763 178.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -97.23 175.47 6.27 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.9 pp -88.85 173.03 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 C-N-CA 124.666 1.186 . . . . 0.0 108.99 179.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -96.46 -65.55 0.96 Allowed 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 105.674 -1.973 . . . . 0.0 105.674 174.257 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 63.7 t-80 . . . . . 0 C--O 1.26 1.651 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 179.853 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -88.89 -62.89 1.38 Allowed 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 172.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -155.12 104.12 2.43 Favored 'General case' 0 N--CA 1.432 -1.358 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 172.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -94.77 161.29 29.14 Favored Pre-proline 0 N--CA 1.444 -0.733 0 C-N-CA 124.607 1.163 . . . . 0.0 108.367 -178.569 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -77.58 -170.93 1.04 Allowed 'Trans proline' 0 CA--C 1.499 -1.231 0 C-N-CA 122.416 2.077 . . . . 0.0 112.43 -171.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -70.63 -37.86 73.83 Favored 'General case' 0 CA--C 1.504 -0.801 0 C-N-CA 126.253 1.821 . . . . 0.0 109.696 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -82.57 -12.65 57.57 Favored 'General case' 0 C--N 1.354 0.792 0 C-N-CA 125.149 1.38 . . . . 0.0 109.913 177.327 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.03 8.42 76.51 Favored Glycine 0 C--N 1.356 1.655 0 C-N-CA 124.253 0.93 . . . . 0.0 111.873 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -92.94 -32.45 14.55 Favored 'General case' 0 CA--C 1.503 -0.858 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.1 mp -76.82 -32.75 20.53 Favored 'Isoleucine or valine' 0 C--N 1.354 0.785 0 C-N-CA 125.734 1.613 . . . . 0.0 109.811 -174.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -71.94 -16.47 62.1 Favored 'General case' 0 C--N 1.35 0.628 0 C-N-CA 123.342 0.657 . . . . 0.0 112.384 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.9 t -98.92 -36.85 5.79 Favored 'Isoleucine or valine' 0 C--N 1.358 0.96 0 C-N-CA 124.103 0.961 . . . . 0.0 108.718 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.57 -19.35 57.99 Favored 'General case' 0 CA--C 1.471 -2.069 0 N-CA-C 114.505 1.298 . . . . 0.0 114.505 -168.057 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.87 -33.61 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.187 0 C-N-CA 125.771 1.628 . . . . 0.0 111.226 177.555 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -77.2 -28.86 54.06 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.617 -2.083 . . . . 0.0 110.863 -176.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 -80.07 -43.3 22.06 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 123.92 0.888 . . . . 0.0 108.63 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 16.7 t-160 -61.36 -51.71 67.67 Favored 'General case' 0 N--CA 1.428 -1.536 0 C-N-CA 127.149 2.179 . . . . 0.0 112.753 -175.434 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -86.33 -34.61 11.93 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 124.453 1.025 . . . . 0.0 111.551 -172.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 58.7 mm-40 66.01 81.04 0.21 Allowed 'General case' 0 C--N 1.36 1.046 0 C-N-CA 125.86 1.664 . . . . 0.0 109.491 -172.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 28.9 m80 -90.51 125.16 35.51 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 -174.362 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.2 mm -87.63 -83.78 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.61 0 C-N-CA 125.02 1.328 . . . . 0.0 107.467 -170.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -91.05 -58.19 2.55 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 106.722 -1.585 . . . . 0.0 106.722 178.185 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 . . . . . 0 C--O 1.26 1.654 0 C-N-CA 124.656 1.182 . . . . 0.0 107.819 -178.031 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 88.39 -65.94 0.02 OUTLIER 'General case' 0 CA--C 1.496 -1.119 0 C-N-CA 129.501 3.121 . . . . 0.0 109.305 171.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -165.12 106.24 0.79 Allowed 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 105.454 -2.054 . . . . 0.0 105.454 -178.175 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -150.03 167.0 13.89 Favored Pre-proline 0 N--CA 1.44 -0.945 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -76.02 -172.01 1.23 Allowed 'Trans proline' 0 CA--C 1.497 -1.334 0 C-N-CA 122.748 2.299 . . . . 0.0 112.293 -171.611 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.1 m-80 -63.23 -47.62 81.71 Favored 'General case' 0 CA--C 1.505 -0.767 0 C-N-CA 126.944 2.098 . . . . 0.0 111.261 -175.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -84.95 -10.96 56.53 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.546 1.138 . . . . 0.0 109.845 178.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.62 -22.98 78.59 Favored Glycine 0 C--N 1.355 1.628 0 C-N-CA 125.162 1.363 . . . . 0.0 111.877 178.262 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -71.12 -40.79 71.21 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 117.934 0.867 . . . . 0.0 111.08 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.8 mp -76.05 -36.51 31.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 C-N-CA 124.925 1.29 . . . . 0.0 110.558 -170.162 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -81.24 -3.8 53.51 Favored 'General case' 0 N--CA 1.446 -0.664 0 O-C-N 121.828 -0.545 . . . . 0.0 112.374 -176.465 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.5 t -112.2 -26.13 3.21 Favored 'Isoleucine or valine' 0 C--N 1.358 0.969 0 C-N-CA 124.424 1.09 . . . . 0.0 108.486 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.73 -20.59 49.64 Favored 'General case' 0 CA--C 1.471 -2.09 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -173.62 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.3 p -64.47 -35.71 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.327 0 C-N-CA 125.009 1.324 . . . . 0.0 110.619 174.004 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -83.01 -24.78 32.72 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-N 112.898 -1.955 . . . . 0.0 109.939 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.2 t-20 -72.25 -43.31 64.55 Favored 'General case' 0 C--N 1.356 0.888 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.5 m170 -78.17 -170.25 1.9 Allowed 'General case' 0 N--CA 1.421 -1.896 0 C-N-CA 126.634 1.974 . . . . 0.0 110.215 176.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -128.18 50.78 0.87 Allowed Glycine 0 C--N 1.352 1.437 0 N-CA-C 106.138 -2.785 . . . . 0.0 106.138 175.141 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -107.38 70.26 0.78 Allowed 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -120.91 -107.19 0.36 Allowed 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 103.868 -2.642 . . . . 0.0 103.868 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.8 pp -86.0 164.42 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 170.664 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -140.07 32.07 1.96 Allowed 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 61.9 m80 . . . . . 0 C--O 1.259 1.603 0 C-N-CA 125.966 1.706 . . . . 0.0 111.152 175.808 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 121.583 0.706 . . . . 0.0 110.677 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -90.61 -84.67 0.24 Allowed 'General case' 0 N--CA 1.44 -0.945 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 -179.205 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -158.98 105.54 1.77 Allowed 'General case' 0 N--CA 1.432 -1.369 0 N-CA-C 104.064 -2.569 . . . . 0.0 104.064 176.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 85.6 mt -96.26 163.55 20.5 Favored Pre-proline 0 N--CA 1.442 -0.853 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.477 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -77.38 -174.84 2.37 Favored 'Trans proline' 0 CA--C 1.499 -1.259 0 C-N-CA 123.192 2.594 . . . . 0.0 110.328 179.298 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -66.43 -39.46 88.94 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 125.792 1.637 . . . . 0.0 110.741 -178.517 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -83.92 -14.99 49.61 Favored 'General case' 0 C--N 1.352 0.713 0 C-N-CA 124.796 1.239 . . . . 0.0 110.159 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.57 -2.83 72.35 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.216 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -93.84 -11.35 31.38 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 118.007 0.903 . . . . 0.0 108.983 174.228 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 47.8 mm -77.09 -36.21 24.31 Favored 'Isoleucine or valine' 0 C--N 1.356 0.861 0 C-N-CA 125.008 1.323 . . . . 0.0 108.842 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.39 0.65 40.99 Favored 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 122.896 0.478 . . . . 0.0 111.436 -179.089 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.78 -40.59 9.26 Favored 'Isoleucine or valine' 0 C--N 1.358 0.94 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 171.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.25 -17.58 58.3 Favored 'General case' 0 CA--C 1.47 -2.106 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -167.448 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -63.67 -34.41 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 C-N-CA 125.402 1.481 . . . . 0.0 110.826 176.01 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -80.44 -29.81 37.58 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 112.724 -2.035 . . . . 0.0 110.357 -177.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.5 t30 -73.05 -40.99 64.64 Favored 'General case' 0 C--N 1.354 0.774 0 C-N-CA 124.216 1.007 . . . . 0.0 108.609 176.449 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -71.96 158.73 35.48 Favored 'General case' 0 N--CA 1.418 -2.026 0 C-N-CA 127.462 2.305 . . . . 0.0 110.266 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -150.36 -85.28 0.05 OUTLIER Glycine 0 CA--C 1.489 -1.558 0 N-CA-C 105.42 -3.072 . . . . 0.0 105.42 179.2 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 58.07 96.83 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.027 0 C-N-CA 127.247 2.219 . . . . 0.0 114.343 177.704 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -96.6 -105.55 0.17 Allowed 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 19.3 pt -87.42 156.81 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 C-N-CA 124.178 0.991 . . . . 0.0 108.518 177.511 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 57.5 t-80 -93.73 -59.12 2.07 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 105.894 -1.891 . . . . 0.0 105.894 175.582 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 62.6 t-80 . . . . . 0 C--O 1.26 1.617 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 179.119 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 . . . . . 0 N--CA 1.487 1.418 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 61.94 6.28 1.65 Allowed 'General case' 0 C--N 1.356 0.86 0 C-N-CA 126.603 1.961 . . . . 0.0 114.141 -172.702 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 71.37 99.25 0.07 Allowed 'General case' 0 N--CA 1.438 -1.055 0 C-N-CA 129.361 3.064 . . . . 0.0 109.174 -166.446 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 95.1 mt -82.63 157.53 67.05 Favored Pre-proline 0 N--CA 1.444 -0.774 0 C-N-CA 124.395 1.078 . . . . 0.0 108.58 178.263 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -78.35 -176.73 3.42 Favored 'Trans proline' 0 CA--C 1.501 -1.132 0 C-N-CA 122.864 2.376 . . . . 0.0 111.315 -172.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -110.02 -67.68 0.97 Allowed 'General case' 0 CA--C 1.498 -1.023 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 177.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -88.94 1.31 55.63 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.681 1.192 . . . . 0.0 110.784 -174.79 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.95 -10.44 80.85 Favored Glycine 0 C--N 1.356 1.666 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 176.756 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.4 m-70 -95.04 -31.22 13.7 Favored 'General case' 0 CA--C 1.502 -0.876 0 C-N-CA 124.122 0.969 . . . . 0.0 108.701 173.779 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.2 mt -75.82 -33.39 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 C-N-CA 125.508 1.523 . . . . 0.0 110.6 -171.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -74.1 -13.14 60.79 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 123.506 0.722 . . . . 0.0 112.163 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.14 -33.18 3.93 Favored 'Isoleucine or valine' 0 C--N 1.357 0.915 0 C-N-CA 124.766 1.226 . . . . 0.0 108.957 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.74 -19.78 47.94 Favored 'General case' 0 CA--C 1.476 -1.883 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -164.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 m -68.98 -30.24 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 C-N-CA 125.207 1.403 . . . . 0.0 110.822 175.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -87.08 -20.7 26.75 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.472 -2.149 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -75.7 -31.25 59.61 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.174 0.99 . . . . 0.0 109.056 177.167 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 8.5 m-70 -57.85 142.74 44.86 Favored 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 125.704 1.602 . . . . 0.0 112.379 177.092 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -106.83 -119.95 4.55 Favored Glycine 0 C--N 1.354 1.562 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -173.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -104.47 67.52 0.83 Allowed 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 -174.302 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 24.0 p80 -147.67 171.4 15.69 Favored 'General case' 0 N--CA 1.437 -1.086 0 N-CA-C 105.96 -1.866 . . . . 0.0 105.96 173.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 20.4 pt -83.67 151.61 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 123.957 0.903 . . . . 0.0 109.665 -176.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 20.2 t-80 -153.13 62.07 0.77 Allowed 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 104.662 -2.347 . . . . 0.0 104.662 176.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 68.3 m80 . . . . . 0 C--O 1.261 1.685 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 179.718 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.631 0.729 . . . . 0.0 110.978 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 62.7 mm-40 -103.3 -55.41 2.41 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.268 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -165.59 110.62 0.87 Allowed 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 -177.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 5.3 mp -76.96 154.6 82.94 Favored Pre-proline 0 N--CA 1.444 -0.725 0 C-N-CA 124.504 1.122 . . . . 0.0 108.897 -178.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -78.21 -176.57 3.32 Favored 'Trans proline' 0 CA--C 1.5 -1.185 0 C-N-CA 122.826 2.35 . . . . 0.0 111.304 -172.721 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 -128.82 -60.09 1.11 Allowed 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 104.538 -2.393 . . . . 0.0 104.538 176.421 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -86.68 -1.09 57.42 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.862 1.265 . . . . 0.0 110.898 -174.805 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.04 -30.02 39.65 Favored Glycine 0 C--N 1.355 1.633 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.1 m80 -76.81 -30.42 56.41 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 124.605 1.162 . . . . 0.0 110.363 177.016 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -73.58 -31.1 31.34 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 C-N-CA 126.029 1.731 . . . . 0.0 109.61 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.38 -27.84 64.63 Favored 'General case' 0 N--CA 1.437 -1.114 0 C-N-CA 125.441 1.497 . . . . 0.0 111.261 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 83.9 t -85.77 -44.87 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.864 0 C-N-CA 123.287 0.635 . . . . 0.0 109.502 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 pptp? -66.69 -21.28 66.09 Favored 'General case' 0 CA--C 1.483 -1.628 0 N-CA-C 116.191 1.922 . . . . 0.0 116.191 -160.279 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -55.39 -30.66 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 C-N-CA 127.953 2.501 . . . . 0.0 113.127 176.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.19 -37.24 71.86 Favored 'General case' 0 CA--C 1.509 -0.629 0 C-N-CA 127.903 2.481 . . . . 0.0 112.974 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -75.61 -47.3 27.17 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 126.007 1.723 . . . . 0.0 108.474 -177.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 44.0 m170 -59.91 -43.34 94.94 Favored 'General case' 0 N--CA 1.432 -1.346 0 C-N-CA 126.22 1.808 . . . . 0.0 113.216 -175.1 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -168.64 -111.93 0.25 Allowed Glycine 0 N--CA 1.434 -1.458 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 66.5 83.04 0.17 Allowed 'General case' 0 C--N 1.356 0.89 0 C-N-CA 126.89 2.076 . . . . 0.0 109.208 -166.046 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 65.1 m80 70.63 -110.6 0.07 Allowed 'General case' 0 C--N 1.358 0.952 0 C-N-CA 126.217 1.807 . . . . 0.0 108.497 -173.167 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 24.6 pt -88.38 173.46 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 124.634 1.174 . . . . 0.0 108.263 176.059 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 86.7 t60 -83.5 -40.67 18.9 Favored 'General case' 0 CA--C 1.501 -0.915 0 C-N-CA 123.859 0.864 . . . . 0.0 109.688 -177.269 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 63.6 t-80 . . . . . 0 C--O 1.261 1.664 0 C-N-CA 124.527 1.131 . . . . 0.0 109.65 -174.588 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 26.6 t80 . . . . . 0 N--CA 1.483 1.196 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -114.39 -68.14 0.95 Allowed 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 105.811 -1.922 . . . . 0.0 105.811 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -156.56 104.66 2.19 Favored 'General case' 0 N--CA 1.433 -1.322 0 N-CA-C 104.534 -2.395 . . . . 0.0 104.534 177.779 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 91.0 mt -102.73 159.46 29.25 Favored Pre-proline 0 N--CA 1.442 -0.859 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 179.135 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -78.17 -177.9 4.22 Favored 'Trans proline' 0 CA--C 1.501 -1.173 0 C-N-CA 122.879 2.386 . . . . 0.0 111.124 -172.621 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -119.36 -62.35 1.52 Allowed 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -82.69 -5.19 58.73 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.928 1.291 . . . . 0.0 111.371 -173.693 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -84.93 2.35 88.31 Favored Glycine 0 C--N 1.356 1.644 0 C-N-CA 124.064 0.84 . . . . 0.0 111.288 176.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -112.3 -26.62 8.67 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.207 1.403 . . . . 0.0 108.302 175.455 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.7 mt -75.73 -34.44 28.49 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 125.503 1.521 . . . . 0.0 109.888 -176.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.33 -11.06 59.79 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 123.799 0.84 . . . . 0.0 111.994 -179.31 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.7 t -98.17 -31.35 3.71 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 124.696 1.198 . . . . 0.0 108.93 -175.627 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.58 -19.25 58.07 Favored 'General case' 0 CA--C 1.475 -1.92 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -167.475 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.3 m -63.86 -31.37 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 C-N-CA 126.31 1.844 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -77.07 -34.72 56.99 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.252 -2.249 . . . . 0.0 109.972 -176.168 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 37.4 t30 -74.67 -43.39 55.5 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 124.369 1.068 . . . . 0.0 108.85 177.249 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.1 t-80 -60.06 146.64 42.19 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 127.124 2.17 . . . . 0.0 112.637 -175.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.11 -32.41 0.19 Allowed Glycine 0 N--CA 1.435 -1.422 0 N-CA-C 106.775 -2.53 . . . . 0.0 106.775 -177.641 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 47.5 mm-40 68.86 85.18 0.14 Allowed 'General case' 0 C--N 1.359 1.021 0 C-N-CA 126.839 2.056 . . . . 0.0 109.856 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 66.0 m-70 -103.28 -167.63 1.41 Allowed 'General case' 0 N--CA 1.437 -1.099 0 C-N-CA 124.412 1.085 . . . . 0.0 108.351 -170.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.539 HD13 ' H ' ' A' ' 21' ' ' ILE . 0.1 OUTLIER -91.34 170.9 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.331 0 C-N-CA 125.008 1.323 . . . . 0.0 108.17 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 58.5 t60 72.92 17.01 4.34 Favored 'General case' 0 C--N 1.357 0.924 0 C-N-CA 126.722 2.009 . . . . 0.0 110.791 -176.127 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 . . . . . 0 C--O 1.259 1.598 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 177.513 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 61.5 mm-40 -108.11 13.9 25.55 Favored 'General case' 0 C--N 1.353 0.747 0 C-N-CA 125.331 1.453 . . . . 0.0 107.783 174.223 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . 0.447 2.3 p30 73.22 112.25 0.06 Allowed 'General case' 0 C--N 1.356 0.851 0 C-N-CA 129.668 3.187 . . . . 0.0 110.164 -171.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 79.7 mt -101.06 163.82 17.23 Favored Pre-proline 0 N--CA 1.441 -0.898 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -172.502 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -77.58 -179.52 5.52 Favored 'Trans proline' 0 CA--C 1.499 -1.247 0 C-N-CA 123.076 2.517 . . . . 0.0 110.314 -176.018 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -65.2 -53.26 47.36 Favored 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 126.295 1.838 . . . . 0.0 110.085 -174.525 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -79.05 -17.06 55.92 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 124.511 1.125 . . . . 0.0 110.247 -178.569 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.56 29.67 7.6 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.107 0.861 . . . . 0.0 111.078 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 55.3 m-70 -112.64 -35.11 5.61 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 168.056 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mp -73.06 -44.75 56.05 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 109.243 -173.202 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 3.2 pp0? -78.69 -6.48 55.87 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.529 0.732 . . . . 0.0 112.22 -176.459 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.91 -28.2 3.82 Favored 'Isoleucine or valine' 0 C--N 1.358 0.949 0 C-N-CA 124.325 1.05 . . . . 0.0 109.171 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.69 -21.7 54.99 Favored 'General case' 0 CA--C 1.473 -2.006 0 N-CA-C 114.181 1.178 . . . . 0.0 114.181 -169.427 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.4 m -64.98 -28.78 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 126.629 1.971 . . . . 0.0 111.428 -176.06 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -71.6 -41.5 68.87 Favored 'General case' 0 CA--C 1.506 -0.746 0 CA-C-N 111.84 -2.436 . . . . 0.0 109.947 -175.585 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -80.94 -41.82 22.3 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.463 1.105 . . . . 0.0 109.594 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 71.0 t60 -62.5 -63.86 1.1 Allowed 'General case' 0 N--CA 1.426 -1.634 0 C-N-CA 127.933 2.493 . . . . 0.0 112.452 -170.065 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.23 -116.52 3.0 Favored Glycine 0 CA--C 1.492 -1.373 0 N-CA-C 107.631 -2.188 . . . . 0.0 107.631 -178.012 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -150.5 48.63 0.88 Allowed 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 -178.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 16.2 m80 72.91 156.27 0.17 Allowed 'General case' 0 C--N 1.354 0.79 0 C-N-CA 126.838 2.055 . . . . 0.0 112.524 175.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 24.3 pt -100.62 -165.82 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 176.573 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 56.7 m170 -82.88 -39.53 21.46 Favored 'General case' 0 CA--C 1.501 -0.905 0 C-N-CA 124.315 1.046 . . . . 0.0 110.06 -177.251 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 82.7 t60 . . . . . 0 C--O 1.26 1.62 0 CA-C-O 117.796 -1.097 . . . . 0.0 109.534 -177.215 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 . . . . . 0 N--CA 1.488 1.463 0 CA-C-O 122.058 0.932 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -85.46 -36.22 20.74 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 173.574 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 40.6 m-20 76.03 99.69 0.07 Allowed 'General case' 0 CA--C 1.498 -1.045 0 C-N-CA 127.768 2.427 . . . . 0.0 108.775 -177.449 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 5.7 mp -101.04 159.21 30.14 Favored Pre-proline 0 N--CA 1.438 -1.052 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 -171.083 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -77.9 -176.72 3.38 Favored 'Trans proline' 0 CA--C 1.5 -1.219 0 C-N-CA 122.87 2.38 . . . . 0.0 111.302 -173.384 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -118.19 -65.88 1.13 Allowed 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 178.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -81.13 -12.46 59.24 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.445 1.098 . . . . 0.0 110.004 -178.028 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.27 9.32 61.42 Favored Glycine 0 C--N 1.356 1.694 0 C-N-CA 123.652 0.644 . . . . 0.0 112.145 178.866 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -109.43 -32.02 7.31 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 168.683 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.3 -34.55 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.827 0 C-N-CA 125.933 1.693 . . . . 0.0 110.956 -170.699 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -80.12 -24.66 40.33 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.149 0.58 . . . . 0.0 110.608 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t -81.92 -28.34 9.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.813 0 C-N-CA 125.224 1.41 . . . . 0.0 109.803 -175.283 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.85 -19.17 57.81 Favored 'General case' 0 CA--C 1.477 -1.846 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 -171.546 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 82.1 t -67.55 -36.02 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.227 0 C-N-CA 125.454 1.502 . . . . 0.0 108.67 176.49 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -85.76 -23.86 27.11 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.659 -1.609 . . . . 0.0 108.808 -175.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -73.95 -35.23 64.53 Favored 'General case' 0 N--CA 1.44 -0.948 0 C-N-CA 123.922 0.889 . . . . 0.0 108.776 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.94 137.09 53.5 Favored 'General case' 0 N--CA 1.427 -1.602 0 C-N-CA 124.5 1.12 . . . . 0.0 109.437 174.801 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.26 -16.12 61.32 Favored Glycine 0 C--N 1.354 1.547 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -174.47 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 57.4 mm-40 64.68 64.81 0.65 Allowed 'General case' 0 C--N 1.359 0.992 0 C-N-CA 127.254 2.222 . . . . 0.0 111.129 179.325 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 -94.8 -66.5 0.91 Allowed 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 176.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 13.3 pt -89.41 161.5 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.332 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 164.685 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -131.14 -48.74 1.01 Allowed 'General case' 0 CA--C 1.493 -1.239 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -174.093 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 56.4 m170 . . . . . 0 C--O 1.26 1.614 0 C-N-CA 126.151 1.78 . . . . 0.0 111.084 -178.735 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 25.6 t80 . . . . . 0 N--CA 1.483 1.208 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 66.4 mm-40 -124.69 -70.61 0.75 Allowed 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 105.026 -2.213 . . . . 0.0 105.026 -177.331 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 43.4 m-20 -149.64 106.09 3.51 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 103.076 -2.935 . . . . 0.0 103.076 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 90.0 mt -90.26 160.69 39.32 Favored Pre-proline 0 N--CA 1.443 -0.796 0 C-N-CA 125.097 1.359 . . . . 0.0 107.691 176.094 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -77.1 -179.78 5.76 Favored 'Trans proline' 0 CA--C 1.5 -1.206 0 C-N-CA 123.199 2.599 . . . . 0.0 110.499 -176.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -70.83 -47.42 59.48 Favored 'General case' 0 CA--C 1.501 -0.922 0 C-N-CA 125.652 1.581 . . . . 0.0 110.284 -173.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -79.66 -18.04 52.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 C-N-CA 124.585 1.154 . . . . 0.0 109.877 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.41 28.82 6.54 Favored Glycine 0 C--N 1.357 1.718 0 C-N-CA 124.376 0.989 . . . . 0.0 111.241 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -115.22 -32.43 5.67 Favored 'General case' 0 CA--C 1.501 -0.916 0 C-N-CA 124.654 1.182 . . . . 0.0 108.08 171.256 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.0 mp -80.59 -37.95 17.16 Favored 'Isoleucine or valine' 0 C--N 1.354 0.774 0 C-N-CA 125.19 1.396 . . . . 0.0 109.005 -172.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -83.32 11.53 6.6 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.435 0.694 . . . . 0.0 111.378 179.16 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 82.0 t -118.16 -33.34 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 C-N-CA 125.253 1.421 . . . . 0.0 107.713 178.413 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.87 -21.65 40.5 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -170.731 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 p -65.93 -33.72 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 C-N-CA 125.317 1.447 . . . . 0.0 110.751 175.257 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -81.68 -24.97 35.92 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 112.797 -2.001 . . . . 0.0 110.052 -178.595 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -71.78 -46.7 57.49 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 54.3 m-70 -72.26 160.76 31.85 Favored 'General case' 0 N--CA 1.424 -1.767 0 C-N-CA 124.701 1.201 . . . . 0.0 112.126 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -119.48 -9.53 8.46 Favored Glycine 0 C--N 1.351 1.38 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 174.794 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -104.33 44.44 1.02 Allowed 'General case' 0 C--N 1.359 1.017 0 CA-C-O 122.7 1.238 . . . . 0.0 108.83 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -161.73 144.04 11.69 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 104.0 -2.592 . . . . 0.0 104.0 177.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 16.8 pt -86.38 149.1 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 178.132 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 58.3 m170 -91.97 -36.67 13.29 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -176.666 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 22.9 p80 . . . . . 0 C--O 1.261 1.683 0 C-N-CA 124.785 1.234 . . . . 0.0 110.965 177.67 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 . . . . . 0 N--CA 1.488 1.468 0 CA-C-O 121.982 0.896 . . . . 0.0 111.023 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 59.0 mm-40 -89.67 -21.39 22.78 Favored 'General case' 0 N--CA 1.443 -0.812 0 C-N-CA 124.703 1.201 . . . . 0.0 108.583 175.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 44.1 m-20 77.8 102.6 0.07 Allowed 'General case' 0 C--N 1.359 0.986 0 C-N-CA 127.877 2.471 . . . . 0.0 108.347 -176.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 64.7 mt -96.41 157.06 36.1 Favored Pre-proline 0 N--CA 1.44 -0.944 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 -169.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -79.37 179.12 6.67 Favored 'Trans proline' 0 CA--C 1.501 -1.148 0 C-N-CA 122.767 2.311 . . . . 0.0 110.902 -170.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -121.0 -56.83 1.91 Allowed 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -85.05 -1.29 56.66 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.733 1.213 . . . . 0.0 110.773 -177.005 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -88.79 8.42 79.53 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.236 0.922 . . . . 0.0 110.929 175.516 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.1 t60 -106.84 -31.21 8.48 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 173.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -74.83 -38.46 44.1 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.889 0 C-N-CA 125.127 1.371 . . . . 0.0 108.798 -174.069 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.0 4.59 11.82 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 179.123 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -105.79 -38.36 4.45 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 C-N-CA 124.909 1.284 . . . . 0.0 108.411 173.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.63 -21.75 51.78 Favored 'General case' 0 CA--C 1.476 -1.868 0 N-CA-C 115.122 1.527 . . . . 0.0 115.122 -163.756 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.9 m -69.35 -29.66 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 C-N-CA 125.468 1.507 . . . . 0.0 110.99 176.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -86.87 -24.74 24.79 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 112.513 -2.131 . . . . 0.0 109.866 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -72.21 -41.09 67.32 Favored 'General case' 0 C--N 1.356 0.868 0 C-N-CA 124.378 1.071 . . . . 0.0 108.202 176.448 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 57.2 m170 -62.87 -50.2 71.86 Favored 'General case' 0 N--CA 1.428 -1.542 0 C-N-CA 126.301 1.841 . . . . 0.0 110.618 174.617 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.85 100.97 2.68 Favored Glycine 0 CA--C 1.491 -1.435 0 N-CA-C 107.441 -2.264 . . . . 0.0 107.441 175.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -100.4 64.89 1.18 Allowed 'General case' 0 C--N 1.355 0.819 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 176.245 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -81.48 -67.87 0.74 Allowed 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 21.0 pt -85.19 158.73 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 125.28 1.432 . . . . 0.0 108.017 174.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -137.09 59.72 1.68 Allowed 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 104.497 -2.408 . . . . 0.0 104.497 177.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 26.8 p80 . . . . . 0 C--O 1.258 1.545 0 C-N-CA 126.928 2.091 . . . . 0.0 112.835 -179.016 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 5.9 t80 . . . . . 0 N--CA 1.487 1.424 0 N-CA-C 110.683 -0.118 . . . . 0.0 110.683 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 76.54 -4.34 2.37 Favored 'General case' 0 N--CA 1.441 -0.901 0 C-N-CA 127.729 2.412 . . . . 0.0 113.224 -176.679 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 72.0 99.43 0.07 Allowed 'General case' 0 CA--C 1.496 -1.11 0 C-N-CA 127.663 2.385 . . . . 0.0 110.878 178.411 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -145.51 159.34 48.41 Favored Pre-proline 0 N--CA 1.441 -0.876 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 176.301 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -78.69 -178.42 4.62 Favored 'Trans proline' 0 CA--C 1.5 -1.193 0 C-N-CA 122.518 2.145 . . . . 0.0 111.215 -172.191 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -77.71 -40.71 40.41 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 125.748 1.619 . . . . 0.0 108.407 -178.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -77.88 -13.87 59.74 Favored 'General case' 0 C--N 1.356 0.863 0 C-N-CA 124.557 1.143 . . . . 0.0 109.872 178.045 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -79.57 0.33 81.65 Favored Glycine 0 C--N 1.357 1.734 0 C-N-CA 124.124 0.868 . . . . 0.0 112.29 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -96.81 -36.23 10.69 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 172.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.2 mt -73.94 -48.47 38.59 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.929 0 C-N-CA 126.073 1.749 . . . . 0.0 110.94 -169.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -75.94 -23.09 55.4 Favored 'General case' 0 CA--C 1.508 -0.671 0 C-N-CA 124.317 1.047 . . . . 0.0 112.397 -171.053 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 84.3 t -81.19 -25.5 10.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 C-N-CA 125.099 1.36 . . . . 0.0 109.658 -175.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 24.9 tptp -84.57 -20.3 31.72 Favored 'General case' 0 N--CA 1.429 -1.501 0 C-N-CA 125.858 1.663 . . . . 0.0 111.454 -171.478 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 58.8 t -60.33 -37.54 74.43 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.927 0 C-N-CA 126.599 1.96 . . . . 0.0 109.563 168.377 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -86.52 -12.35 49.07 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.196 -175.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -80.46 -28.66 37.57 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.38 1.072 . . . . 0.0 108.57 173.263 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 46.3 m170 -60.69 164.49 4.61 Favored 'General case' 0 C--N 1.365 1.276 0 C-N-CA 125.36 1.464 . . . . 0.0 112.754 177.703 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -101.15 70.88 0.4 Allowed Glycine 0 C--N 1.354 1.551 0 N-CA-C 106.122 -2.791 . . . . 0.0 106.122 176.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -95.27 62.11 2.46 Favored 'General case' 0 N--CA 1.442 -0.858 0 C-N-CA 125.575 1.55 . . . . 0.0 108.668 -176.726 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 71.6 m80 -93.49 165.42 12.76 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 31.5 pt -88.92 173.65 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.187 0 C-N-CA 124.446 1.098 . . . . 0.0 108.874 -179.09 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 17.9 p80 -84.88 -32.88 22.95 Favored 'General case' 0 N--CA 1.442 -0.843 0 C-N-CA 124.483 1.113 . . . . 0.0 109.092 177.726 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 70.8 t60 . . . . . 0 C--O 1.261 1.666 0 C-N-CA 126.145 1.778 . . . . 0.0 111.084 177.272 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 . . . . . 0 CA--C 1.505 -0.755 0 N-CA-C 110.641 -0.133 . . . . 0.0 110.641 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -81.96 -13.12 57.91 Favored 'General case' 0 C--N 1.356 0.862 0 C-N-CA 123.847 0.859 . . . . 0.0 110.125 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -69.95 -28.87 71.27 Favored Glycine 0 C--N 1.356 1.642 0 C-N-CA 123.823 0.725 . . . . 0.0 111.745 178.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.4 t-80 -74.35 -39.54 62.72 Favored 'General case' 0 N--CA 1.434 -1.252 0 C-N-CA 124.778 1.231 . . . . 0.0 111.249 175.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.3 mt -73.41 -36.65 49.12 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.731 0 C-N-CA 125.979 1.712 . . . . 0.0 111.435 -169.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 19.8 pt20 -77.07 -7.84 56.41 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 123.693 0.797 . . . . 0.0 112.197 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.35 -35.17 3.46 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.54 -21.23 52.93 Favored 'General case' 0 CA--C 1.47 -2.115 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -169.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -62.07 -32.51 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.272 0 C-N-CA 125.929 1.692 . . . . 0.0 111.529 178.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -75.64 -41.52 53.9 Favored 'General case' 0 CA--C 1.503 -0.844 0 CA-C-N 112.658 -2.064 . . . . 0.0 109.959 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.4 t30 -71.37 -32.5 68.56 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.987 1.315 . . . . 0.0 110.386 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.0 t60 . . . . . 0 N--CA 1.421 -1.882 0 C-N-CA 127.701 2.4 . . . . 0.0 110.98 179.896 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 . . . . . 0 CA--C 1.506 -0.712 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -79.66 -23.33 42.57 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.73 1.212 . . . . 0.0 108.866 174.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -77.76 -14.4 82.43 Favored Glycine 0 C--N 1.355 1.633 0 C-N-CA 124.39 0.995 . . . . 0.0 111.504 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 32.3 m170 -89.49 -35.52 15.92 Favored 'General case' 0 CA--C 1.502 -0.896 0 C-N-CA 124.244 1.018 . . . . 0.0 108.56 174.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -72.57 -30.93 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 C-N-CA 125.898 1.679 . . . . 0.0 111.74 -171.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 5.4 pp0? -78.31 -5.96 53.67 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 124.13 0.972 . . . . 0.0 111.927 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.9 t -83.95 -41.18 16.31 Favored 'Isoleucine or valine' 0 C--N 1.357 0.919 0 C-N-CA 124.023 0.929 . . . . 0.0 108.558 174.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -72.06 -16.23 62.03 Favored 'General case' 0 CA--C 1.491 -1.306 0 C-N-CA 127.426 2.29 . . . . 0.0 113.009 -165.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.1 t -49.55 -37.32 11.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 C-N-CA 129.07 2.948 . . . . 0.0 111.368 170.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -55.97 -36.38 67.78 Favored 'General case' 0 C--N 1.349 0.571 0 C-N-CA 126.886 2.074 . . . . 0.0 113.158 -175.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -86.32 -48.59 8.35 Favored 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 126.089 1.756 . . . . 0.0 107.697 -178.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 . . . . . 0 N--CA 1.431 -1.376 0 C-N-CA 126.722 2.009 . . . . 0.0 112.706 -175.655 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -80.24 -11.06 59.77 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.474 1.109 . . . . 0.0 110.151 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -73.02 -18.52 79.18 Favored Glycine 0 C--N 1.357 1.712 0 C-N-CA 124.205 0.907 . . . . 0.0 111.857 178.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.2 m170 -85.03 -40.63 16.63 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.365 1.066 . . . . 0.0 109.204 175.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.2 mt -68.18 -34.69 67.88 Favored 'Isoleucine or valine' 0 C--N 1.352 0.708 0 C-N-CA 127.185 2.194 . . . . 0.0 111.73 -171.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -80.25 12.6 2.8 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 124.595 1.158 . . . . 0.0 112.719 -176.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -107.32 -32.7 2.57 Favored 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.1 mmmt -86.65 -9.73 55.37 Favored 'General case' 0 CA--C 1.485 -1.551 0 C-N-CA 124.508 1.123 . . . . 0.0 110.647 -170.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.5 p -61.14 -36.74 74.68 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 C-N-CA 126.094 1.758 . . . . 0.0 110.595 170.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -77.37 -29.35 53.25 Favored 'General case' 0 CA--C 1.506 -0.714 0 C-N-CA 126.613 1.965 . . . . 0.0 110.209 -178.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -73.83 -41.07 62.83 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.368 1.067 . . . . 0.0 109.091 177.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 35.5 m-70 . . . . . 0 N--CA 1.428 -1.552 0 C-N-CA 125.357 1.463 . . . . 0.0 110.222 178.245 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.5 m120 . . . . . 0 CA--C 1.503 -0.827 0 CA-C-O 120.354 0.121 . . . . 0.0 111.247 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -84.8 -10.23 57.4 Favored 'General case' 0 CA--C 1.505 -0.76 0 C-N-CA 124.452 1.101 . . . . 0.0 110.045 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.7 5.36 83.92 Favored Glycine 0 C--N 1.355 1.585 0 C-N-CA 124.09 0.852 . . . . 0.0 111.966 179.015 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.2 m-70 -91.37 -40.33 11.51 Favored 'General case' 0 CA--C 1.501 -0.908 0 C-N-CA 123.893 0.877 . . . . 0.0 108.645 175.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.3 mp -72.51 -32.7 42.71 Favored 'Isoleucine or valine' 0 C--N 1.352 0.694 0 C-N-CA 126.476 1.91 . . . . 0.0 110.488 -171.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 4.4 pp0? -80.75 9.07 6.76 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.884 0.873 . . . . 0.0 112.493 -177.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -97.65 -33.27 4.26 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 171.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 mmmt -89.63 -8.75 51.84 Favored 'General case' 0 CA--C 1.483 -1.608 0 C-N-CA 124.843 1.257 . . . . 0.0 111.208 -166.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.9 p -64.23 -37.35 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 C-N-CA 125.295 1.438 . . . . 0.0 110.315 168.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -79.1 -26.87 42.9 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.898 -178.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -75.71 -40.36 55.82 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.263 1.025 . . . . 0.0 109.219 178.106 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.432 -1.355 0 C-N-CA 124.909 1.284 . . . . 0.0 113.072 -172.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 . . . . . 0 CA--C 1.498 -1.03 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 35.4 t80 -80.97 -10.17 59.75 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.489 1.115 . . . . 0.0 110.313 -177.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.06 3.32 77.21 Favored Glycine 0 C--N 1.356 1.686 0 C-N-CA 123.908 0.765 . . . . 0.0 112.005 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 58.5 m170 -109.04 -31.9 7.44 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.174 1.389 . . . . 0.0 107.782 174.164 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -76.71 -33.53 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.742 0 C-N-CA 125.827 1.651 . . . . 0.0 110.563 -172.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.53 -16.98 58.36 Favored 'General case' 0 N--CA 1.445 -0.695 0 C-N-CA 123.495 0.718 . . . . 0.0 111.515 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -91.1 -43.04 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 C-N-CA 124.15 0.98 . . . . 0.0 109.072 -176.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -19.68 65.11 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -163.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.4 m -57.28 -29.42 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.268 0 C-N-CA 127.916 2.487 . . . . 0.0 113.191 177.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.12 -36.77 71.05 Favored 'General case' 0 CA--C 1.511 -0.533 0 C-N-CA 127.745 2.418 . . . . 0.0 112.661 -176.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -70.07 -53.84 15.69 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 126.49 1.916 . . . . 0.0 108.98 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 . . . . . 0 N--CA 1.428 -1.539 0 C-N-CA 125.172 1.389 . . . . 0.0 112.897 -173.706 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 4.0 p30 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -82.46 -5.78 58.9 Favored 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 173.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.72 24.94 9.14 Favored Glycine 0 C--N 1.356 1.666 0 C-N-CA 124.506 1.051 . . . . 0.0 110.803 175.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.7 m-70 -114.29 -40.48 3.65 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 168.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.6 mp -76.71 -42.82 34.17 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.98 0 C-N-CA 125.91 1.684 . . . . 0.0 110.173 -172.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -76.78 -26.25 54.28 Favored 'General case' 0 CA--C 1.508 -0.649 0 O-C-N 121.956 -0.465 . . . . 0.0 110.71 -177.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.9 t -78.23 -24.26 13.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 C-N-CA 125.345 1.458 . . . . 0.0 109.976 -175.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.67 -25.56 53.83 Favored 'General case' 0 CA--C 1.475 -1.923 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -176.422 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.7 -33.06 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 C-N-CA 125.207 1.403 . . . . 0.0 108.286 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 15.8 m-30 -81.45 -28.5 34.15 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 113.317 -1.765 . . . . 0.0 108.787 -172.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -75.89 -46.0 32.45 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.06 1.344 . . . . 0.0 108.521 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 . . . . . 0 N--CA 1.425 -1.677 0 C-N-CA 126.466 1.906 . . . . 0.0 111.649 -175.698 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.3 m-80 . . . . . 0 CA--C 1.502 -0.887 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -83.6 2.2 38.48 Favored 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.604 1.161 . . . . 0.0 110.83 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 12.68 66.48 Favored Glycine 0 C--N 1.355 1.62 0 C-N-CA 124.37 0.986 . . . . 0.0 110.745 173.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -118.44 -27.23 6.02 Favored 'General case' 0 C--N 1.355 0.845 0 C-N-CA 124.93 1.292 . . . . 0.0 108.834 174.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -76.85 -40.26 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.997 0 C-N-CA 125.198 1.399 . . . . 0.0 108.062 -177.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -66.23 -25.17 66.78 Favored 'General case' 0 C--N 1.348 0.514 0 C-N-CA 123.834 0.854 . . . . 0.0 112.375 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 66.5 t -73.81 -29.19 25.62 Favored 'Isoleucine or valine' 0 C--N 1.357 0.914 0 C-N-CA 125.464 1.506 . . . . 0.0 110.132 -176.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.08 -25.7 52.63 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -174.416 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 88.5 t -68.63 -33.32 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 125.163 1.385 . . . . 0.0 108.149 179.228 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.4 m-30 -80.29 -28.29 38.34 Favored 'General case' 0 CA--C 1.504 -0.801 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.351 -172.007 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -76.07 -43.13 45.07 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.838 1.255 . . . . 0.0 108.211 176.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 81.4 t60 . . . . . 0 N--CA 1.421 -1.912 0 C-N-CA 127.268 2.227 . . . . 0.0 110.913 -178.319 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 . . . . . 0 N--CA 1.446 -0.65 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -77.02 -34.22 57.37 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 125.175 1.39 . . . . 0.0 111.029 -178.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.84 14.2 62.4 Favored Glycine 0 C--N 1.35 1.358 0 C-N-CA 124.07 0.843 . . . . 0.0 111.96 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 t60 -102.59 -38.24 7.6 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.855 -1.905 . . . . 0.0 105.855 170.001 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.7 mt -71.2 -31.39 44.09 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 C-N-CA 125.697 1.599 . . . . 0.0 110.249 -175.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -71.72 -26.82 62.64 Favored 'General case' 0 N--CA 1.422 -1.857 0 C-N-CA 127.557 2.343 . . . . 0.0 110.476 -178.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.7 t -94.01 -34.56 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 C-N-CA 124.382 1.073 . . . . 0.0 109.457 -177.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.2 pptp? -79.22 -19.83 49.75 Favored 'General case' 0 CA--C 1.469 -2.159 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -166.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.1 p -64.6 -32.84 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-O 123.293 1.521 . . . . 0.0 111.006 177.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -78.86 -30.52 45.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.669 -2.06 . . . . 0.0 109.921 -178.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -80.42 -36.88 33.09 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 124.073 0.949 . . . . 0.0 110.056 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.43 -1.453 0 C-N-CA 125.616 1.566 . . . . 0.0 113.935 -168.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 . . . . . 0 CA--C 1.498 -1.021 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -82.62 -13.48 56.43 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 124.298 1.039 . . . . 0.0 110.139 -175.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.09 7.88 65.52 Favored Glycine 0 C--N 1.355 1.618 0 C-N-CA 123.702 0.668 . . . . 0.0 111.784 178.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 66.9 m170 -102.99 -30.68 10.63 Favored 'General case' 0 CA--C 1.503 -0.858 0 C-N-CA 124.975 1.31 . . . . 0.0 107.775 171.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 31.9 mm -75.14 -38.74 42.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 C-N-CA 125.832 1.653 . . . . 0.0 110.27 -170.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -77.97 -8.49 58.21 Favored 'General case' 0 N--CA 1.441 -0.915 0 C-N-CA 123.507 0.723 . . . . 0.0 111.435 -176.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -101.48 -31.05 3.12 Favored 'Isoleucine or valine' 0 C--N 1.357 0.899 0 C-N-CA 125.139 1.376 . . . . 0.0 108.679 -177.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.9 pptp? -79.49 -19.13 50.49 Favored 'General case' 0 CA--C 1.472 -2.023 0 N-CA-C 115.107 1.521 . . . . 0.0 115.107 -166.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 28.7 m -67.87 -32.09 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 C-N-CA 125.077 1.351 . . . . 0.0 110.72 175.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -84.58 -24.26 29.28 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-N 112.6 -2.091 . . . . 0.0 109.912 -177.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -73.19 -45.45 56.35 Favored 'General case' 0 C--N 1.356 0.865 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 43.2 m170 . . . . . 0 N--CA 1.425 -1.707 0 C-N-CA 125.869 1.668 . . . . 0.0 111.527 179.865 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 36.1 m120 . . . . . 0 CA--C 1.504 -0.801 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -82.57 -12.65 57.57 Favored 'General case' 0 C--N 1.354 0.792 0 C-N-CA 125.149 1.38 . . . . 0.0 109.913 177.327 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.03 8.42 76.51 Favored Glycine 0 C--N 1.356 1.655 0 C-N-CA 124.253 0.93 . . . . 0.0 111.873 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -92.94 -32.45 14.55 Favored 'General case' 0 CA--C 1.503 -0.858 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.1 mp -76.82 -32.75 20.53 Favored 'Isoleucine or valine' 0 C--N 1.354 0.785 0 C-N-CA 125.734 1.613 . . . . 0.0 109.811 -174.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -71.94 -16.47 62.1 Favored 'General case' 0 C--N 1.35 0.628 0 C-N-CA 123.342 0.657 . . . . 0.0 112.384 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.9 t -98.92 -36.85 5.79 Favored 'Isoleucine or valine' 0 C--N 1.358 0.96 0 C-N-CA 124.103 0.961 . . . . 0.0 108.718 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.57 -19.35 57.99 Favored 'General case' 0 CA--C 1.471 -2.069 0 N-CA-C 114.505 1.298 . . . . 0.0 114.505 -168.057 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.87 -33.61 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.187 0 C-N-CA 125.771 1.628 . . . . 0.0 111.226 177.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -77.2 -28.86 54.06 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.617 -2.083 . . . . 0.0 110.863 -176.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 -80.07 -43.3 22.06 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 123.92 0.888 . . . . 0.0 108.63 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 16.7 t-160 . . . . . 0 N--CA 1.428 -1.536 0 C-N-CA 127.149 2.179 . . . . 0.0 112.753 -175.434 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.1 m-80 . . . . . 0 CA--C 1.505 -0.767 0 CA-C-O 120.405 0.145 . . . . 0.0 111.261 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -84.95 -10.96 56.53 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.546 1.138 . . . . 0.0 109.845 178.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.62 -22.98 78.59 Favored Glycine 0 C--N 1.355 1.628 0 C-N-CA 125.162 1.363 . . . . 0.0 111.877 178.262 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -71.12 -40.79 71.21 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 117.934 0.867 . . . . 0.0 111.08 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.8 mp -76.05 -36.51 31.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 C-N-CA 124.925 1.29 . . . . 0.0 110.558 -170.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -81.24 -3.8 53.51 Favored 'General case' 0 N--CA 1.446 -0.664 0 O-C-N 121.828 -0.545 . . . . 0.0 112.374 -176.465 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.5 t -112.2 -26.13 3.21 Favored 'Isoleucine or valine' 0 C--N 1.358 0.969 0 C-N-CA 124.424 1.09 . . . . 0.0 108.486 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.73 -20.59 49.64 Favored 'General case' 0 CA--C 1.471 -2.09 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -173.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.3 p -64.47 -35.71 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.327 0 C-N-CA 125.009 1.324 . . . . 0.0 110.619 174.004 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -83.01 -24.78 32.72 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-N 112.898 -1.955 . . . . 0.0 109.939 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.2 t-20 -72.25 -43.31 64.55 Favored 'General case' 0 C--N 1.356 0.888 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.5 m170 . . . . . 0 N--CA 1.421 -1.896 0 C-N-CA 126.634 1.974 . . . . 0.0 110.215 176.807 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 . . . . . 0 CA--C 1.507 -0.707 0 CA-C-O 120.576 0.227 . . . . 0.0 110.741 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -83.92 -14.99 49.61 Favored 'General case' 0 C--N 1.352 0.713 0 C-N-CA 124.796 1.239 . . . . 0.0 110.159 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.57 -2.83 72.35 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -93.84 -11.35 31.38 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 118.007 0.903 . . . . 0.0 108.983 174.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 47.8 mm -77.09 -36.21 24.31 Favored 'Isoleucine or valine' 0 C--N 1.356 0.861 0 C-N-CA 125.008 1.323 . . . . 0.0 108.842 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.39 0.65 40.99 Favored 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 122.896 0.478 . . . . 0.0 111.436 -179.089 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.78 -40.59 9.26 Favored 'Isoleucine or valine' 0 C--N 1.358 0.94 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 171.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.25 -17.58 58.3 Favored 'General case' 0 CA--C 1.47 -2.106 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -167.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -63.67 -34.41 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 C-N-CA 125.402 1.481 . . . . 0.0 110.826 176.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -80.44 -29.81 37.58 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 112.724 -2.035 . . . . 0.0 110.357 -177.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.5 t30 -73.05 -40.99 64.64 Favored 'General case' 0 C--N 1.354 0.774 0 C-N-CA 124.216 1.007 . . . . 0.0 108.609 176.449 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.2 t60 . . . . . 0 N--CA 1.418 -2.026 0 C-N-CA 127.462 2.305 . . . . 0.0 110.266 179.905 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 . . . . . 0 CA--C 1.498 -1.023 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -88.94 1.31 55.63 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.681 1.192 . . . . 0.0 110.784 -174.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.95 -10.44 80.85 Favored Glycine 0 C--N 1.356 1.666 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 176.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.4 m-70 -95.04 -31.22 13.7 Favored 'General case' 0 CA--C 1.502 -0.876 0 C-N-CA 124.122 0.969 . . . . 0.0 108.701 173.779 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.2 mt -75.82 -33.39 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 C-N-CA 125.508 1.523 . . . . 0.0 110.6 -171.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -74.1 -13.14 60.79 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 123.506 0.722 . . . . 0.0 112.163 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.14 -33.18 3.93 Favored 'Isoleucine or valine' 0 C--N 1.357 0.915 0 C-N-CA 124.766 1.226 . . . . 0.0 108.957 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.74 -19.78 47.94 Favored 'General case' 0 CA--C 1.476 -1.883 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -164.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 m -68.98 -30.24 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 C-N-CA 125.207 1.403 . . . . 0.0 110.822 175.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -87.08 -20.7 26.75 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.472 -2.149 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -75.7 -31.25 59.61 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.174 0.99 . . . . 0.0 109.056 177.167 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 56.5 m170 . . . . . 0 N--CA 1.434 -1.272 0 C-N-CA 125.704 1.602 . . . . 0.0 112.379 177.092 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 . . . . . 0 N--CA 1.435 -1.215 0 N-CA-C 104.538 -2.393 . . . . 0.0 104.538 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -86.68 -1.09 57.42 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.862 1.265 . . . . 0.0 110.898 -174.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.04 -30.02 39.65 Favored Glycine 0 C--N 1.355 1.633 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.1 m80 -76.81 -30.42 56.41 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 124.605 1.162 . . . . 0.0 110.363 177.016 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -73.58 -31.1 31.34 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 C-N-CA 126.029 1.731 . . . . 0.0 109.61 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.38 -27.84 64.63 Favored 'General case' 0 N--CA 1.437 -1.114 0 C-N-CA 125.441 1.497 . . . . 0.0 111.261 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 83.9 t -85.77 -44.87 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.864 0 C-N-CA 123.287 0.635 . . . . 0.0 109.502 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 pptp? -66.69 -21.28 66.09 Favored 'General case' 0 CA--C 1.483 -1.628 0 N-CA-C 116.191 1.922 . . . . 0.0 116.191 -160.279 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -55.39 -30.66 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 C-N-CA 127.953 2.501 . . . . 0.0 113.127 176.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.19 -37.24 71.86 Favored 'General case' 0 CA--C 1.509 -0.629 0 C-N-CA 127.903 2.481 . . . . 0.0 112.974 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -75.61 -47.3 27.17 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 126.007 1.723 . . . . 0.0 108.474 -177.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 44.0 m170 . . . . . 0 N--CA 1.432 -1.346 0 C-N-CA 126.22 1.808 . . . . 0.0 113.216 -175.1 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 . . . . . 0 N--CA 1.435 -1.219 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -82.69 -5.19 58.73 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.928 1.291 . . . . 0.0 111.371 -173.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -84.93 2.35 88.31 Favored Glycine 0 C--N 1.356 1.644 0 C-N-CA 124.064 0.84 . . . . 0.0 111.288 176.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -112.3 -26.62 8.67 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.207 1.403 . . . . 0.0 108.302 175.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.7 mt -75.73 -34.44 28.49 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 125.503 1.521 . . . . 0.0 109.888 -176.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.33 -11.06 59.79 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 123.799 0.84 . . . . 0.0 111.994 -179.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.7 t -98.17 -31.35 3.71 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 124.696 1.198 . . . . 0.0 108.93 -175.627 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.58 -19.25 58.07 Favored 'General case' 0 CA--C 1.475 -1.92 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -167.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.3 m -63.86 -31.37 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 C-N-CA 126.31 1.844 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -77.07 -34.72 56.99 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.252 -2.249 . . . . 0.0 109.972 -176.168 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 37.4 t30 -74.67 -43.39 55.5 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 124.369 1.068 . . . . 0.0 108.85 177.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.1 t-80 . . . . . 0 N--CA 1.429 -1.499 0 C-N-CA 127.124 2.17 . . . . 0.0 112.637 -175.874 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 41.0 t30 . . . . . 0 N--CA 1.444 -0.739 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -79.05 -17.06 55.92 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 124.511 1.125 . . . . 0.0 110.247 -178.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.56 29.67 7.6 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.107 0.861 . . . . 0.0 111.078 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 55.3 m-70 -112.64 -35.11 5.61 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 168.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mp -73.06 -44.75 56.05 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 109.243 -173.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 3.2 pp0? -78.69 -6.48 55.87 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.529 0.732 . . . . 0.0 112.22 -176.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.91 -28.2 3.82 Favored 'Isoleucine or valine' 0 C--N 1.358 0.949 0 C-N-CA 124.325 1.05 . . . . 0.0 109.171 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.69 -21.7 54.99 Favored 'General case' 0 CA--C 1.473 -2.006 0 N-CA-C 114.181 1.178 . . . . 0.0 114.181 -169.427 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.4 m -64.98 -28.78 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 126.629 1.971 . . . . 0.0 111.428 -176.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -71.6 -41.5 68.87 Favored 'General case' 0 CA--C 1.506 -0.746 0 CA-C-N 111.84 -2.436 . . . . 0.0 109.947 -175.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -80.94 -41.82 22.3 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.463 1.105 . . . . 0.0 109.594 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 71.0 t60 . . . . . 0 N--CA 1.426 -1.634 0 C-N-CA 127.933 2.493 . . . . 0.0 112.452 -170.065 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.7 m120 . . . . . 0 CA--C 1.496 -1.13 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -81.13 -12.46 59.24 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.445 1.098 . . . . 0.0 110.004 -178.028 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.27 9.32 61.42 Favored Glycine 0 C--N 1.356 1.694 0 C-N-CA 123.652 0.644 . . . . 0.0 112.145 178.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -109.43 -32.02 7.31 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 168.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.3 -34.55 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.827 0 C-N-CA 125.933 1.693 . . . . 0.0 110.956 -170.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -80.12 -24.66 40.33 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.149 0.58 . . . . 0.0 110.608 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t -81.92 -28.34 9.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.813 0 C-N-CA 125.224 1.41 . . . . 0.0 109.803 -175.283 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.85 -19.17 57.81 Favored 'General case' 0 CA--C 1.477 -1.846 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 -171.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 82.1 t -67.55 -36.02 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.227 0 C-N-CA 125.454 1.502 . . . . 0.0 108.67 176.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -85.76 -23.86 27.11 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.659 -1.609 . . . . 0.0 108.808 -175.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -73.95 -35.23 64.53 Favored 'General case' 0 N--CA 1.44 -0.948 0 C-N-CA 123.922 0.889 . . . . 0.0 108.776 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.427 -1.602 0 C-N-CA 124.5 1.12 . . . . 0.0 109.437 174.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 . . . . . 0 CA--C 1.501 -0.922 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -79.66 -18.04 52.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 C-N-CA 124.585 1.154 . . . . 0.0 109.877 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.41 28.82 6.54 Favored Glycine 0 C--N 1.357 1.718 0 C-N-CA 124.376 0.989 . . . . 0.0 111.241 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -115.22 -32.43 5.67 Favored 'General case' 0 CA--C 1.501 -0.916 0 C-N-CA 124.654 1.182 . . . . 0.0 108.08 171.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.0 mp -80.59 -37.95 17.16 Favored 'Isoleucine or valine' 0 C--N 1.354 0.774 0 C-N-CA 125.19 1.396 . . . . 0.0 109.005 -172.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -83.32 11.53 6.6 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.435 0.694 . . . . 0.0 111.378 179.16 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 82.0 t -118.16 -33.34 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 C-N-CA 125.253 1.421 . . . . 0.0 107.713 178.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.87 -21.65 40.5 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -170.731 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 p -65.93 -33.72 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 C-N-CA 125.317 1.447 . . . . 0.0 110.751 175.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -81.68 -24.97 35.92 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 112.797 -2.001 . . . . 0.0 110.052 -178.595 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -71.78 -46.7 57.49 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 54.3 m-70 . . . . . 0 N--CA 1.424 -1.767 0 C-N-CA 124.701 1.201 . . . . 0.0 112.126 -179.99 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 . . . . . 0 CA--C 1.494 -1.184 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -85.05 -1.29 56.66 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.733 1.213 . . . . 0.0 110.773 -177.005 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -88.79 8.42 79.53 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.236 0.922 . . . . 0.0 110.929 175.516 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.1 t60 -106.84 -31.21 8.48 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 173.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -74.83 -38.46 44.1 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.889 0 C-N-CA 125.127 1.371 . . . . 0.0 108.798 -174.069 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.0 4.59 11.82 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 179.123 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -105.79 -38.36 4.45 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 C-N-CA 124.909 1.284 . . . . 0.0 108.411 173.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.63 -21.75 51.78 Favored 'General case' 0 CA--C 1.476 -1.868 0 N-CA-C 115.122 1.527 . . . . 0.0 115.122 -163.756 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.9 m -69.35 -29.66 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 C-N-CA 125.468 1.507 . . . . 0.0 110.99 176.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -86.87 -24.74 24.79 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 112.513 -2.131 . . . . 0.0 109.866 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -72.21 -41.09 67.32 Favored 'General case' 0 C--N 1.356 0.868 0 C-N-CA 124.378 1.071 . . . . 0.0 108.202 176.448 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 57.2 m170 . . . . . 0 N--CA 1.428 -1.542 0 C-N-CA 126.301 1.841 . . . . 0.0 110.618 174.617 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 . . . . . 0 N--CA 1.443 -0.811 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -77.88 -13.87 59.74 Favored 'General case' 0 C--N 1.356 0.863 0 C-N-CA 124.557 1.143 . . . . 0.0 109.872 178.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -79.57 0.33 81.65 Favored Glycine 0 C--N 1.357 1.734 0 C-N-CA 124.124 0.868 . . . . 0.0 112.29 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -96.81 -36.23 10.69 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 172.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.2 mt -73.94 -48.47 38.59 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.929 0 C-N-CA 126.073 1.749 . . . . 0.0 110.94 -169.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -75.94 -23.09 55.4 Favored 'General case' 0 CA--C 1.508 -0.671 0 C-N-CA 124.317 1.047 . . . . 0.0 112.397 -171.053 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 84.3 t -81.19 -25.5 10.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 C-N-CA 125.099 1.36 . . . . 0.0 109.658 -175.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 24.9 tptp -84.57 -20.3 31.72 Favored 'General case' 0 N--CA 1.429 -1.501 0 C-N-CA 125.858 1.663 . . . . 0.0 111.454 -171.478 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 58.8 t -60.33 -37.54 74.43 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.927 0 C-N-CA 126.599 1.96 . . . . 0.0 109.563 168.377 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -86.52 -12.35 49.07 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.196 -175.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -80.46 -28.66 37.57 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.38 1.072 . . . . 0.0 108.57 173.263 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 46.3 m170 . . . . . 0 C--N 1.365 1.276 0 C-N-CA 125.36 1.464 . . . . 0.0 112.754 177.703 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 50.2 p90 . . . . . 0 N--CA 1.489 1.493 0 CA-C-O 121.379 0.609 . . . . 0.0 111.788 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 63.2 mm-40 -88.85 -83.1 0.23 Allowed 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -154.66 101.53 2.32 Favored 'General case' 0 N--CA 1.433 -1.299 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 177.094 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 94.8 mt -101.01 159.27 29.96 Favored Pre-proline 0 CA--C 1.501 -0.93 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -75.85 -173.81 1.8 Allowed 'Trans proline' 0 CA--C 1.501 -1.144 0 C-N-CA 123.159 2.573 . . . . 0.0 110.945 177.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.1 m-80 -65.17 -51.3 61.97 Favored 'General case' 0 CA--C 1.505 -0.755 0 C-N-CA 125.806 1.643 . . . . 0.0 110.641 -176.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -81.96 -13.12 57.91 Favored 'General case' 0 C--N 1.356 0.862 0 C-N-CA 123.847 0.859 . . . . 0.0 110.125 179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -69.95 -28.87 71.27 Favored Glycine 0 C--N 1.356 1.642 0 C-N-CA 123.823 0.725 . . . . 0.0 111.745 178.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 20.4 t-80 -74.35 -39.54 62.72 Favored 'General case' 0 N--CA 1.434 -1.252 0 C-N-CA 124.778 1.231 . . . . 0.0 111.249 175.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.3 mt -73.41 -36.65 49.12 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.731 0 C-N-CA 125.979 1.712 . . . . 0.0 111.435 -169.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 19.8 pt20 -77.07 -7.84 56.41 Favored 'General case' 0 N--CA 1.446 -0.663 0 C-N-CA 123.693 0.797 . . . . 0.0 112.197 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -104.35 -35.17 3.46 Favored 'Isoleucine or valine' 0 C--N 1.356 0.887 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.54 -21.23 52.93 Favored 'General case' 0 CA--C 1.47 -2.115 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -169.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -62.07 -32.51 54.68 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.272 0 C-N-CA 125.929 1.692 . . . . 0.0 111.529 178.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -75.64 -41.52 53.9 Favored 'General case' 0 CA--C 1.503 -0.844 0 CA-C-N 112.658 -2.064 . . . . 0.0 109.959 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.4 t30 -71.37 -32.5 68.56 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.987 1.315 . . . . 0.0 110.386 -179.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -67.4 -31.9 72.43 Favored 'General case' 0 N--CA 1.421 -1.882 0 C-N-CA 127.701 2.4 . . . . 0.0 110.98 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -80.85 -97.38 0.38 Allowed Glycine 0 C--N 1.353 1.484 0 N-CA-C 109.094 -1.603 . . . . 0.0 109.094 177.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 48.5 mm-40 63.29 42.41 6.99 Favored 'General case' 0 C--N 1.357 0.902 0 C-N-CA 126.199 1.8 . . . . 0.0 111.428 -176.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 72.6 m80 -152.81 -95.13 0.05 OUTLIER 'General case' 0 CA--C 1.493 -1.249 1 N-CA-C 100.17 -4.011 . . . . 0.0 100.17 177.247 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.3 pp -92.88 155.18 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 105.518 -2.03 . . . . 0.0 105.518 157.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 18.8 t-80 61.49 47.39 6.68 Favored 'General case' 0 C--N 1.356 0.858 0 C-N-CA 125.565 1.546 . . . . 0.0 109.123 -167.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 85.3 t60 . . . . . 0 C--O 1.26 1.62 0 CA-C-O 117.925 -1.036 . . . . 0.0 109.155 -175.55 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 52.9 p90 . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 121.491 0.662 . . . . 0.0 111.993 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -93.19 -71.23 0.66 Allowed 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 177.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -160.26 106.51 1.55 Allowed 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 104.475 -2.417 . . . . 0.0 104.475 175.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -89.13 162.74 36.7 Favored Pre-proline 0 N--CA 1.445 -0.7 0 C-N-CA 124.601 1.16 . . . . 0.0 108.447 177.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -76.7 -168.49 0.58 Allowed 'Trans proline' 0 CA--C 1.498 -1.28 0 C-N-CA 122.583 2.189 . . . . 0.0 112.901 -169.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 -72.19 -30.81 65.32 Favored 'General case' 0 CA--C 1.506 -0.712 0 C-N-CA 126.334 1.854 . . . . 0.0 110.039 175.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -79.66 -23.33 42.57 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.73 1.212 . . . . 0.0 108.866 174.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -77.76 -14.4 82.43 Favored Glycine 0 C--N 1.355 1.633 0 C-N-CA 124.39 0.995 . . . . 0.0 111.504 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 32.3 m170 -89.49 -35.52 15.92 Favored 'General case' 0 CA--C 1.502 -0.896 0 C-N-CA 124.244 1.018 . . . . 0.0 108.56 174.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -72.57 -30.93 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 C-N-CA 125.898 1.679 . . . . 0.0 111.74 -171.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 5.4 pp0? -78.31 -5.96 53.67 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 124.13 0.972 . . . . 0.0 111.927 -177.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 41.9 t -83.95 -41.18 16.31 Favored 'Isoleucine or valine' 0 C--N 1.357 0.919 0 C-N-CA 124.023 0.929 . . . . 0.0 108.558 174.795 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -72.06 -16.23 62.03 Favored 'General case' 0 CA--C 1.491 -1.306 0 C-N-CA 127.426 2.29 . . . . 0.0 113.009 -165.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 51.1 t -49.55 -37.32 11.35 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 C-N-CA 129.07 2.948 . . . . 0.0 111.368 170.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -55.97 -36.38 67.78 Favored 'General case' 0 C--N 1.349 0.571 0 C-N-CA 126.886 2.074 . . . . 0.0 113.158 -175.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -86.32 -48.59 8.35 Favored 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 126.089 1.756 . . . . 0.0 107.697 -178.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -59.57 148.08 34.75 Favored 'General case' 0 N--CA 1.431 -1.376 0 C-N-CA 126.722 2.009 . . . . 0.0 112.706 -175.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -171.29 31.11 0.13 Allowed Glycine 0 N--CA 1.436 -1.36 0 N-CA-C 108.056 -2.018 . . . . 0.0 108.056 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -116.15 64.94 0.7 Allowed 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 178.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 75.7 m80 -91.27 -97.71 0.12 Allowed 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 -177.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 12.2 pt -86.89 157.01 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.212 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 173.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -141.7 -50.92 0.41 Allowed 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 -177.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 81.0 m-70 . . . . . 0 C--O 1.261 1.659 0 C-N-CA 126.251 1.82 . . . . 0.0 110.785 -177.678 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 16.1 t80 . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 121.543 0.687 . . . . 0.0 109.753 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 53.8 mm-40 -79.69 -49.89 11.42 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 125.155 1.382 . . . . 0.0 109.985 -173.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -147.34 98.73 3.05 Favored 'General case' 0 N--CA 1.435 -1.222 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 -177.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 6.6 mp -78.98 152.59 77.14 Favored Pre-proline 0 N--CA 1.44 -0.933 0 C-N-CA 125.431 1.493 . . . . 0.0 108.358 -176.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -78.57 176.93 9.33 Favored 'Trans proline' 0 N--CA 1.449 -1.115 0 C-N-CA 123.112 2.542 . . . . 0.0 109.821 -174.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -81.04 -49.78 10.48 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 124.878 1.271 . . . . 0.0 108.531 -176.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 38.9 t80 -80.24 -11.06 59.77 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.474 1.109 . . . . 0.0 110.151 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -73.02 -18.52 79.18 Favored Glycine 0 C--N 1.357 1.712 0 C-N-CA 124.205 0.907 . . . . 0.0 111.857 178.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 30.2 m170 -85.03 -40.63 16.63 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.365 1.066 . . . . 0.0 109.204 175.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.2 mt -68.18 -34.69 67.88 Favored 'Isoleucine or valine' 0 C--N 1.352 0.708 0 C-N-CA 127.185 2.194 . . . . 0.0 111.73 -171.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -80.25 12.6 2.8 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 124.595 1.158 . . . . 0.0 112.719 -176.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -107.32 -32.7 2.57 Favored 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 173.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.1 mmmt -86.65 -9.73 55.37 Favored 'General case' 0 CA--C 1.485 -1.551 0 C-N-CA 124.508 1.123 . . . . 0.0 110.647 -170.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.5 p -61.14 -36.74 74.68 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.795 0 C-N-CA 126.094 1.758 . . . . 0.0 110.595 170.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -77.37 -29.35 53.25 Favored 'General case' 0 CA--C 1.506 -0.714 0 C-N-CA 126.613 1.965 . . . . 0.0 110.209 -178.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -73.83 -41.07 62.83 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.368 1.067 . . . . 0.0 109.091 177.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 35.5 m-70 -67.83 127.63 33.52 Favored 'General case' 0 N--CA 1.428 -1.552 0 C-N-CA 125.357 1.463 . . . . 0.0 110.222 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 100.55 -43.58 1.73 Allowed Glycine 0 C--N 1.354 1.547 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -175.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 80.21 116.58 0.06 Allowed 'General case' 0 CA--C 1.495 -1.139 0 C-N-CA 127.957 2.503 . . . . 0.0 110.225 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 59.9 m170 -80.02 -75.86 0.24 Allowed 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 173.639 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 15.6 pt -89.9 150.91 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.448 0 N-CA-C 106.814 -1.551 . . . . 0.0 106.814 167.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 39.0 m80 -112.83 -37.06 4.96 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 -179.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 43.4 p-80 . . . . . 0 C--O 1.259 1.593 0 C-N-CA 125.1 1.36 . . . . 0.0 109.312 175.931 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 121.613 0.72 . . . . 0.0 111.037 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 55.0 mt-10 -99.4 -54.39 2.96 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 176.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -164.22 113.65 1.2 Allowed 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 102.673 -3.084 . . . . 0.0 102.673 -178.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 5.4 mp -76.13 156.26 84.02 Favored Pre-proline 0 N--CA 1.443 -0.822 0 C-N-CA 124.624 1.169 . . . . 0.0 109.088 -178.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -76.26 -178.31 4.33 Favored 'Trans proline' 0 CA--C 1.501 -1.158 0 C-N-CA 123.107 2.538 . . . . 0.0 110.795 -176.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.5 m120 -64.23 -53.39 49.85 Favored 'General case' 0 CA--C 1.503 -0.827 0 C-N-CA 126.238 1.815 . . . . 0.0 111.247 -171.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 -84.8 -10.23 57.4 Favored 'General case' 0 CA--C 1.505 -0.76 0 C-N-CA 124.452 1.101 . . . . 0.0 110.045 179.412 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.7 5.36 83.92 Favored Glycine 0 C--N 1.355 1.585 0 C-N-CA 124.09 0.852 . . . . 0.0 111.966 179.015 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.2 m-70 -91.37 -40.33 11.51 Favored 'General case' 0 CA--C 1.501 -0.908 0 C-N-CA 123.893 0.877 . . . . 0.0 108.645 175.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.3 mp -72.51 -32.7 42.71 Favored 'Isoleucine or valine' 0 C--N 1.352 0.694 0 C-N-CA 126.476 1.91 . . . . 0.0 110.488 -171.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 4.4 pp0? -80.75 9.07 6.76 Favored 'General case' 0 C--N 1.351 0.657 0 C-N-CA 123.884 0.873 . . . . 0.0 112.493 -177.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -97.65 -33.27 4.26 Favored 'Isoleucine or valine' 0 C--N 1.354 0.8 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 171.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 19.0 mmmt -89.63 -8.75 51.84 Favored 'General case' 0 CA--C 1.483 -1.608 0 C-N-CA 124.843 1.257 . . . . 0.0 111.208 -166.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.9 p -64.23 -37.35 79.68 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 C-N-CA 125.295 1.438 . . . . 0.0 110.315 168.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.9 m-85 -79.1 -26.87 42.9 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 113.336 -1.756 . . . . 0.0 109.898 -178.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -75.71 -40.36 55.82 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.263 1.025 . . . . 0.0 109.219 178.106 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -65.47 160.81 21.33 Favored 'General case' 0 N--CA 1.432 -1.355 0 C-N-CA 124.909 1.284 . . . . 0.0 113.072 -172.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 82.02 36.84 17.25 Favored Glycine 0 C--N 1.353 1.475 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -177.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -106.53 58.78 0.64 Allowed 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 -176.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 63.8 m80 67.13 -118.03 0.23 Allowed 'General case' 0 C--N 1.357 0.923 0 C-N-CA 126.38 1.872 . . . . 0.0 109.434 -177.107 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 23.6 pt -87.52 166.5 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 C-N-CA 124.723 1.209 . . . . 0.0 108.741 178.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 59.1 t-80 -89.87 -44.33 10.0 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 178.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 9.9 p80 . . . . . 0 C--O 1.258 1.539 0 C-N-CA 125.596 1.558 . . . . 0.0 109.55 -176.916 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 38.5 p90 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 121.324 0.583 . . . . 0.0 112.024 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -83.12 -81.47 0.16 Allowed 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -151.85 100.87 2.71 Favored 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 105.861 -1.903 . . . . 0.0 105.861 175.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 89.8 mt -124.29 161.02 50.01 Favored Pre-proline 0 N--CA 1.44 -0.964 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 176.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -79.4 176.82 9.23 Favored 'Trans proline' 0 CA--C 1.502 -1.08 0 C-N-CA 122.764 2.309 . . . . 0.0 110.085 -171.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -93.85 -56.34 2.92 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -175.389 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 35.4 t80 -80.97 -10.17 59.75 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.489 1.115 . . . . 0.0 110.313 -177.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.06 3.32 77.21 Favored Glycine 0 C--N 1.356 1.686 0 C-N-CA 123.908 0.765 . . . . 0.0 112.005 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 58.5 m170 -109.04 -31.9 7.44 Favored 'General case' 0 CA--C 1.502 -0.899 0 C-N-CA 125.174 1.389 . . . . 0.0 107.782 174.164 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -76.71 -33.53 22.01 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.742 0 C-N-CA 125.827 1.651 . . . . 0.0 110.563 -172.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.53 -16.98 58.36 Favored 'General case' 0 N--CA 1.445 -0.695 0 C-N-CA 123.495 0.718 . . . . 0.0 111.515 -179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -91.1 -43.04 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 C-N-CA 124.15 0.98 . . . . 0.0 109.072 -176.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -19.68 65.11 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 116.608 2.077 . . . . 0.0 116.608 -163.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.4 m -57.28 -29.42 32.63 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.268 0 C-N-CA 127.916 2.487 . . . . 0.0 113.191 177.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.12 -36.77 71.05 Favored 'General case' 0 CA--C 1.511 -0.533 0 C-N-CA 127.745 2.418 . . . . 0.0 112.661 -176.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -70.07 -53.84 15.69 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 126.49 1.916 . . . . 0.0 108.98 179.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.7 m-70 -66.17 150.27 49.03 Favored 'General case' 0 N--CA 1.428 -1.539 0 C-N-CA 125.172 1.389 . . . . 0.0 112.897 -173.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 157.63 -50.71 0.42 Allowed Glycine 0 CA--C 1.492 -1.398 0 N-CA-C 105.501 -3.04 . . . . 0.0 105.501 -175.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 9.7 mp0 66.0 70.91 0.42 Allowed 'General case' 0 C--N 1.358 0.956 0 C-N-CA 126.573 1.949 . . . . 0.0 110.202 178.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 74.3 t60 -103.47 169.74 8.36 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 178.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 19.3 pt -83.08 161.38 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 C-N-CA 124.416 1.086 . . . . 0.0 109.279 -179.654 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -95.35 -60.74 1.6 Allowed 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 175.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 84.2 t60 . . . . . 0 C--O 1.261 1.673 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 179.942 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 . . . . . 0 N--CA 1.488 1.447 0 CA-C-O 121.751 0.786 . . . . 0.0 111.184 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 62.1 mm-40 -102.81 -44.34 5.31 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 173.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -142.9 105.14 4.43 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 101.31 -3.589 . . . . 0.0 101.31 176.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -75.94 154.26 84.87 Favored Pre-proline 0 N--CA 1.443 -0.82 0 C-N-CA 125.323 1.449 . . . . 0.0 110.781 -174.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -77.38 -179.45 5.44 Favored 'Trans proline' 0 CA--C 1.501 -1.167 0 C-N-CA 122.605 2.204 . . . . 0.0 112.016 -168.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -82.04 -45.18 15.63 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 125.905 1.682 . . . . 0.0 110.248 -173.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -82.46 -5.78 58.9 Favored 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 173.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.72 24.94 9.14 Favored Glycine 0 C--N 1.356 1.666 0 C-N-CA 124.506 1.051 . . . . 0.0 110.803 175.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.7 m-70 -114.29 -40.48 3.65 Favored 'General case' 0 N--CA 1.44 -0.956 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 168.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.6 mp -76.71 -42.82 34.17 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.98 0 C-N-CA 125.91 1.684 . . . . 0.0 110.173 -172.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 -76.78 -26.25 54.28 Favored 'General case' 0 CA--C 1.508 -0.649 0 O-C-N 121.956 -0.465 . . . . 0.0 110.71 -177.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.9 t -78.23 -24.26 13.76 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 C-N-CA 125.345 1.458 . . . . 0.0 109.976 -175.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.67 -25.56 53.83 Favored 'General case' 0 CA--C 1.475 -1.923 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -176.422 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 84.3 t -69.7 -33.06 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.352 0 C-N-CA 125.207 1.403 . . . . 0.0 108.286 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 15.8 m-30 -81.45 -28.5 34.15 Favored 'General case' 0 CA--C 1.504 -0.799 0 CA-C-N 113.317 -1.765 . . . . 0.0 108.787 -172.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 17.1 t-20 -75.89 -46.0 32.45 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 125.06 1.344 . . . . 0.0 108.521 177.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 -64.1 -65.37 0.69 Allowed 'General case' 0 N--CA 1.425 -1.677 0 C-N-CA 126.466 1.906 . . . . 0.0 111.649 -175.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 103.4 76.63 1.14 Allowed Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 106.157 -2.777 . . . . 0.0 106.157 -177.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -100.44 67.45 1.32 Allowed 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 107.259 -1.386 . . . . 0.0 107.259 -178.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 73.0 m80 -99.05 -93.93 0.25 Allowed 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 104.826 -2.287 . . . . 0.0 104.826 178.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 20.2 pt -86.34 159.04 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.284 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 170.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -135.74 59.21 1.72 Allowed 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 104.626 -2.361 . . . . 0.0 104.626 177.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 36.4 m170 . . . . . 0 C--O 1.259 1.575 0 C-N-CA 125.926 1.69 . . . . 0.0 110.631 -179.873 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 42.8 p90 . . . . . 0 N--CA 1.488 1.473 0 CA-C-O 121.279 0.562 . . . . 0.0 111.758 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -89.39 -84.51 0.22 Allowed 'General case' 0 CA--C 1.503 -0.827 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -152.93 102.58 2.68 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 104.773 -2.306 . . . . 0.0 104.773 176.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 95.0 mt -121.61 160.32 46.89 Favored Pre-proline 0 N--CA 1.44 -0.951 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -77.13 -179.1 5.1 Favored 'Trans proline' 0 CA--C 1.5 -1.179 0 C-N-CA 123.296 2.664 . . . . 0.0 109.971 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.3 m-80 -68.26 -50.04 56.51 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 125.435 1.494 . . . . 0.0 109.967 -176.015 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -83.6 2.2 38.48 Favored 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.604 1.161 . . . . 0.0 110.83 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.76 12.68 66.48 Favored Glycine 0 C--N 1.355 1.62 0 C-N-CA 124.37 0.986 . . . . 0.0 110.745 173.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -118.44 -27.23 6.02 Favored 'General case' 0 C--N 1.355 0.845 0 C-N-CA 124.93 1.292 . . . . 0.0 108.834 174.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -76.85 -40.26 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.997 0 C-N-CA 125.198 1.399 . . . . 0.0 108.062 -177.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -66.23 -25.17 66.78 Favored 'General case' 0 C--N 1.348 0.514 0 C-N-CA 123.834 0.854 . . . . 0.0 112.375 -179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 66.5 t -73.81 -29.19 25.62 Favored 'Isoleucine or valine' 0 C--N 1.357 0.914 0 C-N-CA 125.464 1.506 . . . . 0.0 110.132 -176.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.08 -25.7 52.63 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -174.416 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 88.5 t -68.63 -33.32 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 125.163 1.385 . . . . 0.0 108.149 179.228 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 16.4 m-30 -80.29 -28.29 38.34 Favored 'General case' 0 CA--C 1.504 -0.801 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.351 -172.007 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 40.9 t30 -76.07 -43.13 45.07 Favored 'General case' 0 N--CA 1.441 -0.884 0 C-N-CA 124.838 1.255 . . . . 0.0 108.211 176.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -70.32 159.18 34.59 Favored 'General case' 0 N--CA 1.421 -1.912 0 C-N-CA 127.268 2.227 . . . . 0.0 110.913 -178.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -157.13 -96.14 0.12 Allowed Glycine 0 N--CA 1.434 -1.475 0 N-CA-C 105.03 -3.228 . . . . 0.0 105.03 178.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 45.1 mt-10 61.46 78.74 0.28 Allowed 'General case' 0 C--N 1.356 0.863 0 C-N-CA 126.2 1.8 . . . . 0.0 112.095 176.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 19.2 p80 -94.48 179.0 5.42 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 36.1 pt -88.0 -167.36 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 C-N-CA 124.888 1.275 . . . . 0.0 109.544 -173.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -78.83 -42.6 27.23 Favored 'General case' 0 CA--C 1.503 -0.831 0 C-N-CA 124.596 1.159 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 56.5 m80 . . . . . 0 C--O 1.26 1.623 0 C-N-CA 127.433 2.293 . . . . 0.0 109.841 -177.85 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 . . . . . 0 N--CA 1.487 1.401 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 79.57 -6.89 1.77 Allowed 'General case' 0 C--N 1.36 1.045 0 C-N-CA 128.239 2.616 . . . . 0.0 110.943 -171.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -159.27 108.17 1.86 Allowed 'General case' 0 N--CA 1.428 -1.545 0 N-CA-C 102.045 -3.317 . . . . 0.0 102.045 176.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 88.7 mt -80.15 156.7 74.06 Favored Pre-proline 0 N--CA 1.443 -0.82 0 C-N-CA 124.218 1.007 . . . . 0.0 109.582 -174.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -75.53 -177.21 3.4 Favored 'Trans proline' 0 CA--C 1.501 -1.166 0 C-N-CA 123.926 3.084 . . . . 0.0 109.764 175.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 17.5 t-20 -71.07 -49.9 39.63 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 124.647 1.179 . . . . 0.0 109.15 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -77.02 -34.22 57.37 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 125.175 1.39 . . . . 0.0 111.029 -178.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.84 14.2 62.4 Favored Glycine 0 C--N 1.35 1.358 0 C-N-CA 124.07 0.843 . . . . 0.0 111.96 -175.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 t60 -102.59 -38.24 7.6 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.855 -1.905 . . . . 0.0 105.855 170.001 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.7 mt -71.2 -31.39 44.09 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 C-N-CA 125.697 1.599 . . . . 0.0 110.249 -175.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -71.72 -26.82 62.64 Favored 'General case' 0 N--CA 1.422 -1.857 0 C-N-CA 127.557 2.343 . . . . 0.0 110.476 -178.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.7 t -94.01 -34.56 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 C-N-CA 124.382 1.073 . . . . 0.0 109.457 -177.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.2 pptp? -79.22 -19.83 49.75 Favored 'General case' 0 CA--C 1.469 -2.159 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -166.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.1 p -64.6 -32.84 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-O 123.293 1.521 . . . . 0.0 111.006 177.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -78.86 -30.52 45.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.669 -2.06 . . . . 0.0 109.921 -178.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -80.42 -36.88 33.09 Favored 'General case' 0 N--CA 1.443 -0.788 0 C-N-CA 124.073 0.949 . . . . 0.0 110.056 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -71.44 -174.71 1.12 Allowed 'General case' 0 N--CA 1.43 -1.453 0 C-N-CA 125.616 1.566 . . . . 0.0 113.935 -168.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -147.93 -50.33 0.02 OUTLIER Glycine 0 CA--C 1.491 -1.434 0 N-CA-C 106.442 -2.663 . . . . 0.0 106.442 -178.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 49.4 mm-40 65.25 56.89 0.96 Allowed 'General case' 0 C--N 1.357 0.933 0 C-N-CA 126.126 1.77 . . . . 0.0 110.946 177.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 8.7 p80 -123.61 -164.65 1.24 Allowed 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 105.22 -2.141 . . . . 0.0 105.22 178.594 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 11.8 pt -95.83 143.82 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.262 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 175.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 48.0 m80 70.39 23.99 4.79 Favored 'General case' 0 C--N 1.356 0.888 0 C-N-CA 126.15 1.78 . . . . 0.0 109.91 -169.326 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 82.3 t60 . . . . . 0 C--O 1.259 1.581 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 178.959 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.347 0.594 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -84.16 -20.34 32.58 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 125.012 1.325 . . . . 0.0 107.951 170.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 31.8 t0 -93.08 -143.13 0.22 Allowed 'General case' 0 N--CA 1.422 -1.86 0 N-CA-C 103.56 -2.755 . . . . 0.0 103.56 170.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.415 ' HG ' ' H ' ' A' ' 4' ' ' LEU . 0.8 OUTLIER -64.71 155.71 81.25 Favored Pre-proline 0 N--CA 1.445 -0.712 0 C-N-CA 127.755 2.422 . . . . 0.0 111.471 -177.382 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -79.42 -175.34 2.68 Favored 'Trans proline' 0 CA--C 1.5 -1.199 0 C-N-CA 122.241 1.961 . . . . 0.0 112.026 -169.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 -112.4 -63.71 1.39 Allowed 'General case' 0 CA--C 1.498 -1.021 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -82.62 -13.48 56.43 Favored 'General case' 0 C--N 1.356 0.89 0 C-N-CA 124.298 1.039 . . . . 0.0 110.139 -175.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.09 7.88 65.52 Favored Glycine 0 C--N 1.355 1.618 0 C-N-CA 123.702 0.668 . . . . 0.0 111.784 178.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 66.9 m170 -102.99 -30.68 10.63 Favored 'General case' 0 CA--C 1.503 -0.858 0 C-N-CA 124.975 1.31 . . . . 0.0 107.775 171.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 31.9 mm -75.14 -38.74 42.46 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 C-N-CA 125.832 1.653 . . . . 0.0 110.27 -170.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -77.97 -8.49 58.21 Favored 'General case' 0 N--CA 1.441 -0.915 0 C-N-CA 123.507 0.723 . . . . 0.0 111.435 -176.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 57.2 t -101.48 -31.05 3.12 Favored 'Isoleucine or valine' 0 C--N 1.357 0.899 0 C-N-CA 125.139 1.376 . . . . 0.0 108.679 -177.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 2.9 pptp? -79.49 -19.13 50.49 Favored 'General case' 0 CA--C 1.472 -2.023 0 N-CA-C 115.107 1.521 . . . . 0.0 115.107 -166.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 28.7 m -67.87 -32.09 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.37 0 C-N-CA 125.077 1.351 . . . . 0.0 110.72 175.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -84.58 -24.26 29.28 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-N 112.6 -2.091 . . . . 0.0 109.912 -177.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -73.19 -45.45 56.35 Favored 'General case' 0 C--N 1.356 0.865 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 43.2 m170 -69.73 158.65 34.99 Favored 'General case' 0 N--CA 1.425 -1.707 0 C-N-CA 125.869 1.668 . . . . 0.0 111.527 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -178.73 55.02 0.09 OUTLIER Glycine 0 CA--C 1.491 -1.442 0 N-CA-C 107.085 -2.406 . . . . 0.0 107.085 178.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 67.16 100.5 0.05 OUTLIER 'General case' 0 C--N 1.358 0.937 0 C-N-CA 126.716 2.007 . . . . 0.0 111.763 178.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -97.23 175.47 6.27 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 1.9 pp -88.85 173.03 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.049 0 C-N-CA 124.666 1.186 . . . . 0.0 108.99 179.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -96.46 -65.55 0.96 Allowed 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 105.674 -1.973 . . . . 0.0 105.674 174.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 63.7 t-80 . . . . . 0 C--O 1.26 1.651 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 179.853 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 55.1 mt-10 -88.89 -62.89 1.38 Allowed 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 172.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -155.12 104.12 2.43 Favored 'General case' 0 N--CA 1.432 -1.358 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 172.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -94.77 161.29 29.14 Favored Pre-proline 0 N--CA 1.444 -0.733 0 C-N-CA 124.607 1.163 . . . . 0.0 108.367 -178.569 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -77.58 -170.93 1.04 Allowed 'Trans proline' 0 CA--C 1.499 -1.231 0 C-N-CA 122.416 2.077 . . . . 0.0 112.43 -171.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -70.63 -37.86 73.83 Favored 'General case' 0 CA--C 1.504 -0.801 0 C-N-CA 126.253 1.821 . . . . 0.0 109.696 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -82.57 -12.65 57.57 Favored 'General case' 0 C--N 1.354 0.792 0 C-N-CA 125.149 1.38 . . . . 0.0 109.913 177.327 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -87.03 8.42 76.51 Favored Glycine 0 C--N 1.356 1.655 0 C-N-CA 124.253 0.93 . . . . 0.0 111.873 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 53.6 m-70 -92.94 -32.45 14.55 Favored 'General case' 0 CA--C 1.503 -0.858 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 173.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.1 mp -76.82 -32.75 20.53 Favored 'Isoleucine or valine' 0 C--N 1.354 0.785 0 C-N-CA 125.734 1.613 . . . . 0.0 109.811 -174.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.0 pt20 -71.94 -16.47 62.1 Favored 'General case' 0 C--N 1.35 0.628 0 C-N-CA 123.342 0.657 . . . . 0.0 112.384 -178.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.9 t -98.92 -36.85 5.79 Favored 'Isoleucine or valine' 0 C--N 1.358 0.96 0 C-N-CA 124.103 0.961 . . . . 0.0 108.718 -178.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.57 -19.35 57.99 Favored 'General case' 0 CA--C 1.471 -2.069 0 N-CA-C 114.505 1.298 . . . . 0.0 114.505 -168.057 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.87 -33.61 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.187 0 C-N-CA 125.771 1.628 . . . . 0.0 111.226 177.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 46.0 m-85 -77.2 -28.86 54.06 Favored 'General case' 0 CA--C 1.504 -0.821 0 CA-C-N 112.617 -2.083 . . . . 0.0 110.863 -176.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.1 t-20 -80.07 -43.3 22.06 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 123.92 0.888 . . . . 0.0 108.63 176.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 16.7 t-160 -61.36 -51.71 67.67 Favored 'General case' 0 N--CA 1.428 -1.536 0 C-N-CA 127.149 2.179 . . . . 0.0 112.753 -175.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -86.33 -34.61 11.93 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 124.453 1.025 . . . . 0.0 111.551 -172.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 58.7 mm-40 66.01 81.04 0.21 Allowed 'General case' 0 C--N 1.36 1.046 0 C-N-CA 125.86 1.664 . . . . 0.0 109.491 -172.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 28.9 m80 -90.51 125.16 35.51 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 -174.362 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.2 mm -87.63 -83.78 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.427 -1.61 0 C-N-CA 125.02 1.328 . . . . 0.0 107.467 -170.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -91.05 -58.19 2.55 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 106.722 -1.585 . . . . 0.0 106.722 178.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 . . . . . 0 C--O 1.26 1.654 0 C-N-CA 124.656 1.182 . . . . 0.0 107.819 -178.031 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 88.39 -65.94 0.02 OUTLIER 'General case' 0 CA--C 1.496 -1.119 0 C-N-CA 129.501 3.121 . . . . 0.0 109.305 171.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -165.12 106.24 0.79 Allowed 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 105.454 -2.054 . . . . 0.0 105.454 -178.175 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -150.03 167.0 13.89 Favored Pre-proline 0 N--CA 1.44 -0.945 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 179.332 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_exo -76.02 -172.01 1.23 Allowed 'Trans proline' 0 CA--C 1.497 -1.334 0 C-N-CA 122.748 2.299 . . . . 0.0 112.293 -171.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.1 m-80 -63.23 -47.62 81.71 Favored 'General case' 0 CA--C 1.505 -0.767 0 C-N-CA 126.944 2.098 . . . . 0.0 111.261 -175.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -84.95 -10.96 56.53 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.546 1.138 . . . . 0.0 109.845 178.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.62 -22.98 78.59 Favored Glycine 0 C--N 1.355 1.628 0 C-N-CA 125.162 1.363 . . . . 0.0 111.877 178.262 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -71.12 -40.79 71.21 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 117.934 0.867 . . . . 0.0 111.08 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.8 mp -76.05 -36.51 31.56 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.666 0 C-N-CA 124.925 1.29 . . . . 0.0 110.558 -170.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 7.5 pt20 -81.24 -3.8 53.51 Favored 'General case' 0 N--CA 1.446 -0.664 0 O-C-N 121.828 -0.545 . . . . 0.0 112.374 -176.465 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.5 t -112.2 -26.13 3.21 Favored 'Isoleucine or valine' 0 C--N 1.358 0.969 0 C-N-CA 124.424 1.09 . . . . 0.0 108.486 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.73 -20.59 49.64 Favored 'General case' 0 CA--C 1.471 -2.09 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -173.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.3 p -64.47 -35.71 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.327 0 C-N-CA 125.009 1.324 . . . . 0.0 110.619 174.004 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -83.01 -24.78 32.72 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-N 112.898 -1.955 . . . . 0.0 109.939 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.2 t-20 -72.25 -43.31 64.55 Favored 'General case' 0 C--N 1.356 0.888 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.5 m170 -78.17 -170.25 1.9 Allowed 'General case' 0 N--CA 1.421 -1.896 0 C-N-CA 126.634 1.974 . . . . 0.0 110.215 176.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -128.18 50.78 0.87 Allowed Glycine 0 C--N 1.352 1.437 0 N-CA-C 106.138 -2.785 . . . . 0.0 106.138 175.141 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -107.38 70.26 0.78 Allowed 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 79.3 m80 -120.91 -107.19 0.36 Allowed 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 103.868 -2.642 . . . . 0.0 103.868 179.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.8 pp -86.0 164.42 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.362 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 170.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -140.07 32.07 1.96 Allowed 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 61.9 m80 . . . . . 0 C--O 1.259 1.603 0 C-N-CA 125.966 1.706 . . . . 0.0 111.152 175.808 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 121.583 0.706 . . . . 0.0 110.677 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.9 mp0 -90.61 -84.67 0.24 Allowed 'General case' 0 N--CA 1.44 -0.945 0 N-CA-C 106.516 -1.661 . . . . 0.0 106.516 -179.205 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -158.98 105.54 1.77 Allowed 'General case' 0 N--CA 1.432 -1.369 0 N-CA-C 104.064 -2.569 . . . . 0.0 104.064 176.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 85.6 mt -96.26 163.55 20.5 Favored Pre-proline 0 N--CA 1.442 -0.853 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 -178.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -77.38 -174.84 2.37 Favored 'Trans proline' 0 CA--C 1.499 -1.259 0 C-N-CA 123.192 2.594 . . . . 0.0 110.328 179.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 73.0 m-80 -66.43 -39.46 88.94 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 125.792 1.637 . . . . 0.0 110.741 -178.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -83.92 -14.99 49.61 Favored 'General case' 0 C--N 1.352 0.713 0 C-N-CA 124.796 1.239 . . . . 0.0 110.159 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -90.57 -2.83 72.35 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 177.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -93.84 -11.35 31.38 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-N 118.007 0.903 . . . . 0.0 108.983 174.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 47.8 mm -77.09 -36.21 24.31 Favored 'Isoleucine or valine' 0 C--N 1.356 0.861 0 C-N-CA 125.008 1.323 . . . . 0.0 108.842 -179.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.39 0.65 40.99 Favored 'General case' 0 N--CA 1.442 -0.836 0 C-N-CA 122.896 0.478 . . . . 0.0 111.436 -179.089 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t -98.78 -40.59 9.26 Favored 'Isoleucine or valine' 0 C--N 1.358 0.94 0 N-CA-C 108.075 -1.084 . . . . 0.0 108.075 171.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.25 -17.58 58.3 Favored 'General case' 0 CA--C 1.47 -2.106 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -167.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -63.67 -34.41 67.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.323 0 C-N-CA 125.402 1.481 . . . . 0.0 110.826 176.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -80.44 -29.81 37.58 Favored 'General case' 0 CA--C 1.502 -0.893 0 CA-C-N 112.724 -2.035 . . . . 0.0 110.357 -177.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 39.5 t30 -73.05 -40.99 64.64 Favored 'General case' 0 C--N 1.354 0.774 0 C-N-CA 124.216 1.007 . . . . 0.0 108.609 176.449 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -71.96 158.73 35.48 Favored 'General case' 0 N--CA 1.418 -2.026 0 C-N-CA 127.462 2.305 . . . . 0.0 110.266 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -150.36 -85.28 0.05 OUTLIER Glycine 0 CA--C 1.489 -1.558 0 N-CA-C 105.42 -3.072 . . . . 0.0 105.42 179.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 58.07 96.83 0.02 OUTLIER 'General case' 0 N--CA 1.438 -1.027 0 C-N-CA 127.247 2.219 . . . . 0.0 114.343 177.704 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -96.6 -105.55 0.17 Allowed 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 19.3 pt -87.42 156.81 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.204 0 C-N-CA 124.178 0.991 . . . . 0.0 108.518 177.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 57.5 t-80 -93.73 -59.12 2.07 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 105.894 -1.891 . . . . 0.0 105.894 175.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 62.6 t-80 . . . . . 0 C--O 1.26 1.617 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 179.119 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 . . . . . 0 N--CA 1.487 1.418 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 61.94 6.28 1.65 Allowed 'General case' 0 C--N 1.356 0.86 0 C-N-CA 126.603 1.961 . . . . 0.0 114.141 -172.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 71.37 99.25 0.07 Allowed 'General case' 0 N--CA 1.438 -1.055 0 C-N-CA 129.361 3.064 . . . . 0.0 109.174 -166.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 95.1 mt -82.63 157.53 67.05 Favored Pre-proline 0 N--CA 1.444 -0.774 0 C-N-CA 124.395 1.078 . . . . 0.0 108.58 178.263 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_exo -78.35 -176.73 3.42 Favored 'Trans proline' 0 CA--C 1.501 -1.132 0 C-N-CA 122.864 2.376 . . . . 0.0 111.315 -172.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -110.02 -67.68 0.97 Allowed 'General case' 0 CA--C 1.498 -1.023 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 177.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -88.94 1.31 55.63 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.681 1.192 . . . . 0.0 110.784 -174.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.95 -10.44 80.85 Favored Glycine 0 C--N 1.356 1.666 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 176.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.4 m-70 -95.04 -31.22 13.7 Favored 'General case' 0 CA--C 1.502 -0.876 0 C-N-CA 124.122 0.969 . . . . 0.0 108.701 173.779 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.2 mt -75.82 -33.39 25.67 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 C-N-CA 125.508 1.523 . . . . 0.0 110.6 -171.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 20.5 pt20 -74.1 -13.14 60.79 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 123.506 0.722 . . . . 0.0 112.163 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.4 t -99.14 -33.18 3.93 Favored 'Isoleucine or valine' 0 C--N 1.357 0.915 0 C-N-CA 124.766 1.226 . . . . 0.0 108.957 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.74 -19.78 47.94 Favored 'General case' 0 CA--C 1.476 -1.883 0 N-CA-C 115.284 1.587 . . . . 0.0 115.284 -164.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 21.3 m -68.98 -30.24 46.04 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 C-N-CA 125.207 1.403 . . . . 0.0 110.822 175.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -87.08 -20.7 26.75 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.472 -2.149 . . . . 0.0 110.015 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 13.4 t-20 -75.7 -31.25 59.61 Favored 'General case' 0 C--N 1.356 0.882 0 C-N-CA 124.174 0.99 . . . . 0.0 109.056 177.167 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 56.5 m170 -57.85 142.74 44.86 Favored 'General case' 0 N--CA 1.434 -1.272 0 C-N-CA 125.704 1.602 . . . . 0.0 112.379 177.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -106.83 -119.95 4.55 Favored Glycine 0 C--N 1.354 1.562 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -173.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -104.47 67.52 0.83 Allowed 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 -174.302 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 24.0 p80 -147.67 171.4 15.69 Favored 'General case' 0 N--CA 1.437 -1.086 0 N-CA-C 105.96 -1.866 . . . . 0.0 105.96 173.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 20.4 pt -83.67 151.61 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 123.957 0.903 . . . . 0.0 109.665 -176.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 65.6 t60 -153.13 62.07 0.77 Allowed 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 104.662 -2.347 . . . . 0.0 104.662 176.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 68.3 m80 . . . . . 0 C--O 1.261 1.685 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 179.718 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.631 0.729 . . . . 0.0 110.978 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 62.7 mm-40 -103.3 -55.41 2.41 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.686 -1.598 . . . . 0.0 106.686 177.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -165.59 110.62 0.87 Allowed 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 104.48 -2.415 . . . . 0.0 104.48 -177.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 5.3 mp -76.96 154.6 82.94 Favored Pre-proline 0 N--CA 1.444 -0.725 0 C-N-CA 124.504 1.122 . . . . 0.0 108.897 -178.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -78.21 -176.57 3.32 Favored 'Trans proline' 0 CA--C 1.5 -1.185 0 C-N-CA 122.826 2.35 . . . . 0.0 111.304 -172.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 15.5 t-20 -128.82 -60.09 1.11 Allowed 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 104.538 -2.393 . . . . 0.0 104.538 176.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -86.68 -1.09 57.42 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.862 1.265 . . . . 0.0 110.898 -174.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.04 -30.02 39.65 Favored Glycine 0 C--N 1.355 1.633 0 N-CA-C 109.763 -1.335 . . . . 0.0 109.763 176.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 62.1 m80 -76.81 -30.42 56.41 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 124.605 1.162 . . . . 0.0 110.363 177.016 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.6 mt -73.58 -31.1 31.34 Favored 'Isoleucine or valine' 0 C--N 1.354 0.769 0 C-N-CA 126.029 1.731 . . . . 0.0 109.61 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -70.38 -27.84 64.63 Favored 'General case' 0 N--CA 1.437 -1.114 0 C-N-CA 125.441 1.497 . . . . 0.0 111.261 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 83.9 t -85.77 -44.87 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.864 0 C-N-CA 123.287 0.635 . . . . 0.0 109.502 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 pptp? -66.69 -21.28 66.09 Favored 'General case' 0 CA--C 1.483 -1.628 0 N-CA-C 116.191 1.922 . . . . 0.0 116.191 -160.279 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -55.39 -30.66 25.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.225 0 C-N-CA 127.953 2.501 . . . . 0.0 113.127 176.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -57.19 -37.24 71.86 Favored 'General case' 0 CA--C 1.509 -0.629 0 C-N-CA 127.903 2.481 . . . . 0.0 112.974 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.8 t30 -75.61 -47.3 27.17 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 126.007 1.723 . . . . 0.0 108.474 -177.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 44.0 m170 -59.91 -43.34 94.94 Favored 'General case' 0 N--CA 1.432 -1.346 0 C-N-CA 126.22 1.808 . . . . 0.0 113.216 -175.1 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -168.64 -111.93 0.25 Allowed Glycine 0 N--CA 1.434 -1.458 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 66.5 83.04 0.17 Allowed 'General case' 0 C--N 1.356 0.89 0 C-N-CA 126.89 2.076 . . . . 0.0 109.208 -166.046 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 65.1 m80 70.63 -110.6 0.07 Allowed 'General case' 0 C--N 1.358 0.952 0 C-N-CA 126.217 1.807 . . . . 0.0 108.497 -173.167 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 24.6 pt -88.38 173.46 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 124.634 1.174 . . . . 0.0 108.263 176.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 86.7 t60 -83.5 -40.67 18.9 Favored 'General case' 0 CA--C 1.501 -0.915 0 C-N-CA 123.859 0.864 . . . . 0.0 109.688 -177.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 63.6 t-80 . . . . . 0 C--O 1.261 1.664 0 C-N-CA 124.527 1.131 . . . . 0.0 109.65 -174.588 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 26.6 t80 . . . . . 0 N--CA 1.483 1.196 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -114.39 -68.14 0.95 Allowed 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 105.811 -1.922 . . . . 0.0 105.811 -179.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -156.56 104.66 2.19 Favored 'General case' 0 N--CA 1.433 -1.322 0 N-CA-C 104.534 -2.395 . . . . 0.0 104.534 177.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 91.0 mt -102.73 159.46 29.25 Favored Pre-proline 0 N--CA 1.442 -0.859 0 N-CA-C 106.726 -1.583 . . . . 0.0 106.726 179.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -78.17 -177.9 4.22 Favored 'Trans proline' 0 CA--C 1.501 -1.173 0 C-N-CA 122.879 2.386 . . . . 0.0 111.124 -172.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -119.36 -62.35 1.52 Allowed 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -82.69 -5.19 58.73 Favored 'General case' 0 C--N 1.354 0.788 0 C-N-CA 124.928 1.291 . . . . 0.0 111.371 -173.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -84.93 2.35 88.31 Favored Glycine 0 C--N 1.356 1.644 0 C-N-CA 124.064 0.84 . . . . 0.0 111.288 176.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -112.3 -26.62 8.67 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.207 1.403 . . . . 0.0 108.302 175.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 14.7 mt -75.73 -34.44 28.49 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 125.503 1.521 . . . . 0.0 109.888 -176.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -77.33 -11.06 59.79 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 123.799 0.84 . . . . 0.0 111.994 -179.31 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.7 t -98.17 -31.35 3.71 Favored 'Isoleucine or valine' 0 C--N 1.356 0.888 0 C-N-CA 124.696 1.198 . . . . 0.0 108.93 -175.627 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.58 -19.25 58.07 Favored 'General case' 0 CA--C 1.475 -1.92 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -167.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.3 m -63.86 -31.37 52.91 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 C-N-CA 126.31 1.844 . . . . 0.0 111.241 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.6 m-85 -77.07 -34.72 56.99 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 112.252 -2.249 . . . . 0.0 109.972 -176.168 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 37.4 t30 -74.67 -43.39 55.5 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 124.369 1.068 . . . . 0.0 108.85 177.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.1 t-80 -60.06 146.64 42.19 Favored 'General case' 0 N--CA 1.429 -1.499 0 C-N-CA 127.124 2.17 . . . . 0.0 112.637 -175.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 168.11 -32.41 0.19 Allowed Glycine 0 N--CA 1.435 -1.422 0 N-CA-C 106.775 -2.53 . . . . 0.0 106.775 -177.641 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 47.5 mm-40 68.86 85.18 0.14 Allowed 'General case' 0 C--N 1.359 1.021 0 C-N-CA 126.839 2.056 . . . . 0.0 109.856 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.537 ' H ' ' CE1' ' A' ' 23' ' ' HIS . 66.0 m-70 -103.28 -167.63 1.41 Allowed 'General case' 0 N--CA 1.437 -1.099 0 C-N-CA 124.412 1.085 . . . . 0.0 108.351 -170.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.539 HD13 ' H ' ' A' ' 21' ' ' ILE . 0.1 OUTLIER -91.34 170.9 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.331 0 C-N-CA 125.008 1.323 . . . . 0.0 108.17 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 58.5 t60 72.92 17.01 4.34 Favored 'General case' 0 C--N 1.357 0.924 0 C-N-CA 126.722 2.009 . . . . 0.0 110.791 -176.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . 0.537 ' CE1' ' H ' ' A' ' 20' ' ' HIS . 38.6 m170 . . . . . 0 C--O 1.259 1.598 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 177.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 61.5 mm-40 -108.11 13.9 25.55 Favored 'General case' 0 C--N 1.353 0.747 0 C-N-CA 125.331 1.453 . . . . 0.0 107.783 174.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . 0.447 2.3 p30 73.22 112.25 0.06 Allowed 'General case' 0 C--N 1.356 0.851 0 C-N-CA 129.668 3.187 . . . . 0.0 110.164 -171.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 79.7 mt -101.06 163.82 17.23 Favored Pre-proline 0 N--CA 1.441 -0.898 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -172.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -77.58 -179.52 5.52 Favored 'Trans proline' 0 CA--C 1.499 -1.247 0 C-N-CA 123.076 2.517 . . . . 0.0 110.314 -176.018 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -65.2 -53.26 47.36 Favored 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 126.295 1.838 . . . . 0.0 110.085 -174.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -79.05 -17.06 55.92 Favored 'General case' 0 CA--C 1.505 -0.776 0 C-N-CA 124.511 1.125 . . . . 0.0 110.247 -178.569 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.56 29.67 7.6 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.107 0.861 . . . . 0.0 111.078 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 55.3 m-70 -112.64 -35.11 5.61 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 168.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.6 mp -73.06 -44.75 56.05 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 109.243 -173.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 3.2 pp0? -78.69 -6.48 55.87 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 123.529 0.732 . . . . 0.0 112.22 -176.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.1 t -96.91 -28.2 3.82 Favored 'Isoleucine or valine' 0 C--N 1.358 0.949 0 C-N-CA 124.325 1.05 . . . . 0.0 109.171 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.69 -21.7 54.99 Favored 'General case' 0 CA--C 1.473 -2.006 0 N-CA-C 114.181 1.178 . . . . 0.0 114.181 -169.427 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 27.4 m -64.98 -28.78 45.6 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 126.629 1.971 . . . . 0.0 111.428 -176.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -71.6 -41.5 68.87 Favored 'General case' 0 CA--C 1.506 -0.746 0 CA-C-N 111.84 -2.436 . . . . 0.0 109.947 -175.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -80.94 -41.82 22.3 Favored 'General case' 0 N--CA 1.443 -0.783 0 C-N-CA 124.463 1.105 . . . . 0.0 109.594 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 71.0 t60 -62.5 -63.86 1.1 Allowed 'General case' 0 N--CA 1.426 -1.634 0 C-N-CA 127.933 2.493 . . . . 0.0 112.452 -170.065 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -95.23 -116.52 3.0 Favored Glycine 0 CA--C 1.492 -1.373 0 N-CA-C 107.631 -2.188 . . . . 0.0 107.631 -178.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -150.5 48.63 0.88 Allowed 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 -178.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 16.2 m80 72.91 156.27 0.17 Allowed 'General case' 0 C--N 1.354 0.79 0 C-N-CA 126.838 2.055 . . . . 0.0 112.524 175.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 24.3 pt -100.62 -165.82 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 176.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 56.7 m170 -82.88 -39.53 21.46 Favored 'General case' 0 CA--C 1.501 -0.905 0 C-N-CA 124.315 1.046 . . . . 0.0 110.06 -177.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 82.7 t60 . . . . . 0 C--O 1.26 1.62 0 CA-C-O 117.796 -1.097 . . . . 0.0 109.534 -177.215 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 73.5 m-85 . . . . . 0 N--CA 1.488 1.463 0 CA-C-O 122.058 0.932 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -85.46 -36.22 20.74 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 107.533 -1.284 . . . . 0.0 107.533 173.574 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 40.6 m-20 76.03 99.69 0.07 Allowed 'General case' 0 CA--C 1.498 -1.045 0 C-N-CA 127.768 2.427 . . . . 0.0 108.775 -177.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 5.7 mp -101.04 159.21 30.14 Favored Pre-proline 0 N--CA 1.438 -1.052 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 -171.083 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -77.9 -176.72 3.38 Favored 'Trans proline' 0 CA--C 1.5 -1.219 0 C-N-CA 122.87 2.38 . . . . 0.0 111.302 -173.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -118.19 -65.88 1.13 Allowed 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 178.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -81.13 -12.46 59.24 Favored 'General case' 0 C--N 1.356 0.856 0 C-N-CA 124.445 1.098 . . . . 0.0 110.004 -178.028 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -83.27 9.32 61.42 Favored Glycine 0 C--N 1.356 1.694 0 C-N-CA 123.652 0.644 . . . . 0.0 112.145 178.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -109.43 -32.02 7.31 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 168.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.3 -34.55 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.827 0 C-N-CA 125.933 1.693 . . . . 0.0 110.956 -170.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -80.12 -24.66 40.33 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.149 0.58 . . . . 0.0 110.608 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t -81.92 -28.34 9.66 Favored 'Isoleucine or valine' 0 C--N 1.355 0.813 0 C-N-CA 125.224 1.41 . . . . 0.0 109.803 -175.283 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.85 -19.17 57.81 Favored 'General case' 0 CA--C 1.477 -1.846 0 N-CA-C 114.204 1.187 . . . . 0.0 114.204 -171.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 82.1 t -67.55 -36.02 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.227 0 C-N-CA 125.454 1.502 . . . . 0.0 108.67 176.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 44.6 m-85 -85.76 -23.86 27.11 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.659 -1.609 . . . . 0.0 108.808 -175.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 9.8 t-20 -73.95 -35.23 64.53 Favored 'General case' 0 N--CA 1.44 -0.948 0 C-N-CA 123.922 0.889 . . . . 0.0 108.776 175.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.94 137.09 53.5 Favored 'General case' 0 N--CA 1.427 -1.602 0 C-N-CA 124.5 1.12 . . . . 0.0 109.437 174.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.26 -16.12 61.32 Favored Glycine 0 C--N 1.354 1.547 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -174.47 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 57.4 mm-40 64.68 64.81 0.65 Allowed 'General case' 0 C--N 1.359 0.992 0 C-N-CA 127.254 2.222 . . . . 0.0 111.129 179.325 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 -94.8 -66.5 0.91 Allowed 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 176.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 13.3 pt -89.41 161.5 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.332 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 164.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 87.2 m-70 -131.14 -48.74 1.01 Allowed 'General case' 0 CA--C 1.493 -1.239 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 -174.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 56.4 m170 . . . . . 0 C--O 1.26 1.614 0 C-N-CA 126.151 1.78 . . . . 0.0 111.084 -178.735 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 25.6 t80 . . . . . 0 N--CA 1.483 1.208 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 66.4 mm-40 -124.69 -70.61 0.75 Allowed 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 105.026 -2.213 . . . . 0.0 105.026 -177.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 43.4 m-20 -149.64 106.09 3.51 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 103.076 -2.935 . . . . 0.0 103.076 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 90.0 mt -90.26 160.69 39.32 Favored Pre-proline 0 N--CA 1.443 -0.796 0 C-N-CA 125.097 1.359 . . . . 0.0 107.691 176.094 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -77.1 -179.78 5.76 Favored 'Trans proline' 0 CA--C 1.5 -1.206 0 C-N-CA 123.199 2.599 . . . . 0.0 110.499 -176.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -70.83 -47.42 59.48 Favored 'General case' 0 CA--C 1.501 -0.922 0 C-N-CA 125.652 1.581 . . . . 0.0 110.284 -173.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -79.66 -18.04 52.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 C-N-CA 124.585 1.154 . . . . 0.0 109.877 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -89.41 28.82 6.54 Favored Glycine 0 C--N 1.357 1.718 0 C-N-CA 124.376 0.989 . . . . 0.0 111.241 177.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 41.2 m170 -115.22 -32.43 5.67 Favored 'General case' 0 CA--C 1.501 -0.916 0 C-N-CA 124.654 1.182 . . . . 0.0 108.08 171.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.0 mp -80.59 -37.95 17.16 Favored 'Isoleucine or valine' 0 C--N 1.354 0.774 0 C-N-CA 125.19 1.396 . . . . 0.0 109.005 -172.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -83.32 11.53 6.6 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.435 0.694 . . . . 0.0 111.378 179.16 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 82.0 t -118.16 -33.34 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 C-N-CA 125.253 1.421 . . . . 0.0 107.713 178.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.87 -21.65 40.5 Favored 'General case' 0 CA--C 1.473 -1.991 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -170.731 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.6 p -65.93 -33.72 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.412 0 C-N-CA 125.317 1.447 . . . . 0.0 110.751 175.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -81.68 -24.97 35.92 Favored 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 112.797 -2.001 . . . . 0.0 110.052 -178.595 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 16.9 t-20 -71.78 -46.7 57.49 Favored 'General case' 0 C--N 1.354 0.798 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 54.3 m-70 -72.26 160.76 31.85 Favored 'General case' 0 N--CA 1.424 -1.767 0 C-N-CA 124.701 1.201 . . . . 0.0 112.126 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -119.48 -9.53 8.46 Favored Glycine 0 C--N 1.351 1.38 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 174.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -104.33 44.44 1.02 Allowed 'General case' 0 C--N 1.359 1.017 0 CA-C-O 122.7 1.238 . . . . 0.0 108.83 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 77.2 m-70 -161.73 144.04 11.69 Favored 'General case' 0 N--CA 1.435 -1.2 0 N-CA-C 104.0 -2.592 . . . . 0.0 104.0 177.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 16.8 pt -86.38 149.1 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 178.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 58.3 m170 -91.97 -36.67 13.29 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -176.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 22.9 p80 . . . . . 0 C--O 1.261 1.683 0 C-N-CA 124.785 1.234 . . . . 0.0 110.965 177.67 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 . . . . . 0 N--CA 1.488 1.468 0 CA-C-O 121.982 0.896 . . . . 0.0 111.023 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 59.0 mm-40 -89.67 -21.39 22.78 Favored 'General case' 0 N--CA 1.443 -0.812 0 C-N-CA 124.703 1.201 . . . . 0.0 108.583 175.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 44.1 m-20 77.8 102.6 0.07 Allowed 'General case' 0 C--N 1.359 0.986 0 C-N-CA 127.877 2.471 . . . . 0.0 108.347 -176.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 64.7 mt -96.41 157.06 36.1 Favored Pre-proline 0 N--CA 1.44 -0.944 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 -169.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.8 Cg_exo -79.37 179.12 6.67 Favored 'Trans proline' 0 CA--C 1.501 -1.148 0 C-N-CA 122.767 2.311 . . . . 0.0 110.902 -170.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -121.0 -56.83 1.91 Allowed 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -85.05 -1.29 56.66 Favored 'General case' 0 C--N 1.354 0.797 0 C-N-CA 124.733 1.213 . . . . 0.0 110.773 -177.005 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -88.79 8.42 79.53 Favored Glycine 0 C--N 1.356 1.693 0 C-N-CA 124.236 0.922 . . . . 0.0 110.929 175.516 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 65.1 t60 -106.84 -31.21 8.48 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 173.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.9 mp -74.83 -38.46 44.1 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.889 0 C-N-CA 125.127 1.371 . . . . 0.0 108.798 -174.069 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.0 4.59 11.82 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 179.123 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -105.79 -38.36 4.45 Favored 'Isoleucine or valine' 0 C--N 1.358 0.97 0 C-N-CA 124.909 1.284 . . . . 0.0 108.411 173.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -77.63 -21.75 51.78 Favored 'General case' 0 CA--C 1.476 -1.868 0 N-CA-C 115.122 1.527 . . . . 0.0 115.122 -163.756 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.9 m -69.35 -29.66 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 C-N-CA 125.468 1.507 . . . . 0.0 110.99 176.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -86.87 -24.74 24.79 Favored 'General case' 0 CA--C 1.504 -0.825 0 CA-C-N 112.513 -2.131 . . . . 0.0 109.866 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 38.5 t30 -72.21 -41.09 67.32 Favored 'General case' 0 C--N 1.356 0.868 0 C-N-CA 124.378 1.071 . . . . 0.0 108.202 176.448 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 57.2 m170 -62.87 -50.2 71.86 Favored 'General case' 0 N--CA 1.428 -1.542 0 C-N-CA 126.301 1.841 . . . . 0.0 110.618 174.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.85 100.97 2.68 Favored Glycine 0 CA--C 1.491 -1.435 0 N-CA-C 107.441 -2.264 . . . . 0.0 107.441 175.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -100.4 64.89 1.18 Allowed 'General case' 0 C--N 1.355 0.819 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 176.245 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -81.48 -67.87 0.74 Allowed 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 21.0 pt -85.19 158.73 3.4 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.459 0 C-N-CA 125.28 1.432 . . . . 0.0 108.017 174.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -137.09 59.72 1.68 Allowed 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 104.497 -2.408 . . . . 0.0 104.497 177.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 26.8 p80 . . . . . 0 C--O 1.258 1.545 0 C-N-CA 126.928 2.091 . . . . 0.0 112.835 -179.016 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 5.9 t80 . . . . . 0 N--CA 1.487 1.424 0 N-CA-C 110.683 -0.118 . . . . 0.0 110.683 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 76.54 -4.34 2.37 Favored 'General case' 0 N--CA 1.441 -0.901 0 C-N-CA 127.729 2.412 . . . . 0.0 113.224 -176.679 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 72.0 99.43 0.07 Allowed 'General case' 0 CA--C 1.496 -1.11 0 C-N-CA 127.663 2.385 . . . . 0.0 110.878 178.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -145.51 159.34 48.41 Favored Pre-proline 0 N--CA 1.441 -0.876 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 176.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -78.69 -178.42 4.62 Favored 'Trans proline' 0 CA--C 1.5 -1.193 0 C-N-CA 122.518 2.145 . . . . 0.0 111.215 -172.191 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -77.71 -40.71 40.41 Favored 'General case' 0 N--CA 1.443 -0.811 0 C-N-CA 125.748 1.619 . . . . 0.0 108.407 -178.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -77.88 -13.87 59.74 Favored 'General case' 0 C--N 1.356 0.863 0 C-N-CA 124.557 1.143 . . . . 0.0 109.872 178.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -79.57 0.33 81.65 Favored Glycine 0 C--N 1.357 1.734 0 C-N-CA 124.124 0.868 . . . . 0.0 112.29 176.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -96.81 -36.23 10.69 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 172.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.2 mt -73.94 -48.47 38.59 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.929 0 C-N-CA 126.073 1.749 . . . . 0.0 110.94 -169.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -75.94 -23.09 55.4 Favored 'General case' 0 CA--C 1.508 -0.671 0 C-N-CA 124.317 1.047 . . . . 0.0 112.397 -171.053 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 84.3 t -81.19 -25.5 10.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 C-N-CA 125.099 1.36 . . . . 0.0 109.658 -175.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 24.9 tptp -84.57 -20.3 31.72 Favored 'General case' 0 N--CA 1.429 -1.501 0 C-N-CA 125.858 1.663 . . . . 0.0 111.454 -171.478 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 58.8 t -60.33 -37.54 74.43 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.927 0 C-N-CA 126.599 1.96 . . . . 0.0 109.563 168.377 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -86.52 -12.35 49.07 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-N 114.256 -1.338 . . . . 0.0 110.196 -175.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 41.0 t30 -80.46 -28.66 37.57 Favored 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.38 1.072 . . . . 0.0 108.57 173.263 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 46.3 m170 -60.69 164.49 4.61 Favored 'General case' 0 C--N 1.365 1.276 0 C-N-CA 125.36 1.464 . . . . 0.0 112.754 177.703 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -101.15 70.88 0.4 Allowed Glycine 0 C--N 1.354 1.551 0 N-CA-C 106.122 -2.791 . . . . 0.0 106.122 176.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -95.27 62.11 2.46 Favored 'General case' 0 N--CA 1.442 -0.858 0 C-N-CA 125.575 1.55 . . . . 0.0 108.668 -176.726 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 71.6 m80 -93.49 165.42 12.76 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 31.5 pt -88.92 173.65 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.187 0 C-N-CA 124.446 1.098 . . . . 0.0 108.874 -179.09 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' HIS . . . . . . . . . . . . . 17.9 p80 -84.88 -32.88 22.95 Favored 'General case' 0 N--CA 1.442 -0.843 0 C-N-CA 124.483 1.113 . . . . 0.0 109.092 177.726 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' HIS . . . . . . . . . . . . . 70.8 t60 . . . . . 0 C--O 1.261 1.666 0 C-N-CA 126.145 1.778 . . . . 0.0 111.084 177.272 . . . . . . . . 0 0 . 1 stop_ save_